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1 Introduction 
Sections (1.1-1.3) have been partly adapted from: Ruth Röder and Ernst Wagner, 
“Sequence-defined shuttles for targeted nucleic acid and protein delivery”, 
Therapeutic Delivery (2014) 5(9), 1025–1045. 
 
1.1 Novel molecular therapeutics: in search of the perfect delivery         
strategy 
The rapid progress in medicine is always calling for more effective drugs, which 
provide satisfactory therapeutic benefits without showing adverse effects. Nucleic 
acid therapy as well as protein transduction are novel strategies to treat diseases at 
the point of their very origin. Within the past few years, these kinds of molecular 
therapies have emerged as very promising treatments for life-threatening diseases 
resulting from defective genes. With 65% of all ongoing clinical gene therapy trials 
worldwide, cancer is by far the most common disease treated by gene therapy, 
followed by monogenic, cardiovascular and infectious diseases (see [1] and The 
Journal of Gene Medicine Clinical Trial site www.abedia.com/wiley). In July 2012 the 
first gene therapy product, Glybera (UniQure), was recommended for approval in the 
EU. It is an adeno-associated viral vector, which expresses lipoprotein lipase in the 
muscle tissue, to treat patients with severe lipoprotein lipase deficiency [2]. The 
inherent problems associated with gene therapy include the lack of efficient delivery, 
the risk of triggering immune responses and the risk of uncontrolled genetic changes, 
although a lot of already approved drugs hold the same risks [1]. Even though 
peptides, proteins or nucleic acids are not able to cross cell membranes and enter 
the intracellular space, this obvious restriction in delivery has been turned into a 
possible advantage through the development of a number of specific cell targeted 
shuttles for nucleic acid and protein delivery. Therefore many different synthetic 
carriers have been designed to overcome the various delivery hurdles. Based on the 
long experience in liposome technology, lipid-based gene carriers have been 
developed [3-6]. Cationic lipids of medium and low molecular weight, well accessible 
in high purity by synthetic routes, are the basis. Alternatively, cationic 
macromolecules with inherently high binding capacity for nucleic acids were 
evaluated. Polymers such as polyamidoamine (PAMAM) and polyethylenimine (PEI) 
are among the most widely investigated carriers for pDNA delivery [7]. PEI, which 
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has been introduced by the lab of Behr in 1995, is probably the most prominently 
utilized polymer, based on its relatively high transfection efficiency [8]. It is either 
used as branched PEI or the more defined linear PEI. To overcome its high toxicity, 
succinylated PEI [9] or various conjugates can be used. PEI as well as PAMAM 
dendrimers, which were first reported for transfection by Haensler and Szoka [10], 
have a very high amine density, but only 15–20% of the amines are protonated under 
physiological pH. This leads to a very efficient endosomal release due to high 
buffering capacity, cationization and endosomal membrane lysis (Figure 1b, proton 
sponge hypothesis) [7, 11, 12]. Although these carriers have been converted by 
modifications and conjugation into more advanced delivery systems, their most 
crucial drawback is their inherent polydispersity and heterogeneity, especially with 
regard to their lack of specific modification sites. Particularly with regard to clinical 
development, it is important to have chemically precise and well-defined carriers, 
enabling reproducible manufacturing. A precise chemical structure is required for 
providing the carrier with defined functions, and it is essential for generating good 
predictions and correlations between chemical and resulting biological properties. 
Nature has already provided excellent examples of delivery systems with highly 
defined macromolecular structures displaying multiple functions in precise positions: 
currently, the most advanced systems are viral vectors. The most prominent vector 
systems used in numerous clinical studies are adeno-associated virus systems [2, 
13, 14], retroviral [15] and lentiviral vectors [16]. Therapeutic nucleic acids replace 
most of the virus genome, and the virus proteins (often together with lipid envelopes) 
mediate the delivery process [17]. However, various disadvantages are also 
associated with viral vectors; they are limited in their capacities for cargo loading, 
they carry the risk of insertional mutagenesis, can have a high inflammatory potential 
and optimization is caught within the limits of their biosynthesis using proteinaceous 
amino acid sequences [7, 17]. Nevertheless, virus-based delivery systems provide 
proof that highly efficient sequence-defined macromolecular carriers are reality. The 
biological clue has been to assemble small units in a defined sequence. Utilizing 
precise solid-phase-assisted synthesis, researchers recently started to mimic such 
procedures by designing sequence-defined carriers putting standard building blocks 
(amino acids, lipids, nucleotides) or artificial building blocks into sequence. 
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1.2 Nucleic acid versus protein delivery 
Delivery requirements differ for the individual molecular therapeutics: pDNA, siRNA 
or intracellularly active proteins. The different delivery pathways are shown in Figure 
1a.  
 
Figure 1: The challenging way into the cell –protein versus nucleic acid delivery. a) Both 
proteins and nucleic acids have to form stable complexes (polyplexes) with polymers or defined 
oligomers, including PEG shielding and targeting ligand. After intravenous injection, polyplexes have 
to extravasate into the tissue and migrate through the extracellular matrix. They are recognized by 
their specific receptor and endocytosed into the cell. After endosomal escape, siRNAs are processed 
in the cytosol. The guide strand is bound to the Argonaute protein and the passenger strand is 
discarded. Target mRNA is cleaved (middle). In contrast, pDNA has to be imported into the nucleus 
(left), transcribed and translated into a protein to interact with its molecular target. Protein delivery 
(right) is the most straightforward process of the three. After endosomal escape, the protein has to find 
its molecular target to induce signaling cascades, leading to the desired effect (right). b) Endosomal 
escape can be explained by the proton sponge hypothesis: protonation of the oligomer causes 
increased influx of chloride counterions and H2O, leading to osmotic pressure, interaction of cationic 
oligomer residues with endosomal membrane and rupture of the endosome [17-19]. 
 
As both pDNA and siRNA are double- stranded nucleic acids with anionic 
phosphodiester backbones, one would assume that their deliveries require similar 
elements. Both types of nucleic acids are highly negatively charged, which allows 
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electrostatic interactions with positively charged delivery agents. In reality, very 
significant differences for optimum transfer have been observed [20]. First of all, their 
different structural, chemical and biological properties need to be considered. Due to 
the much smaller size of siRNA, it shows far less electrostatic interaction with 
polycations. Therefore special attention has to be paid to the polyplex stability. In 
terms of hydrolysis, siRNA due to its 2′-hydroxy group is more fragile than pDNA [21]. 
Moreover, RNA is more prone to degradation by nucleases, which can be avoided 
through the introduction of stabilizing modifications such as 2′-fluorine and 2′-
methoxy. These modifications do not only improve the stability of siRNA, but they can 
also reduce off-target effects and even improve the specificity for the target mRNA 
[20, 22]. When introduced into the cytosol of cells, siRNAs are processed by natural 
mechanisms into the so-called RNA-induced silencing complex. The guide strand, 
where the first nucleotides comprise the seed sequence and initialize binding to the 
target mRNA, is bound to the Argonaute protein and the passenger strand is 
discarded. Most commonly, mRNA and siRNA are perfectly matching in sequence, 
leading to cleavage of target mRNA in the presence of the catalytic Argonaute 
protein Ago2. If not, such as in the case of endogenous miRNAs, silencing can also 
be achieved via pre- or post initiation translational repression and deadenylation, 
followed by degradation of the mRNA [23]. Compared to the cytosolic delivery of 
siRNA, pDNA has to overcome another obstacle after endosomal escape: the import 
into the nucleus. This presents a limiting factor for transfection as the cytosol 
impedes the migration of DNA, and the nuclear pore presents an additional barrier for 
larger nucleic acids. Passive nuclear uptake of pDNA can only take place during cell 
division. If not sufficient, an active transport mechanism is needed. Coupling of DNA 
to short peptide sequences such as nuclear localization signals (NLS) has provided 
only limited success; nuclear entry remains a major limitation [20, 24]. After 
successful delivery to the nucleus, DNA still presents a prodrug. The delivered pDNA 
first has to be transcribed into mRNA and translated into the active corresponding 
protein before it can exhibit its effect. The obstacles of nuclear delivery and 
transcriptional and translational processing can be overcome by the transduction of 
bioactive proteins (Figure 1a right). The delivery of therapeutic proteins is regarded 
as safe because it does not introduce potentially recombinogenic nucleic acid 
material [1, 25]. In comparison to the delivery of nucleic acids, the delivery of proteins 
is the most straightforward way to address diseases which result from missing or 
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mutated forms or misfolded proteins. Regarding siRNA transfer, cytosolic delivery of 
intact and bioactive molecules is the primary goal. As opposed to nucleic acid cargos, 
simple electrostatic complexation cannot generally be applied. In addition, proteins 
display far more variation in biophysical properties than the rather uniform 
oligonucleotide drugs. Therapeutic protein molecules usually have to be covalently 
modified, to ensure a robust binding with the carrier in the first steps of their delivery. 
However, at their intracellular site of action, they must disassemble from the carrier. 
Thus, bioreversible modifications are in the focus of delivery studies. 
 
1.3 Sequence-defined delivery systems for the delivery of proteins 
Protein therapeutics are pharmaceutically well established in applications where their 
sites of action are targeted to the extracellular environment. In vaccination 
approaches, pharmaceutical proteins are required to act also intracellularly: 
specifically immune cells must internalize and process the provided protein antigens. 
Apart from desired uptake by immune cells upon vaccination, there is an enormous 
number of intracellular molecular targets where an active, targeted intracellular 
delivery process termed ‗protein transduction‘ would tremendously broaden the 
scope of therapeutic protein application. Various strategies such as virus like 
particles [26], silica nanoparticles [27, 28], nanocapsules [29], charge-conversional 
polyion complex micelles [30-32], liposomal carriers [33], or cell penetrating peptides 
[34-36] have been applied to deliver therapeutic proteins. Although efficient, most of 
these carriers are not sequence-defined. The next sections will describe different 
sequence-defined protein delivery agents in more detail. 
 
1.3.1 Protein delivery using cell penetrating peptides 
Based on the knowledge of existing natural intracellular protein delivery, the most 
widely investigated tools are cell penetrating peptides (CPPs) [37-39]. CPPs are 
water-soluble, polybasic and/or amphipathic peptides which are usually less than 30 
amino acids in length with a net positive charge at physiological pH [40]. A prominent 
field in which CPPs have been applied is the generation of induced pluripotent stem 
cells (iPS). Kim et al. [41] as well as Yu et al. [42] succeeded in efficient delivery of 
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four reprogramming factors Oct4, Sox2, Klf4 and c-Myc into human newborn 
fibroblasts or chicken embryonic stem cells resulting in successful maintenance and 
differentiation of these cells. 
Liu et al. [43] presented an application of protein delivery to circumvent the delivery of 
pDNA or mRNA in a case where it has been proven to be quite challenging, by 
showing the delivery of functional transcription activator-like effector nucleases 
(TALENs) into cells using the commercially available CPP (Npys)-(D-Arg)9. A 
disadvantage of using CPPs might be that the irreversible modification of a protein 
with a CPP domain can disturb its tertiary structure leading to a permanent 
inactivation, especially in the case of enzymes. To overcome this problem, Dowdy 
and co-workers [44] designed a system where they developed a pH-sensitive CPP. In 
this approach they made use of the fact that thousands of recombinant proteins are 
carrying a hexahistidine (H6)- tag for purification. A fact on which will also be played 
on in the second part of this thesis (Chapter 3.2). At pH >6, in the presence of a 
metal ion, a coordinate bond can be formed between two imidazole rings on adjacent 
histidine residues and one molecule of nitrilotriacetic acid (NTA). In the work of June 
et al. [44], the coupling of the CPP TAT with three NTAs enables the pH-sensitive 
coupling of H6-tagged proteins or other H6-tagged macromolecular cargos to any 
NTA-tagged CPP. Applying this system they showed the transduction of H6-β-
Galactosidase, as well as H6-Cre recombinase into CHO reporter cells, as well as the 
in vivo delivery, upon intravenous injection of Cre recombinase in ROSA26 loxP-
Stop-loxP luciferase mice [44].  
A quite novel alternative approach is the utilization of sequence-defined 
oligoaminoamides. The development of these oligomers will be further described in 
the next section. 
 
1.3.2 Development of sequence-defined oligomers 
Due to the various extra- and intracellular barriers, a defined carrier has to 
accomplish numerous activities. One strategy to design oligomer-based carriers 
meeting all the above-described requirements involves the use of solid-phase 
supported synthesis, thus putting the smaller delivery subdomains into defined 
precise sequences. It is a very elegant approach to assemble sequence-defined and 
therefore also activity-defined, macromolecular carriers. In contrast to standard 
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peptides, artificial non amino acid building blocks are also incorporated. 
Polyamidoamines (PAAs) were usually generated through polyaddition reactions, 
leading to polydisperse products, making the design of precise multifunctional 
oligomers difficult. To circumvent this problem, Hartmann et al. applied solid-phase 
supported synthesis to generate sequence-defined multifunctional PAAs [45]. Using 
this method, the synthesis of larger oligomers failed, due to unexpected cross-links 
which block further oligomer extension [46]. Schaffert et al. introduced novel artificial 
Fmoc/Boc-protected amino acids which contain short defined repeats of the 
diaminoethane motif [46] (Figure 2a). Like PEI, this motif provides protonable amines 
for proton sponge capacity, which are considered to be responsible for the high 
transfection efficiency of PEI [47]. Using these building blocks, linear polycations, 
with or without modification as well as branched structures were synthesized. 
Confirming this strategy, oligomers synthesized with full control of their chemical 
composition and structure resulted in equally high transfection levels as those 
achieved with PEI. In addition, these medium-sized precise carriers displayed far 
higher biocompatibility than PEI both in vitro and in vivo [48]. Development of novel 
building blocks for such strategies is an interesting area of ongoing research. For 
example, Wojcik et al. [49] introduced a new set of building blocks, allowing separate 
building of the main and side chain leading to asymmetrically branched PAAs [49]. 
Martin et al. [47] reported the first description of the synthesis of PEG-shielded, 
sequence-defined monodisperse PAAs containing targeting ligands [47]. The 
schematic structure of a sequence-defined oligomaminoamide carrier is depicted in 
Figure 2b. Carriers comprise different diaminoethane building blocks and α,ε-
amidated lysines as branching points. Optionally histidines as protonable buffering 
units or oleic acids to enhance endosomal escape, as well as cysteines which are 
supposed to serve as bioreversible crosslinkage of oligomers, to stabilize the 
polyplexes [50]. Ligand-PEG can be included as functional shielding and cell 
targeting domain and glutamic acid or succinic acid as non-functional subunits 
(Figure 2).  
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Figure 2: Building blocks and general structure of a sequence-defined oligomer. a) Succinoyl 
tetraethylene pentamine (Stp) (three protonatable amines within an oligomer chain); glutaroyl 
tetraethylene pentamine (Gtp) (three protonatable amines), glutaroyl triethylene tetramine (Gtt) (two 
protonatable amines), phthaloyl tetraethylene pentamine (Ptp) (three protonatable amines), succinoyl 
pentaethylene hexamine (Sph) (four protonatable amines) [46, 48, 51]. b) Schematic structure of a 
sequence-defined oligoaminoamide carrier, including different units for targeting such as proteins, 
peptides, small molecules (green), shielding such as polyethyleneglycol (PEG) (blue), branching such 
as lysines (purple), buffering and nucleic acid binding such as histidines, and other natural or artificial 
amino acids (orange, brown, grey) and cross-linking such as cysteines (yellow). 
 
1.3.3 Delivery of proteins using sequence-defined oligomers 
Polyplexes built out of oligomers and nucleic acids are usually held together by 
electrostatic interactions. As proteins exhibit a much lower charge density than 
nucleic acids, oligomers usually have to be covalently attached. The protein can be 
coupled bioreversibly either through an acid labile or a reducible disulfide linker to a 
sequence-defined carrier. Maier et al. [52] modified amino groups of nlsEGFP 
(enhanced green fluorescence protein containing a nuclear targeting sequence, NLS) 
as well as β-Galactosidase with N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), 
followed by covalent attachement of a cationic three-arm transfection oligomer (386) 
to the activated thiol groups of the linker through a disulfide bond. Successful 
transduction and effective delivery to the nucleus in 3T3 fibroblasts and Neuro2A 
cells could be shown for 386-SS-nlsEGFP. β-Galactosidase-SS-386, was able to 
hydrolyze X-Gal or C12-FDG, which led to fluorescence after transduction into 
Neuro2A. The same approach was applied by Zhang et al. [53] leading to the 
effective folate receptor dependent delivery of active RNAse and GFP using a three-
Introduction 
9 
  
arm oligomer (729) including oleic acid to enhance endosomal escape, PEG as 
shielding domain and folate to enable receptor dependent cellular uptake. A 
drawback of this approach is that the SPDP linker still results in thiol-modified amino 
groups after cleavage. To overcome this problem, and to achieve an acid labile 
release, the azidomethyl-methylmaleic anhydride (AzMMMan) linker was designed 
[54]. Again, amino groups of nlsEGFP, β-Galactosidase and also human serum 
albumin were modified and acidic- and time dependent release was displayed for 
covalent coupled Dye or PEG. Successful transduction and effective delivery to the 
nucleus in human cervical cancer cells, HeLa, could be shown for 386-AzMMMan-
nlsEGFP compared with irreversible thioether linkage using succinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (SMCC) [54]. A similar pH-sensitive 
system for protein delivery was developed by the group of Kataoka. They used 
charge-conversional polyion complex (PIC) micelles to deliver proteins. Here, the 
charge density of proteins is increased to result in more stable PIC [30]. Positively 
charged lysines of IgG or cytochromeC are converted into negatively charged 
carboxylic groups by modifying them with citraconic acid amide (Cit) or cis-aconitic 
acid amide (Aco) to form stable PIC micelles with cationic block copolymers such as 
PEG–poly[N-{N‘- (2-aminoethyl)-2-aminoethyl aspartamide] (PEGpAsp(DET)). After 
internalization into the cells, the Cit and Aco amide linkages rapidly hydrolyze at the 
endosomal pH of 5.5, leading to dissociation of the PIC micelle. The original protein 
is regenerated, releasing the cationic block copolymer, which induces the pH-
dependent destabilization of the endosomal membrane to aid the endosomal escape 
of the protein into the cytoplasm [30, 31]. This approach also functions in reverse, by 
forming PICs containing a highly negatively charged block copolymer and a highly 
positively charged protein such as lysozyme [55].  
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1.4 Nanobodies as therapeutic agents or imaging tools 
Nanobodies (Figure 3) are single domain- antibody fragments (VHH) derived from 
heavy-chain only camelid antibodies (HcAb) [56]. HcAbs which, compared to 
conventional IgG antibodies, are devoid of the light chains, were first discovered in 
the 1990s [57] in Camelidae (Bactrian camels, dromedaries, vicugnas, and lamas) 
[58].  
 
Figure 3: Structure of a nanobody. Camelide heavy chain Antibody (HcAb), which compared to a 
normal antibody lacks the light chain and the CH1 domain and comprises a single antigen binding 
domain the VHH domain. A Nanobody (Nb) is derived from HcAb and consists of one VHH domain only. 
Adapted from [59]. 
 
Especially with regard to their possible use as biopharmaceuticals [60, 61] or imaging 
tools [62-64], nanobodies have significant advantages compared to standard 
antibodies. They can be easily screened for affinity and specificity; due to their 
compact, single domain structure, they stay chemically active in the reducing 
environment of the cell; they can be produced in prokaryotic systems in high yield 
and be easily chemically and genetically modified [65-67]. Additionally, due to their 
small size (15kDa), nanobodies can better diffuse through tissues or also 
intracellularly across nuclear pores, and also bind and inhibit targets such as 
enzymes which are addressed by standard antibodies to a far lesser extend [68, 69]. 
Until today, nanobodies have been used in a broad field of diverse applications. 
Rothbauer et al. [70] described on the one hand the use of an immobilized GFP 
binding nanobody (GBP) for the generation of a GFP-nanotrap, enabeling a fast and 
efficient isolation of GFP fusion proteins as well as their interacting factors. On the 
other hand they also showed that GBP can be fused with structural proteins to recruit 
GFP fusion proteins and interacting factors at defined regions in living cells [70]. The 
usage of nanobodies for a different application has been shown by Heukers et al. 
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[71]. They used albumin nanoparticles decorated with anti hepatocyte growth factor 
receptor (HGFR, Met) nanobodies to interfere with the Met/HGF pathway for 
anticancer therapy. 
Ekstrand et al. [72] used GBPs to tag ribosomes, and engineered this systems to 
selectively capture translating mRNA from neurons retrogradely labeled with GFP. 
Like that, they were able to profile neurons projecting to the nucleus accumbens. 
Leduc et al. [73] modified gold nanoparticles with GBP to enable tracking of proteins 
using photothermal imaging. They were able to label GFP-proteins in very crowded 
environments such as cytoskeletal structures and adhesion sites both in vitro and in 
live cells. The use of GBP to mediate knockout of fluorescent fusion proteins, by 
manipulating the ubiquitine pathway, has been described by Caussinus et al. [74]. 
Last but not least, nanobodies have already been used in various clinical applications 
such as Caplacizumab for acquired thrombotic thrombocytopenic purpura, which was 
the first nanobody to enter phase III studies [75]. Ozoralizumab and ATN-192 were 
developed by Ablynx for the therapy of autoimmune diseases with initial focus on 
rheumatoid arthritis. Ozoralizumab also called ATN-103 is a humanized trivalent, 
bispecific Nb. It binds with high affinity to Tumor necrocis factor (TNF). ATN-192 with 
which a Phase I clinical trial was already completed is the PEGylated form of 
ozoralizumab [76]. 
 
1.5 Metal-organic frameworks (MOFs) 
Porous coordination polymers or metal-organic frameworks (MOFs) are a relatively 
new class of nanomaterials which have been discovered in 1989 by Robson and his 
group [77]. MOFs consist of metal ions or secondary building units (SBUs) or metal 
oxide clusters, which are coordinatively connected by organic linkers to create porous 
three-dimensional crystalline frameworks (Figure 4) [78, 79].  
These first MOFs consisted of Cu(I) centers and were linked with 4,4′,4″,4‴-
tetracyanotetraphenylmethane adopting a tetrahedral geometry [80]. Compared to 
silica and zeolithes, metal clusters and organic linkers can be varied almost 
indefinitely, providing innumerable possibilities and great flexibility for creating 
different well-defined MOF nanoparticles (NPs). Their ultra high porousity together 
with the exceptional big internal surface area and the variability in design verify their 
various fields of applications, such as luminescence [81], adsorption and gas storage 
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[82, 83], catalysis [84] or drug delivery [85, 86]. MOFs can be synthesized via 
different synthesis methods. Examples are hydrosolvothermal, microwave assisted, 
atmospheric pressure and reflux, ultrasonic and mechanochemical conditions or 
reverse phase microemulsions [85, 87].  
 
 
Figure 4: Molecular composition of metal-organic frameworks (MOFs). MOFs consist of metal 
ions (red) and an organic linker (blue) to create porous three-dimensional crystalline frameworks. 
Adapted from [158]. 
 
Generally MOFs can be built out of two different kinds of linkers. Exogenous linkers 
such as imidazole, trimesic- or terephtalic acic do not intervene in the body cycle and 
should be excreted after administration. Here, an advantage depicts the use of 
already functionalized linkers so-called presynthetic modification, where the linker is 
altered before the MOF formation [88]. In contrast, the postsynthetic modification 
process describes the use of already synthesized frameworks with presynthetic 
modified linkers to which molecules with corresponding functional groups can be 
introduced; e.g. modification of amino functionalized benzene-1,4-dicarboxylate in 
MIL-101(Al) with peptide coupling agents [89] or introducing metal-coordinating 
ligands into MOFs [90]. Endogenous linkers are a constitutive part of the body 
composition and can be reused after administration, such as fumaric acid in the 
Krebs cycle decreasing the risk of side effects [85]. 
The controlled functionalization of the surface of NPs has become more and more 
popular in recent years. As the surface-to-volume ratio of NPs is quite high, the 
attachment of functional molecules to the surface is fundamental to control overall 
properties [91]. Especially in the field of biomedicine, surface modification is of great 
importance to inhibit agglomeration and to include specifc targeting ligands [92, 93]. 
Surface modification can occur via a self assembly process; examples are micelle, 
liposome or polymerosome formation of amphiphilic compounds [94-97], ionic 
complex formation [98, 99], cyclodextrin-adamantane host-guest interaction [100, 
Introduction 
13 
  
101] and gold-sulfur interaction [102-106]. Another possibility is the covalent 
modification which has amongst others been described for sequence-defined 
polyplexes [107, 108], MOF NPs [109-111], silica NPs [112, 113], carbon nanotubes 
[114], or liposomes [115, 116]. 
 
1.5.1 MIL-88A 
MIL-88A (MIL stands for Materials from Institute Lavoisier) MOF NPs have a 
hexagonal symmetry. They correspond to a coordination polymer built from 
oxocentered trimers of iron (III) octahedra connected by hydrophilic fumarate anions 
that delimit a three dimensional pore system (ϕ∼5–7 Å) [117, 118]. They consist of 
fumaric acid as organic linker, which has also been used as food additive, and Fe3+ 
as metal ion. 
Until today, the better part of applications of MIL-88A lies in their usage as catalysts. 
MIL-88A has very high swelling capacities (above 80%) upon exposure to polar 
solvents. This property is very useful in photocatalytic reaction. Through this large 
volume swelling, the reactants can be easily adsorbed onto the reaction sites, 
followed by the redox reaction and desorption of the reaction products [119]. Li et al. 
[120] applied MIL-88A NPs as a heterogenous persulfat catalyst, for the 
decolorization of the organic pollutant, Rhodamin B, in water, proofing that 
decolorization does not simply occur via adsorption of Rhodamin B to MIL-88A, but 
just after the MOF induced activation of persulfate generating sulfate radicals to 
degrade Rhodamin B [120]. 
The use of iron based MOFs as potential drug delivery and imaging tool was 
amongst others investigated by Horcajada et al. [121]. First, anticancer or antiviral 
drugs (busulfan, azidothymidine triphosphate, cidofovir) as well as some cosmetic 
molecules, such as caffeine (liporeductor), urea (hydrating agent), benzophenone 3 
and benzophenone 4 (UVA and UVB filters) were entrapped in different non-toxic 
iron(III) carboxylate MOFs and for biological applications, the surface was coated 
with PEG. Long-term stability studies revealed a major degradation of MIL-88A only 
after 7 days at 37 °C. In vitro and in vivo toxicity studies showed no toxicity even after 
prolonged exposure. Further investigations in Wistar female rats revealed that MIL-
88A can also be used as contrast agents. Upon PEGylation of MIL-88A MOF NPs, 
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slightly higher relaxivity values were obtained compared to the usage of non-
PEGylated ones [121]. 
 
1.5.2 HKUST-1 
HKUST-1 (HKUST stands for Hong Kong University of Science and Technology) was 
among the first synthesized and characterized MOFs in 1999 [122]. It is one of the 
few MOFs that is already produced by BASF at large scale and is commercially 
available (Basolite C300) [122]. This MOF forms face-centered-cubic crystals that 
contain an intersecting three-dimensional (3D) system of large square-shaped pores 
(9 Å by 9 Å) [122], with a thermal stability up to 240 °C. HKUST-1 were the first open 
metal site MOFs to be characterized [85]. Compared to the two other MOF NPs used 
in this work, HKUST-1 is assembled using trimesic acid as an organic linker.  
HKUST-1 is one of the best verified MOFs for hydrogen adsorption and storage 
[123]. Taking advantage of its great adsorption abilities, HKUST-1 MOF NPs can also 
be used to remove pollutants from water. Conde-González et al. successfully 
investigated their usage as adsorbent to remove silver nanoparticles from water 
[124]. 
In terms of drug delivery, Ke et al. reported the encapsulation and delivery of the 
hydrophobic anticancer drug, Nimesulide. They used a magnetic nanocomposite 
material, prepared by incorporating Fe3O4 nanorods in HKUST-1 nanoparticles [125]. 
Furthermore HKUST-1 is one of the MOF NPs which has the best NO absorption 
abilities. NO loaded HKUST-1 NPs were able to completely inhibit antiplatelet 
aggregation in human platelet rich plasma, while HKUST-1 NPs alone did not exhibit 
any significant effect. Another purpose NO loaded HKSUT-1 NPs can be used for is 
their antibacterial effect, which could be shown in methicillin resistant Staphylococcus 
auereus, Pseudomonas aeruginosa and Clostridium Difficile [85]. 
 
1.5.3 Zr-fum 
The Zr-fum MOF NPs used in this work are composed of ZrCl4 and, just as MIL-88A, 
of fumaric acid as a linker [126]. As a modulator formic acid is used. Therefore all 
components are naturally occurring molecules, thus their usage for biological 
applications is obvious.  
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Until today, a variety of different Zr-MOFs have been synthesized. The first were 
University of Oslo-66 (UiO-66) (with terephtalate as a linker), UiO-67 (with biphenyl 
dicarboxylate as a linker) and UiO-68 (with terphenyl dicarboxylate as a linker) [127, 
128]. 
In comparison to these MOFs the crystal structure of the Zr-fum MOF NPs used in 
this work can be derived from UiO-66. Zr-fum NPs have a primitive cubic lattic with 
the space group Pn3  compared to a face-centered one of UiO-66. This stems from 
the nature of its linker, fumaric acid. The MOF features stability towards aqueous 
solutions and is stable up to 260 °C. The Zr-fum MOFs used in this work were 
synthesized according to the protocol described by Wißman et al. [129], but instead 
of performing the synthesis in DMF, it was done in water.  
To date, Zr4+ based MOF NPs have been used in various applications such as the 
detection and removal of antibiotics and organic explosives in water [130] or also in 
Photo- [131, 132], Electro- [133], or Lewis acid catalysis [134, 135].  
The application of MOFs in the field of drug delivery is difficult as they often exhibit 
poor chemical and thermal stabilities. In contrast to that, the above described Zr-
MOFs are considered to be ideal candidates for drug delivery. Zhu et al. [136] for 
example used UiO-66 to deliver alendronate into cancer cells, leading to growth 
inhibition after pH dependent release. Fillippousi et al. [137] also investigated UiO-66 
and UiO-67 for their use as anticancer drug carriers. They adsorbed hydrophobic 
taxol and hydrophilic cisplatin onto/ into MOFs, which were then encapsulated in 
biodegradable polymeric matrix (modified poly(ε-caprolactone) with d-α-tocopheryl 
polyethylene glycol succinate) in order to improve solubility, reduce toxicity and 
prepare sustained release formulations. The polymer coated drug loaded MOFs 
exhibited better antitumor activity compared to the free drug solutions [137]. 
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1.6 Aims of the thesis 
1.6.1 Delivery of nanobodies for imaging of target proteins 
Nowadays, nanobodies are being used in various fields of applications, such as 
imaging of target proteins or as biopharmaceuticals. A drawback of their use is the 
access of intracellular molecular targets only upon fixation and permeabilization of 
cells. The transduction of functional nanobodies into living cells would therefore be a 
great advancement for functional biological or therapeutic applications. Besides, also 
labeling of proteins, prior to their delivery would be possible, broadening the scope of 
dyes which can be used from intracellular expressed fluorescent proteins to any 
desired marker.  
The first aim of this thesis was to establish a system for the efficient delivery of a 
model nanobody into living cells. A broad screening was to be conducted evaluating 
different targeted and non-targeted sequence-defined oligoaminoamide carriers from 
our lab, for their potential to efficiently transduce a GFP binding nanobody into living 
HeLa_ PCNA-GFP cells.  
The second aim was to investigate molecular details of the involved nanoparticles 
formed by the nanobody and selected oligoaminoamides. 
The third aim was to investigate if this approach works in various cell lines and can 
be extended to other nanobodies. Therefore the delivery of a lamin binding nanobody 
into KB_wt cells had to be evaluated. 
As the fourth aim the potential of the newly developed nanobody delivery system for 
the visualization of intracellular targets in time laps studies had to be evaluated, 
being able to trace the nanobody through the whole delivery process and the cell 
cycle. 
 
1.6.2 MOF nanoparticles as a defined carrier system for His-tagged 
functional units 
MOFs are a class of materials synthesized of inorganic building units, metal ions or 
metal clusters that are coordinatively connected by organic linkers to create porous 
three-dimensional frame works. Their crystallinity, chemically functionalizable pores 
and potential systematic structural variation are factors that allow to precisely design 
these materials for particular purposes. In the thesis, a new functionalization concept 
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had to be evaluated using the interaction between Lewis bases, such as the 
imidazole function of histidine and coordinatively unsaturated metal sites present on 
the external surface of MOF NPs to self-assemble different functional units onto MOF 
NPs. The versatility of the general assembly concept had already been shown in pilot 
studies by Dr. Ulrich Lächelt (Pharmaceutical Biotechnology, LMU München). The 
aim within the current thesis was to evaluate its potential to be used as a carrier for 
the intracellular delivery of various His-tagged compounds. 
The first specific aim was to evaluate the toxicity of the three selected MOF NPs, 
MIL-88A, HKUST-1 and Zr-fum on cells to proof their general feasibility to be used as 
intracellular carriers. 
The second aim was to further investigate the functionalized MOF NPs in terms of 
size, their behavior under biological conditions as well as the characteristics of the 
interaction of the His-tagged compounds with the MOF NPs. 
The third aim was the actual application of the different MOF NPs to carry proteins as 
well as small molecules into the cells, including the investigation of various His-
tagged units to enhance cellular uptake as well as endosomal escape. For this 
purpose different endosomolytic peptides, and two lipids DOPC and DOPE had to be 
evaluated. 
The fourth aim was to investigate the applicability of this system to deliver biological 
active proteins or peptides into cells. Therefore the delivery of H6-luciferase in order 
to serve as a reporter system and the ability to deliver three apoptotic membrane 
impermeable bioactive pro-apoptotic peptides, Bad, Bak and KLK as well as 
mitochondrial cytochromeC were to be evaluated. 
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2 Material and Methods 
2.1 Chemicals and solvents 
Table 1: Chemicals and solvents 
Chemical or Solvent (Abbreviation) Manufacturer 
2-Chlorotrityl chloride resin Iris Biotech (Marktredwitz, Germany) 
Atto-647N (NHS ester) Atto-Tec GmbH (Siegen, Germany) 
(Benzotriazol-1-yloxy)-tripyrrolidinophospho-
nium hexafluorophosphate (Pybop) 
Multisyntech GmbH (Witten, Germany) 
Protein Standard, Broad Range NEB (Frankfurt am Main). 
Collagen A Merck KGaA (Grafing Germany) 
Copper(II) nitrate hemipentahydrate  Riedel-de Haën (Seelze, Germany) 
DBCO-PEG4-NHS ester Jena Biosciences (Jena, Germany) 
Dimethylsulfoxide (DMSO) Bernd Kraft GmbH (Duisburg, Germany) 
Ethanol (99.9 %) VWR (Darmstadt, Germany 
Fmoc or Boc protected α-amino acids Iris Biotech (Marktredwitz, Germany) 
Fmoc-N-amido-dPEG12-acid Quanta Biodesign (Powell, USA) 
Fmoc-N-amido-dPEG36-acid Quanta Biodesign (Powell, USA) 
Fmoc-NH-(PEG)27-COOH (PEG28 Polypure (Oslo, Norway) 
Fumaric acid (≥ 99.5 %) Fluka (Buchs, Switzerland) 
HPLC grade acetonitrile  VWR (Darmstadt, Germany) 
Iron(III) chloride hexahydrate (99 %) Grüssing GmbH (Filsum, Germany) 
N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-
yl)uronium hexafluorophosphate (HBTU) 
Multisyntech GmbH (Witten, Germany) 
N,N-Diisopropylethylamine (DIPEA), Iris Biotech (Marktredwitz, Germany 
Peptide grade dimethylformamide (DMF) Iris Biotech (Marktredwitz, Germany) 
Piperidine, and trifluoroacetic acid (TFA) Iris Biotech (Marktredwitz, Germany) 
TentaGel S RAM resin Rapp Polymere GmbH (Tübingen, 
Germany) 
 
All chemicals which are not listed in Table 1 have been purchased from Sigma-
Aldrich (Germany). 
 
2.2 Proteins 
CytochromeC (equine heart) and transferrin (from human plasma) were bought from 
Sigma-Aldrich (Germany).  
Transferrin was modified with a H6-tag and labeled with Atto647N (NHS-ester) by Dr. 
Ulrich Lächelt (Pharmaceutical Biotechnology, LMU München). It is called H6-Tf* in 
the following work. 
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H6-GFP and H6-luciferase have been expressed and purified as described in (2.11.1, 
2.11.2). GFP binding nanobody (GBP, α-GFP-Nb), and lamin binding nanobody (α-
lamin-Nb) have been expressed and purified as is described in (2.11.3). 
 
2.3 Buffers 
Table 2: Buffers used for experimental procedures 
Buffer Description 
2-(4-(2-hydroxyethyl)-1-piperazinyl)-
ethansulfonic acid (HEPES) Biomol (Hamburg, Germany) 
Phosphate buffered saline If another pH value is stated it was adjusted with 
aqueous 1 M HCl or NaOH solution 
Lysis buffer 20 mM Tris, 20% Succrose (w/v), 0.2 M NaCl, 
10 mM MgCl2, pH 7.5 
LAR buffer 20 mM Glycylglycine, 1mM MgCl2, 0.1 mM EDTA, 
0.051 % (w/v) DTT, 0.0278 % (w/v) ATP, 0.5 % (v/v) 
Coenzyme A Stock solution, pH 8-8.5 
Ellman‘s buffer 0.2 M Na2HPO4, 1 mM EDTA, pH 8.0 
 
2.4 Solutions 
DOPC solution: DOPC 3.6 mM in 60/40 H2O/EtOH 
DOPE solution: DOPE 3.6 mM in 54/46 H2O/EtOH 
 
2.5 Bacterial strains 
E. coli strain DH5α was bought from Invitrogen (Karlsruhe, Germany) and was used 
for plasmid amplification. 
For expression of H6-GFP, E.coli protein expression strain BL21(DE3)plysS was 
purchased from Novagen (Merck4biosciences, Darmstadt , Germany). 
For expression of H6-luciferase RosettaBL21(DE3)pLysS  from Merck Millipore, 
Germany were used. 
Chemical competent bacteria strains were prepared in house. 
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2.6 Cell culture 
Antibiotics, fetal bovine serum (FBS) and cell culture medium were bought from Life 
Technologies (Carlsbad, USA). 
All cell lines were grown in medium supplemented with 10% FBS, 100 U ml-1 
penicillin, 100 µg ml-1 streptomycin and 4 mM stable glutamine. All cells were 
cultured at 37 °C and 5% CO2 in a humified incubator. 
 
Table 3: Cell lines, description and media 
Cell line Description Media 
HeLa_wt ATCC CCL-2; Subline of human 
epithelial cervical adenocarcinoma cell DMEM 
HeLa_Actin-GFP Recombinant HeLa_wt cell line 
expressing Actin-GFP RPMI-1640, folate-free  
HeLa_PCNA-GFP Recombinant HeLa_wt cell line 
expressing PCNA-GFP RPMI-1640, folate-free 
HeLa_Tubulin-GFP Recombinant HeLa_wt cell line 
expressing Tubulin-GFP RPMI-1640, folate-free  
HUH7_wt Human hepatocellular carcinoma cells DMEM/Ham‘s F12 1:1 
KB_wt ATCC CCL-17; Subline of human 
epithelial cervical adenocarcinoma cell 
line HeLa_wt 
RPMI-1640, folate-free 
 
HeLa_Actin-GFP and HeLa_Tubulin-GFP cells were generated by Dr. K. von 
Gersdorff according to the procedure of the generation of HUH7_Actin-GFP and 
HUH7_Tubulin-GFP cell lines, which has been described elsewhere (PhD thesis 
LMU, 2006). 
HeLa_PCNA-GFP [138] cells were kindly provided by Prof. Dr. Heinrich Leonhardt 
(Department of Biology II, LMU München). 
  
Material and Methods 
21 
  
2.7 Metal-organic frameworks (MOFs) 
All metal-organic frameworks (MOFs) have been synthesized and analyzed by 
Patrick Hirschle (Department of Chemistry, LMU München). 
 
Table 4: Metal-organic frameworks (MOF) used for the experiments 
Name Organic linker Metal Ref 
MIL-88A Fumaric acid FeCl3 x 6 H2O [139] 
HKUST-1 Trimesic acid Cu(NO3)2 x 2.5 H2O [140] 
Zr-fum Fumaric acid ZrCl4 [129] 
 
2.8 Oligomer and peptide synthesis 
Sequence-defined oligomers were synthesized by Dr. Dongsheng He, Dr. Edith 
Salcher, Dr. Claudia Scholz and Philipp Klein as has been described in [50, 51, 53, 
141-143]. The oligomers including their exact sequence are listed in Table 5. 
A6/H6-Acr (Acridine-PEG28-A6/H6-NH2), H6-CF, H6-A647N, H6-Tf and 6-azido-
hexanoic acid were synthesized by Dr. Ulrich Lächelt (Pharmaceutical Biotechnology, 
LMU München), H0/3/6-Acr (Acridine-STOTDA-H0/3/6/) were synthesized by Benjamin 
Steinborn (Pharmaceutical Biotechnology, LMU München).  
H6-Bad, H6-KLK, H6-Bak were synthesized on TentaGel S RAM (C-terminal amide) 
using an automated Syro Wave or semi-automated Initiator+ SP Wave Peptide 
Synthesizer (Biotage, Uppsala, Sweden). Syringe microreactors were obtained from 
Multisyntech GmbH (Witten, Germany).The peptides were sequentially assembled 
from C- to N-terminus under standard Fmoc solid phase peptide synthesis conditions. 
Automated synthesis using the Syro Wave was carried out with HBTU as activating 
reagent and double-coupling steps. Semi-automated synthesis with the Initiator+ SP 
Wave and manual coupling steps were carried out with Pybop as activating reagent. 
Coupling steps were carried out using 4 eq Fmoc L-amino acid (relative to free resin-
bound amines), 4 eq HOBt, 4 eq activating reagent and 8 eq DIPEA in NMP – DMF 6 
: 4 (7 mL per g resin) and 10 min incubation at room temperature. Fmoc deprotection 
was accomplished by 4 x 10 min incubation with 20 % piperidine in DMF (10 mL per 
g resin) at room temperature. After each coupling and deprotection step a washing 
procedure comprising 5 x 1 min DMF incubation (10 mL per g resin) was carried out. 
Finally, all peptides were cleaved off the resin by incubation with TFA–TIS–H2O 
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95 : 2.5 : 2.5 (10 mL per g resin) for 90 min at room temperature. In case of intense 
yellow color of collected cleavage solution, TIS was added in small portions until 
decolorization occurred.  
The cleavage solution was concentrated by evaporation under nitrogen stream and 
peptides were precipitated in 50 mL pre-cooled MTBE (2-methoxy-2-methylpropane) 
– n-hexane 1 : 1. All peptides were purified by size exclusion chromatography (SEC) 
using an Äkta purifier system (GE Healthcare Bio-Sciences AB, Sweden) based on a 
P-900 solvent pump module, a UV-900 spectrophotometrical detector, a pH/C-900 
conductivity module, a Frac-950 automated fractionator, a Sephadex G-10 column 
and 10 mM hydrochloric acid solution – acetonitrile 7 : 3 as solvent. All peptides were 
lyophilized after SEC resulting in hydrochloride salts of the peptides. The compounds 
were analyzed by matrix-assisted laser desorption/ionization mass spectrometry 
(MALDI-MS, 2.10.2). The peptides were used without further purification. 
 
2.9 Synthesis of AzMMMan linker 
The AzMMMan linker was synthesized as has previously been described by Beckert 
et al. [107]. 
 
2.9.1 Synthesis of 3-(bromomethyl)-4-methyl-2,5-furandione (BrMMan) 
Dimethylmaleic anhydride (DMMan) (5.04 g, 39.97 mmol), N-bromosuccinimide 
(4.56 g, 25.62 mmol), and benzoyl peroxide (64 mg, 0.36 mmol) were dissolved in 
250 mL carbon tetrachloride (dried over molecular sieve UOP Type 3A). This mixture 
was gently refluxed under nitrogen for 5 h in a 500 mL round-bottom flask at 110-
120 °C. Afterwards the reaction mixture was allowed to cool to room temperature and 
an additional amount of benzoyl peroxide (64 mg, 0.36 mmol) was added. The 
refluxing was continued for 5 h. After cooling to room temperature the residue was 
filtered and washed two times with 25 mL carbontetrachloride (dried over molecular 
sieve UOP Type 3A). Subsequently, the organic phase was washed two times with 
water (100 mL) and one time with brine (100 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo to result in a yellow oil (DiBrMMan : BrMMan : 
DMMan; 1 : 10 : 4).  
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To remove the benzoyl peroxide, this oil was first purified by chromatography on a 
silica gel column (0.035-0.07 mm, 60A) and eluted with a mixture of petroleum 
ether/ethyl acetate (8:2) (DiBrMMan : BrMMan : DMMan; 0.3 : 10 : 4) . 
Finally the residue was distilled with the help of a kugelrohr apparatus under vacuum. 
First DMMan was removed at 110-120 °C, 7 mbar. DMMan might be recovered and 
reused. The second fraction destilling at a temperature of 140 °C, 7 mbar contained 
BrMMan (1.8 g, yield 22%). Di-(bromomethyl)-1,5-furandione (DiBrMMan) was left in 
the still pot.  
BrMMan: 1H NMR (400 MHz, CDCl3) 4.17 (s 2H), 2.17 (s 3H).  
DiBrMMan: 1H NMR (400 MHz, CDCl3) 4.27 (s 4H) 
DMMan: 1H NMR (400 MHz, CDCl3) 2.07 (s 6H) 
 
2.9.2 Synthesis of 3-(azidomethyl)-4-methyl-2,5-furandione (AzMMMan) 
3-(bromomethyl)-4-methyl-2,5-furandione (310.5 mg, 1.5 mmol) was dissolved in 
10mL acetone (dried over molecular sieve UOP Type 3A). Sodium azide (97.5 mg, 
1.5 mmol) was added in one portion. The suspension was stirred for 24 h at 37 °C. 
After filtering the solvent was evaporated. The remaining oil was dissolved in ethyl 
acetate (20 mL) and washed two times with water (20 mL). Afterwards the organic 
layer was washed with 20 mL brine and dried over Na2SO4. The liquid was 
concentrated in vacuo to result in a brown oil. (222 mg, yield 88 %). 
1H NMR (400 MHz ,CDCl3) 4.29 (s, 2H), 2.22 (s, 3H).  
IR νmax 2101, 1759, 1679 cm-1.  
 
2.10 Analytics 
2.10.1 1H-NMR 
1H-NMR spectra were recorded at room temperature using a Jeol JNMR-GX 400 
(400 MHz) or JNMR-GX 500 (500 MHz). Chloroform-d (CDCl3) was used as solvent. 
5 mg sample were used per measurement. Chemical shifts were calibrated to the 
residual proton signals of the solvent and are reported in ppm. Data is indicated with 
s = singlet. Spectra were analyzed using MestReNova (Mestrelab Research).   
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2.10.2 Mass spectroscopy 
The compounds were analyzed by matrix-assisted laser desorption/ionization mass 
spectrometry (MALDI-MS) using 2,5-dihydroxybenzoic acid matrix and an Autoflex II 
mass spectrometer (Bruker Daltonics, Bremen, Germany).  
 
2.11 Heterologous protein expression and purification 
2.11.1 Cloning of H6-luciferase expression plasmid 
The plasmid containing the firefly luciferase gene (pEGFPLuc) was obtained from 
Clontech (USA). After transformation of the plasmid into DH-5α, amplification and re-
purification, the coding region of the plasmid was amplified using the following 
primers, carrying a HindIII and EcoRI restriction side and a standard PCR Protocol 
(denaturation: 4 min 95 °C, 30 cycles: 95 °C, 30 sec; 56 °C 30 sec; 68 °C 2 min; final 
extension: 68 °C 4 min; hold: 4 °C) 
eGFP1:  5'-CCGGAATTCATGGTGAGCAAGGGCGAGG-3' 
Luc2:     5'-CCCAAGCTTTTACACGGCGATCTTTCCGC-3' 
Using HindIII and EcoRI, this gene was cloned into a pET-28a vector (Novagen, 
Merck Millipore, Germany), following the pET System Manual 11th Edition. The 
resulting protein should carry a His-tag at the N- and C-terminus. 
The resulting plasmid was verified by restriction digest using EcoRI and Hind III. 
 
2.11.2 Green fluorescent protein (GFP) and luciferase 
Recombinant green fluorescent protein containing a His-tag (H6-GFP) was expressed 
and purified as has been described previously [54].  
The H6-luciferase expression plasmid was transformed into RosettaBL21(DE3)pLysS 
(MerckMillipore, Germany), following the standard transformation protocol 
(Novagen®, User Protocol TB009 Rev. H 0211JN). 
BL21(DE3)plysS (H6-GFP) or RosettaBL21(DE3)plysS (H6-luciferase) were grown in 
LB Medium at 37 °C with shaking (H6-luciferase: 15 µg/mL kanamycin, 34 µg/mL 
chloramphenicol; H6-GFP: 100 µg/mL ampicillin, 50 µg/mL chloramphenicol) until an 
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optical density of 0.4-0.6 (600 nm). Afterwards the bacteria were cooled to room 
temperature (RT), protein expression was induced by adding 0.5 mM IPTG and they 
were incubated at 25 °C with shaking over night. Bacteria were harvested by 
centrifugation (30 min, 4000 x g, 4 °C). The supernatant was discarded and the pellet 
was resuspended in Lysis buffer (Table 2). RNase at a final concentration of 
10 µg/mL, DNase at a final concentration of 30 µg/mL, lysozyme at a final 
concentration of 1 mg/mL and 1 mM PMSF were added. The solutions were frozen 
and thawed and sonicated (3 x 20 sec on ice, full power). The bacterial lysate was 
ultracentrifuged (1 h, 20000 rpm, 4 °C) and filtered using a 0.45 µm syringe filter.  
The proteins were purified by nickel chromatography using a gradient from binding 
buffer (PBS pH 7.4, 20 mM imidazole) to elution buffer (PBS pH 7.4, 500 mM 
imidazole). Afterwards, the proteins were subjected to size exclusion chromatography 
(Sephadex G25 super fine size exclusion column) using PBS pH 7.4 as mobile phase 
for buffer exchange to remove the extend of salt. Finally the proteins were 
concentrated with Amicon Ultra centrifugal filter units (MWCO=10 kDa (H6-GFP); 
MWCO=30 kDa (H6-luciferase), Millipore, USA) and stored at -20 °C. The amount of 
purified protein was quantified using a Nanodrop (Thermo Scientific, Massachusetts, 
USA) and an ɛ(H6-GFP)= 21890 M
-1cm-1; 26.9 kDa or an ɛ(H6-luciferase)= 37200 M
-
1cm-1; 63 kDa. 
 
2.11.3 GFP- and lamin nanobody 
GFP- or lamin nanobody (α-GFP-Nb or α-lamin-Nb) have been expressed and 
purified, similar to the purification of H6-GFP and H6-luciferase (2.11.2), as has been 
described elsewhere [63, 64]. Instead of lysis buffer, PBS pH 7.4 (500 mM NaCl, 
20 mM imidazole, 2 mM PMSF) was used. After freezing, lysozyme at a final 
concentration of 100 µg/ mL and DNase I at a final concentration of 25 µg/mL were 
added. The bacteria lysate was incubated for 1 h at 4 °C under agitation, followed by 
sonication, ultracentrifugation and purification as has been described above. The 
amount of purified nanobody was quantified using a Nanodrop (Thermo Scientific, 
Massachusetts, USA) and ɛ= 27.000 M-1cm-1. 
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2.12 Modification of proteins with dyes, linkers or functional units 
2.12.1 Modification of nanobodies with Atto647N 
α-GFP-Nbs or α-lamin-Nbs were diluted in PBS (pH 8.0) to a concentration of 
1 mg/ml (0.08 µmol/mL). Atto647N was solubilized in DMSO (10 mM) and 0.2 molar 
equivalents were added to the protein solution. The mixture was incubated under 
constant stirring for 3 h at 37 °C. Uncoupled dye was removed by size exclusion 
chromatography (Äkta purifier system GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden) via a Sephadex G25 column using PBS (pH 8.0) as a mobile phase. The 
purified protein-dye conjugate was concentrated using Amicon Ultra centrifugal filter 
units (MWCO=10 kDa, Millipore, USA). Protein concentration was determined 
spectrophotometrically (NanoDrop 2000 Spectrophotometer, Thermo Scientific) using 
an extinction coefficient of 27.000 M-1cm-1. The purity of the protein- dye conjugate 
was confirmed on SDS-PAGE. 
 
2.12.2  Modification of nanobodies with fluorescein isothiocyanate 
α-GFP-Nbs or α-lamin-Nbs were diluted in PBS to a concentration of 2 mg/mL 
(0.16 µmol/mL). Fluorescein isothiocyanate (FITC) was solubilized in DMSO (13 mM) 
and 0.2 molar equivalents were added to the protein solution. The mixture was 
incubated under constant stirring for 4 h at 37 °C. Uncoupled dye was removed by 
size exclusion chromatography (Äkta purifier system GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden) via a Sephadex G25 column using PBS (pH 7.4) as a mobile 
phase. The purified protein-dye conjugate was concentrated using Amicon Ultra 
centrifugal filter units (MWCO=10 kDa, Millipore, USA). Protein concentration was 
determined spectrophotometrically (NanoDrop 2000 Spectrophotometer, Thermo 
Scientific) using an extinction coefficient of 27.000 M-1 cm-1. 
 
2.12.3 Modification of cytochromeC with His-tag 
CytochromeC (CytC) from equine heart was solubilized in PBS (20 mg/mL) and a 
DBCO-PEG4-NHS ester was solubilized in DMSO (50 mg/mL). One molar equivalent 
of linker was added to the protein solution and incubated for 3 h at 37 °C with 
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shaking. Non coupled linker was removed by size exclusion chromatography using 
an Äkta purifier system (GE Healthcare Bio-Sciences AB, Uppsala, Sweden), a 
Sephadex G25 super fine size exclusion column and PBS pH 7.4 as mobile phase. 
Afterwards four molar equivalents of H6-azide were added to the DBCO modified 
CytC (3.56 mg/mL) and the mixture was incubated for 3 h at 37 °C. Non modified 
CytC was removed by nickel chromatography using an Äkta purifier system (GE 
Healthcare Bio-Sciences AB, Uppsala, Sweden), PBS (pH 7.4, 500 mM NaCl, 20 mM 
Imidazole) as binding buffer and PBS (pH 7.4, 500 mM NaCl, 500 mM imidazole) as 
elution buffer, followed by size exclusion chromatography (Sephadex G25 super fine 
size exclusion column) using PBS (pH7.4) as mobile phase to remove non coupled 
H6-azide and for buffer exchange. The purified protein was concentrated using 
Amicon Ultra centrifugal filter units (MWCO=10kDa; Millipore, USA). The modified 
CytC is called H6-CytC in the thesis. 
 
2.12.4  Modification of H6-GFP with AzMMMan 
AzMMMan was dissolved in ACN (0.1 mg/mL). H6-GFP was diluted in Hepps pH 8.0 
at a final concentration of 10 mg/mL. The two solutions were mixed at a molar ratio of 
GFP to AzMMMan 1:200; 1:8 if calculated on the free terminal amino groups, as GFP 
has 25 lysines. The mixture was incubated for 2 h at 25 °C with shaking. To remove 
non-bound AzMMMan the protein solution was subjected to size exclusion 
chromatography (Sephadex G25 super fine size exclusion column) usingPBS 
(pH 8.0) as mobile phase. Afterwards, the purified H6-GFP-AzMMMan was 
concentrated with Amicon Ultra centrifugal filter units (MWCO = 10 kDa, Millipore, 
USA) and stored at -20 °C. 
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2.12.5 Modification of H6-GFP-AzMMMan with DBCO-K-H6-K(H6-DBCO)2 (1070) 
H6-GFP-AzMMMan was diluted in PBS pH 8.0 (0.33 mg/mL). After dilution of DBCO-
K-H6-K(H6-DBCO)2 (1070) in ACN at final concentration of 2.5 mg/mL it was added to 
the H6-GFP-AzMMMan solution and incubated for 3 h at 37 °C (molar ratio of H6-
GFP-AzMMMan : 1070 of 1:1. The H6-GFP-AzMMMan-1070 conjugate was stored at 
-20 °C and used without any further purification. 
 
2.12.6 Preparation of nanobody/oligomer formulations 
Nanobodies were formulated with oligomers (Table 5) at a molar ratio of 1:5. Different 
oligomer amounts were diluted in HEPES buffer (pH 8.0) and the pH was adjusted 
with NaOH (1 M) to pH 8.0. Afterwards the dye modified nanobody was added to a 
final concentration of 0.5 mg/mL (0.04 µmol/mL). The mixture was incubated for 4 h 
with shaking at 37 °C and used for further experiments. 
 
2.13 Preparation of MOF suspensions in HBG 
MOF suspensions in HBG were always freshly prepared prior to performing the 
experiment. The necessary amount of MOF material in ethanol was centrifuged 
(10 min, 10.000 rpm), followed by carefully inverting the tubes and gently tapping 
them on a paper towel in order to get rid of the ethanol supernatant without damaging 
the MOF-pellet. The MOF pellet was then resuspended in HBG at a final 
concentration of 5 or 10 mg/mL by continuous pipetting, followed by 10 min 
sonication. 
 
2.14 Modification of functionalized MOFs with different lipids  
2.14.1 Micelle formation 
100 µg MOFs were incubated with 2.5 nmol His-tag in a final volume of 1 mL HBG 
buffer for 15 min at room temperature, followed by centrifugation for 5 min at 
13.000 rpm. Afterwards, micelle encapsulation was carried out as has been 
described in [86]. The supernatant was removed, and the functionalized MOFs were 
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resuspended in 10 µL DOPC solution (2.4), which was sonicated for 5 sec before 
usage. The MOF/DOPC mixture was sonicated for further 3-5 min until obtaining a 
homogenous solution. Afterwards 100 µL H2O were added really fast, the solution 
was mixed thoroughly and used for further experiments. 
 
2.14.2 Addition of lipids 
MOFs were functionalized with His-tags at a final concentration of 7.3 mol His-tag/mg 
MOF per 333 µL HBG buffer for 15 min at room temperature. Afterwards definite 
amounts of a DOPC or DOPE solution were added. If a mixture of both solutions was 
added, the two solutions were mixed prior to usage. Afterwards the mixture was filled 
up to a final MOF concentration of 1 mg MOF/3333 µL HBG buffer and used for 
further experiments. 
 
2.15 Ellman’s assay 
The oligomers to be measured were diluted in 30 µL HBG and 170 µL working 
solution (2.44 mL Ellman‘s buffer (Table 2) and 60 µL DTNB solution (c= 4 mg/mL in 
Ellman‘s buffer) were added. The mixture was incubated for 15 min at 37 °C with 
shaking and absorption (412 nm) was measured using a GENESYS UV-VIS 
spectrophotometer (Thermo Scientific, Massachusetts, USA). The concentration of 
free cysteines was calculated using a calibration curve, based on free cysteine. The 
percentage of free mercapto groups was calculated on the theoretical amount 
(100 %) of cysteines being present in the oligomer solution. 
 
2.16 Inhibition of disulfide formation via NEM blocking 
The oligomer solution was diluted in HEPES to a final concentration of 2 mg/mL, 
adjusted to a pH of 7.0 with NaOH (1 M) and reacted with a tenfold molar excess of 
N-ethylmaleimid (NEM), calculated on the amount of cysteines, for 2 h. Subsequently 
free NEM was reacted with a 20-fold molar excess of N-acetylcysteine for 2 h. The 
oligomer solutions were purified by size exclusion chromatography (Äkta purifier 
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system GE Healthcare Bio-Sciences AB, Uppsala, Sweden) via a Sephadex G10 
column using acetonitrile/H2O (7/3) (10 mM HCl) as a mobile phase. 
 
2.17 Investigation of pH dependent binding of H6-tags to Zr-fum over a 
longer period 
This experiment has been carried out by Benjamin Steinborn (Pharmaceutical 
Biotechnology, LMU München). A 10 mg/mL Zr-fum stock solution in HBG (pH 7.4) 
was prepared as described above (2.13). In order to evaluate the stable binding and 
extent of acidic release of His-tags and Zr-fum MOF NPs over a longer period, Zr-fum 
NPs in HBG were loaded with H6-A647N. 50 μL of the freshly prepared Zr-fum NPs 
were diluted in ~500 μL HBG pH 7.4 (depending on the amount of HCl added to the 
sample in the next step), followed by addition of 4 μL 1 mM H6-A647N. The HBG 
volume therefore slightly varied in order to always allow for equal final sample 
volumes of 500 μL. Samples were briefly vortexed and incubated under agitation for 
15 min (25 °C, 600 rpm, light protection).  
Afterwards, samples were acidified to pH 3, pH 5 and pH 7.4 by addition of 9.2 μL, 
4.5 μL or 0 μL 1 M HCl respectively. After 0.5 h, 3 h and 24 h, the respective samples 
were centrifuged (5 min, 14.000 rpm). The presence of free dye in the supernatant 
was determined photometrically at 646 nm (n=3). Independent samples were used 
for each time point. 
 
2.18 Zeta potential measurements of MOF nanoparticle functionalization 
3 nmol H6-Acr or A6-Acr were diluted in HBG buffer. In case of pro-apoptotic peptides 
and CytC 5 nmol were used. 100 μg MOF NPs were added (final volume 30 μL) and 
samples were incubated at room temperature for 15 min with shaking. Shortly before 
the measurement in a folded capillary cell (DTS1070), samples were diluted to a final 
MOF concentration of 0.1 mg/mL. Zeta potential was measured by electrophoretic 
laser-light scattering using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, U.K.). Zeta potentials were calculated by the Smoluchowski 
equation, each sample was measured 3 times with 10 to 30 subruns at 25 °C. 
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2.19 Fluorescence correlation spectroscopy (FCS) and fluorescence 
cross-correlation spectroscopy (FCCS) 
2.19.1 Measurements of nanobody/oligomer mixtures 
FCS measurements were carried out together with Dr. Tobias Preiß (Faculty of 
Physics, LMU München). To permit measurements at the same nanobody/oligomer 
concentrations which were used for cell experiments, non-modified nanobody was 
spiked with 1 % A647N-labeled nanobody. Afterwards nanobody/oligomer 
formulations were prepared as described above and diluted 1 : 1 to the same 
concentration as subsequently was put on cultured cells. Nanobody or 
nanobody/oligomer formulations (at a molar ratio of 1 : 5) were measured at a final 
nanobody concentration of 0.25 mg mL-1 (0.02 µmol mL-1) in HEPES buffer (pH 7.4). 
The measurements were conducted on a ConfoCor2 setup (Zeiss Germany) using a 
40× NA1.2 water immersion objective (Zeiss Germany) that focuses the exciting laser 
light (633 nm) into the sample. Fluorescence fluctuations of labeled molecules 
diffusing through the focal spot were recorded by an avalanche photodiode and 
correlated with the correlation function G(τ) = (⟨F(t)F(t + τ)⟩)/⟨F⟩2 – 1. To derive the 
hydrodynamic radius of nanobody/oligomer formulations, correlation curves were 
fitted using two component fit were the first component was fixed to the diffusion time 
of freely diffusing nanobodies.  
 
2.19.2  Measurements of functionalized MOFs 
FCS and FCCS measurements were carried out by Dr. Tobias Preiß (Faculty of 
Physics, LMU München). The non-fluorescent MOF nanoparticles are not detectable 
by the FCS unless fluorescently labeled His-tags are attached to the nanoparticles. 
Thus a shift to higher diffusion times of correlation curve after addition of NPs to 
fluorescently labeled His-tags certifies the binding of His-tags to NPs surface. 
Normalization of autocorrelation curves helps to clearly visualize that the 
autocorrelation function of the MOF/His-tag is shifted towards higher correlation times 
with respect to the free His-tag molecules. Dual-color fluorescence cross-correlation 
spectroscopy (FCCS) allows for a comparison between spectrally separated 
channels to extract codiffusion events that reflect interactions between differently 
labeled molecules [144, 145].  
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For FCS and FCCS measurements, an Axiovert 200 microscope with a ConfoCor 
2unit (Carl Zeiss, Jena, Germany) equipped with a 40x (NA 1.2) water immersion 
apochromat objective (Carl Zeiss) was used. A helium neon laser (633 nm) and for 
FCCS additionally an argon laser (488 nm) was used for illumination. Samples were 
measured in eight-well LabTekchamber slides (Nunc, Rochester, NY). If nothing else 
mentioned, measurements were performed in HBG (pH 7.4) at a temperature of 
22.5 °C. Correlation was performed using ConfoCor 2 software.  
 
2.19.2.1 Investigation of functionalization of MOFs with H6-A647N by FCS 
200 μL of H6-A647N in HBG (pH 7.4) were measured in a 8-well chamber slide 
(Nunc™ Lab-Tek™ II) prior to and after addition of 2 μL of MOF stock solution.  
The hydrodynamic radius of H6-A647N was found to be RH
H6A647N = 2 nm (DH6A647N = 
120 μm²/s). A two-component analysis (taking into account that part of His-tag 
molecules are not bound) resulted in an apparent diffusion time of 3.5 ms which 
corresponds to a hydrodynamic radius of Zr-fum/H6-A647N of RH
Zr-fum/H6A647N = 56 nm 
and a diffusion constant DZr-fum/H6A647N = 4.1 μm²/s (using finite size correction 
according to Wu et al. [146]).  
 
2.19.2.2 Investigation of acidic release of H6-A647N from Zr-fum by FCS 
Investigation of the acidic release of H6-A647N from Zr-fum nanoparticles by FCS  
The Zr-fum/H6-A647N solution was prepared as described above and acidified by the 
addition of 3 μL of HCl (1 M) / 200 μL sample. The two-component analysis provides 
a fraction of the fast diffusing species (His-tag molecules) of 50 %. As the curve is 
biased by agglomerates this value is just a rough estimation. But by comparison with 
the autocorrelation function in neutral environment the separation of His-tag in acidic 
environment is evident, providing an indication of pH-dependent detachment of His-
tags from MOF nanoparticles.   
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2.19.2.3 Investigation of the influence of serum on Zr-fum/H6-A647N stability by 
FCS 
As described above, Zr-fum nanoparticles were functionalized with H6-A647N in HBG 
at pH 7.4. Subsequently the coated NPs were diluted in Dulbecco's Modified Eagle's 
Medium (DMEM) containing 10 % FBS. To confirm the results, the same experiment 
was repeated but replacing the NP suspension by pure HBG as a control. H6-A647N 
in HBG at pH 7.4 was diluted with DMEM (10 % FBS). The ensuing FCS 
measurements showed the same fast decay as before for H6-A647N in HBG at 
pH 7.4, proving that H6-A647N is not clustering/agglomerating in DMEM (10 % FBS).  
 
2.19.2.4 Fluorescence cross-correlation spectroscopy 
FCCS analysis was performed in order to confirm the co-localization of two proteins 
(H6-GFP and H6-Tf*) at the nanoparticles surface. 100 μL of a 60 nM H6-GFP solution 
in HBG (pH 7.4) and 100 μL of a 50 nM H6-Tf* solution in HBG (pH 7.4) were mixed 
in a 8-well chamber slide and measured prior to and after addition of 2 μL of MOF 
stock solution.  
 
2.20 Cell experiments 
2.20.1 Cell fixation and staining 
Cells were seeded in 8-well Nunc chamber slights (Thermo Scientific, Germany) at a 
density of 12.000 cells/well. In case of KB_wt cells, wells were coated with collagen A 
prior to seeding. After 24 h incubation at 37 °C and 5 % CO2 in a humified incubator, 
medium was removed and cells were washed with PBS (pH 7.4). 4 % (w/v) cold 
paraformaldehyde solution was added and cells were incubated for 10 min at room 
temperature with shaking. Cells were washed three times with PBS (pH 7.4) 
containing 0.1 % Tween 20 (PBST). Afterwards cells were permeabilized for 5 min by 
adding PBS (pH 7.4) containing 0.5 % Triton X-100. Cells were washed twice with 
PBST and incubated for 10 min in blocking solution (PBST containing 4% (w/v) 
bovine serum albumin). Atto647N labeled α-GFP-Nb or α-lamin-Nb were diluted in 
blocking solution (7 µg/mL) and incubated on the cells for 45 min at room 
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temperature. Cells were washed three times for five minutes with PBST and stored at 
4 °C. 
 
2.20.2 Screening of different oligomers for nanobody delivery 
Nanobody was always formulated with oligomer at a molar ratio of 1:5. Different 
oligomer amounts were diluted in HEPES buffer (pH 8.0) and the pH was adjusted 
with NaOH (1 M) to pH 8.2. Afterwards the dye modified nanobody was added to a 
final concentration of 0.5 mg/mL (0.04 µmol/mL). The mixture was incubated for 4 h 
with shaking at 37 °C. For the screening experiment, cells were seeded in 96-well 
plates (Greiner bio-one) at a density of 4.000 cells/well. In case of KB_wt cells, wells 
were coated with collagen A prior to seeding. After 24 h medium was replaced with 
80 µL fresh, serum-containing folate free RPMI medium. The various samples were 
added into each well at a final concentration of nanobody of 1.5 µM or 3.6 µM and 
incubated in case of targeted oligomers for 1 h at 37°C. Medium was removed and 
cells were incubated for 18 h in fresh serum containing folate free RPMI medium. 
Mixtures containing non-targeted oligomers were incubated for 15 h on the cells 
followed by 4 h incubation in fresh medium. Medium was replaced with PBS (pH 7.4) 
and cells were imaged using PerkinElmer Operetta® High Content Imaging System 
(Germany).  
 
2.20.3 Luciferase assay 
10.000 KB_wt cells/well were seeded in collagen A coated 96 well plate (PS 
Microplatte 96 well F Boden µClear TC weiß, Greiner, Frickenhausen, Germany) and 
grown in medium containing 10 % FBS for 24 h at 37 °C, 5 % CO2 in a humified 
incubator. After 24 h the cell culture medium was replaced with 80 µL fresh medium 
and different samples were added. Cells were incubated for further 24 h at 37 °C, 
5 % CO2 in a humified incubator.  
To measure intracellular delivered H6- luciferase, cells were washed with PBS 
(pH 7.4) and PBS (pH 7.4) containing 0.5 mM D-luciferin was added. 
To measure the extracellular luciferase signal, cells were washed with PBS (pH 7.4) 
and 100 µL LAR buffer (Table 2) were added to the cells.  
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To measure luciferase signal of intra- and extracellular H6-luciferase, cells were 
treated with 100 μL cell culture lysis reagent (Promega, Mannheim, Germany) and 
incubated for 30 min at RT. The luciferase activity in the cell lysate was measured 
using the luciferase assay kit (Promega, Mannheim, Germany). 
For all three different cases, the luciferase signal was always determined using a 
Centro LB 960 plate reader luminometer (Berthold Technologies, Bad Wildbad, 
Germany). 
 
2.20.4 Cell viability assay (MTT assay) 
Setup A) Nanobody experiments. Cells were seeded in 96-well plates at a density of 
6.000 cells/well. In case of KB_wt cells, wells were coated with collagen A prior to 
seeding. Samples were prepared as described above. After 24 h medium was 
replaced with 80 µL of fresh medium containing 10 % FBS. Samples were diluted 1:1 
with HEPES buffer (pH 8.0) (0.02 µmol/mL), 20µL of each sample were added to 
each well (final protein concentration 3.6 µM) and incubated on cells for 1 h at 37 °C 
and 5 % CO2. Afterwards medium was replaced with fresh serum containing folate 
free RPMI medium and cells were incubated for 18 h.  
Setup B) MOF experiments. Cells were seeded in 96-well plates at a density of 4.000 
cells/well. After 24 h medium was replaced with 80 µL of fresh medium. The 
appropriate amount of compound to be tested was diluted in HBG (pH 7.4) and 20 µL 
of each sample/well were added. Cells were incubated for 48 h at 37 °C and 5 % CO2 
in a humified incubator. 
A) and B) Afterwards the MTT assay was performed for both experimental setups in 
the same way. 10 μL of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) (5 mg/mL) were added to each well reaching a final concentration of 
0.5 mg/mL. After an incubation time of 2 h, unreacted dye and medium were 
removed and the 96-well plates were frozen at −80 °C for at least 30 min. To dissolve 
the purple formazan product 100 μL DMSO were added per well and the plate was 
incubated for 30 min at 37 °C with shaking. The wells were quantified by measuring 
absorbance at 590 nm with background correction at 630 nm using a microplate 
reader (TecanSpectrafluor Plus, Tecan, Switzerland). All studies were performed in 
quintuplicates. The relative cell viability (%) related to control wells treated only with 
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20 μL buffer (specified in the results sections) was calculated as ([A] test/[A] control) 
× 100 %. 
 
2.20.5 Fluorescence microscopy 
Cells were seeded in 96-well plates (Greiner bio-one) at a density of 4.000 cells/well. 
In case of KB_wt cells, wells were coated with collagen A prior to seeding. After 24 h 
medium was replaced with 80 µL fresh, serum-containing folate free RPMI medium. 
Then the various Atto647N labeled samples were prepared as described above, 
added into each well and incubated in case of targeted oligomers for 1 h at 37°C. 
Medium was removed and cells were incubated for 18 h in fresh serum containing 
folate free RPMI medium. Mixtures containing non-targeted oligomers were 
incubated for 15 h on the cells followed by 4 h incubation in fresh medium. Medium 
was replaced with PBS and cells were imaged using PerkinElmer Operetta® High 
Content Imaging System (Germany). For time series experiments, medium was 
replaced with DMEM without phenol red supplemented with 10 % FBS, 100 U mL-1 
penicillin, 100 μg mL-1 streptomycin. Imaging was started either 1.5 h or 19 h after 
transduction. Cells were imaged for 2 h every 5 min followed by imaging every 
15 min for 22 h. 
 
2.20.6 Confocal microscopy 
2.20.6.1 Nanobody/oligomer formulations 
Cells were seeded in 8-well Nunc chamber slights (Thermo Scientific, Germany) at a 
density of 12.000 cells/well. In case of KB_wt cells, wells were coated with collagen A 
prior to seeding. After 24 h medium was replaced with 240 µL fresh, serum-
containing folic acid free RPMI medium. Then the various samples were prepared as 
described above, added into each well and incubated for 1 h at 37 °C. Medium was 
removed and cells were incubated for 18 h in fresh serum containing folate free RPMI 
medium. Medium was replaced by PBS (pH 7.4) and cells were imaged using a Leica 
TCS SP8 confocal microscope with an 63x DIC oil immersion objective (Plan-
Apochromat, Zeiss, USA).  
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2.20.6.2 Functionalized MOF nanoparticles 
Cells were seeded in 8-Well Nunc chamber slights (Thermo Scientific, Germany) at a 
density of 12.000 cells/well. Wells were coated with collagen A prior to seeding. After 
24 h medium was replaced with 240 μL fresh medium. The various samples were 
prepared as described above but in a final volume of 60 μL HBG (pH 7.4). 30 μg 
MOF NPs were functionalized with 0.3 nmol H6-CF or H6-GFP. In case of the co-
delivery experiment, 0.15 nmol H6-GFP were mixed with 0.15 nmol H6-Tf* before the 
addition of 30 μg Zr-fum MOF NPs. The mixtures were added to the cells and 
incubated for 24 h. In case of HKUST-1 MOF NPs, the medium was changed after 2 
h. Prior to imaging nuclei were stained with Hoechst dye. Medium was replaced by 
DMEM without phenol red supplemented with 10 % FBS, 100 U mL-1 penicillin, 
100 μg mL-1 streptomycin and cells were imaged using a Leica TCS SP8 confocal 
microscope with an 63x DIC oil immersion objective (Plan-Apochromat, Zeiss, USA). 
 
2.20.7 Determination of efficiencies of co-localization of nanobody and target 
protein 
To evaluate efficiencies of nanobody delivery leading to specific co-localization of 
nanobody and target protein, experiments were carried out as has been described 
above for the screening experiments. To determine efficiencies, at least 500 cells 
were imaged using PerkinElmer Operetta® High Content Imaging System 
(Germany). Cells in which specific co-localization of nanobody and target protein was 
visible were counted. The percentage of cells in which co-localization of nanobody 
and target protein occurred was calculated as follows: (Number of cells with co-
localization of nanobody and target protein / total number of cells ) x 100%. 
 
2.20.8 Flow cytometry 
2.20.8.1 Cellular uptake experiments of nanobody/oligomer formulations 
Cells were seeded in 24-well plates at a density of 30.000 cells/well. In case of 
KB_wt cells, wells were coated with collagen A prior to seeding. After 24 h medium 
was replaced with 400 µL fresh, serum-containing medium. For folic-acid competition 
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experiments, medium was changed to medium containing 100 µM folic acid, 30 min 
prior to the addition of the samples. The various samples were prepared as described 
above, diluted in HEPES buffer (pH 8.0) and 100 µL of the sample was added into 
each well at a final nanobody concentration of 3.6 µM and incubated for 1 h at 37 °C.  
Cells were put on ice, washed with PBS (pH 7.4), detached with trypsin/EDTA and 
diluted in cold PBS (pH 7.4) containing 10 % FBS. Cells were centrifuged and 
resuspended in PBS (10 % FBS, pH 4) to extinguish the outside fluorescence. The 
cellular fluorescence was assayed by excitation of fluorescein at 488 nm and 
detection of emission at 510 nm.  
For long-time uptake experiments, medium was changed after 1 h incubation at 
37 °C and cells were incubated for 18 h in fresh serum containing folate free RPMI 
medium. Cells were washed with PBS (pH 7.4), detached with trypsin/EDTA and 
diluted with fresh medium. After centrifugation the cells were taken up in PBS (10 % 
FBS, pH 7.4). The cellular fluorescence was assayed by excitation of Atto647N at 
635 nm and detection of emission at 665 nm.  
Cells were appropriately gated by forward/sideward scatter and pulse width for 
exclusion of doublets. DAPI (4′,6-diamidino-2-phenylindole) was used to discriminate 
between viable and dead cells. Data were recorded by Cyan™ ADP flow cytometer 
(Dako, Hamburg, Germany) using Summit™ acquisition software (Summit, 
Jamesville, NY) Gated cells (10.000 per sample) were collected. Analysis was done 
by FlowJo 7.6.5 flow cytometric analysis software. All experiments were performed in 
triplicates.  
 
2.20.8.2 Cellular uptake experiments of functionalized MOF NPs 
Cells were seeded in 24-well plates at a density of 20.000 cells/well. After 24 h, 
medium was replaced with 400 μL fresh medium. 0.5 nmol H6-CF or H6-GFP were  
diluted in HBG (pH 7.4), 50 μg MOF NPs (5 mg/mL in HBG) were added (final 
volume 50 μL) and the solution was strongly mixed. For the co-delivery of H6-GFP 
and H6-Tf* 0.25 nmol H6-GFP and 0.25 nmol H6-Tf* were pre-mixed in HBG (pH 7.4) 
before Zr-fum MOF NPs (5 mg/mL in HBG) were added (final volume 50 μL).  
The mixture was incubated for 15 min at room temperature, diluted 1:1 with HBG 
(pH 7.4) and added to the cells. Cells were incubated for 24 h at 37 °C and 5 % CO2 
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in a humidified incubator. In case of HKUST-1 MOF NPs, medium was changed after 
2 h.  
Cells were washed with PBS (pH 7.4), detached with trypsin/EDTA and diluted with 
fresh medium. Cells were centrifuged and resuspended in PBS containing 10 % FBS 
at pH 4 to quench extracellular fluorescence. The cellular fluorescence was assayed 
by excitation of fluorescein at 488 nm and detection of emission at 510 nm. For the 
co-delivery of H6-GFP and H6-Tf* the cellular fluorescence was also assayed by 
excitation of A647N at 635 nm and detection of emission at 665 nm.  
Cells were appropriately gated by forward/sideward scatter and pulse width for 
exclusion of doublets. DAPI (4′,6-diamidino-2-phenylindole) was used to discriminate 
between viable and dead cells. Data were recorded by Cyan™ ADP flow cytometer 
(Dako, Hamburg, Germany) using Summit™ acquisition software (Summit, 
Jamesville, NY). Gated cells (10.000 per sample) were collected. Analysis was done 
by FlowJo 7.6.5 flow cytometric analysis software. All experiments were performed in 
triplicates. Mean fluorescence intensity (MFI) was calculated by FlowJo 7.6.5 flow 
cytometric analysis software and is depicted as normalization to HBG. 
 
2.20.8.3 Determination of receptor status 
Estimation of folate receptor status 
Different cell lines were washed with PBS (pH 7.4), detached with trypsin/EDTA and 
diluted with fresh medium. Cells were centrifuged and resuspended in 100 µL PBS 
(10 % FBS, pH 7.4). Allophycocyanin (APC)-conjugated anti folic acid receptor 1 
IgG1 antibody (10 μL; R&D Systems, USA) or IgG1 (Dako, Germany) (1:100 dilution) 
as isotype control were added. Cells were incubated for 1 h on ice, washed twice with 
PBS (10 % FBS, pH 7.4) and resuspended in 500 µL PBS (10 % FBS, pH 7.4). The 
amount of folate receptor positive cells was analyzed through excitation of APC at 
635 nm and detection of emission at 665 nm. Cells were appropriately gated by 
forward/sideward scatter and pulse width for exclusion of doublets. DAPI (4′,6-
diamidino-2-phenylindole) was used to discriminate between viable and dead cells. 
Data were recorded by Cyan™ ADP flow cytometer (Dako, Hamburg, Germany) 
using Summit™ acquisition software (Summit, Jamesville, NY). Analysis was done by 
FlowJo 7.6.5 flow cytometric analysis software.   
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Estimation of transferrin receptor status 
HeLa_wt cells were washed with PBS (pH 7.4), detached with trypsin/EDTA and 
diluted with fresh medium. Cells were centrifuged and resuspended in 100 μL PBS 
(10 % FBS, pH 7.4). 1 μL mouse anti-hCD71 (Dako, Germany) (1:100 dilution) for 
detection of the transferrin receptor or IgG1 (Dako, Germany) (1:100 dilution) as 
isotype control were added, cells were incubated for 1 h on ice and washed twice 
with PBS (10 % FBS, pH 7.4). Cells were then stained with 0.5 μL Alexa Fluor 
488Goat Anti -Mouse IgG(H+L) (Life technologies) as secondary antibody (1:200 
dilution) for 1 h on ice, washed twice with PBS (10 % FBS, pH 7.4) and resuspended 
in 700 μL PBS (10 % FBS, pH 7.4). The cellular fluorescence was assayed by 
excitation at 488 nm and detection of emission at 510 nm. Cells were appropriately 
gated by forward/sideward scatter and pulse width for exclusion of doublets. DAPI 
(4′,6-diamidino-2-phenylindole) was used to discriminate between viable and dead 
cells. Data were recorded by Cyan™ ADP flow cytometer (Dako, Hamburg, 
Germany) using Summit™ acquisition software (Summit, Jamesville, NY). Analysis 
was done by FlowJo 7.6.5 flow cytometric analysis software. 
 
2.20.9 Endocytosis inhibition assay 
HeLa_wt cells were seeded in 24-Well plates at a density of 50.000 cells/well. After 
24 h, medium was replaced with 400 µL fresh medium containing the different 
endocytosis inhibitors, chlorpromazine (5 µM, 10 µM, 20 µM), amiloride (1 mM, 
2 mM, 5 mM) and genistein (100 µM, 150 µM, 200 µM). Cells were pre-incubated 
with the different inhibitors or at 4 °C for 30 min before addition of the H6-GFP/Zr-fum 
MOF NPs. 0.5 nmol H6-GFP were diluted in HBG (pH 7.4), 50 µg Zr-fum MOF NPs 
(5 mg/mL in HBG) were added (final volume 50 µL) and the solution was strongly 
mixed.  
The mixture was incubated for 15 min at room temperature, diluted 1:1 with HBG (pH 
7.4) and added to the cells. Cells were incubated for 2 h at 37 °C, 5 % CO2 or at 
4 °C. 
Cells were washed with PBS (pH 7.4), detached with trypsin/EDTA and diluted with 
fresh medium. Cells were centrifuged and resuspended in PBS containing 10 % FBS 
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at pH 4 to quench extracellular fluorescence. The cellular fluorescence was assayed 
by excitation of fluorescein at 488 nm and detection of emission at 510 nm. 
Cells were appropriately gated by forward/sideward scatter and pulse width for 
exclusion of doublets. DAPI (4′,6-diamidino-2-phenylindole) was used to discriminate 
between viable and dead cells. Data were recorded by Cyan™ ADP flow cytometer 
(Dako, Hamburg, Germany) using Summit™ acquisition software (Summit, 
Jamesville, NY). Five thousand gated cells per sample were collected. Analysis was 
done by FlowJo 7.6.5 flow cytometric analysis software. All experiments were 
performed in triplicates. Data is presented as % cellular uptake, of cellular uptake of 
Zr-fum/H6-GFP NPs at 37 °C.  
 
2.20.10 Delivery of pro-apoptotic peptides and cytochromeC 
Cells were seeded in 96-Well plates at a density of 4.000 cells/well. After 24 h, 
medium was replaced with 80 µL fresh medium. 1 nmol of H6-Bak, H6-Bad, H6-KLK 
or H6-CytC was diluted in HBG (pH 7.4), 20 µg Zr-fum MOF NPs were added 
followed by strongly mixing of the samples. Controls were performed without the 
addition of Zr-fum MOF NPs. The mixtures were incubate for 15 min at room 
temperature, diluted 1:1 with HBG (pH 7.4, final volume 20 µL), added to the cells 
and incubated for 48 h at 37 °C and 5 % CO2 in a humified incubator. Cell viability 
assay (MTT) was carried out as has been described above (2.20.4). 
 
2.21 Statistical analysis 
The statistical significances of experiments were analyzed using the t- test, **** 
p<0.0001, *** p<0.0003, ** p<0.001, * p<0.01. 
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3 Results 
3.1 Intracellular delivery of nanobodies for imaging of target proteins 
in live cells 
This chapter has been adapted from: 
Intracellular Delivery of Nanobodies for Imaging of Target Proteins in Live Cells. Ruth 
Röder, Jonas Helma, Tobias Preiß, Joachim O. Rädler, Heinrich Leonhardt, Ernst 
Wagner. Pharmaceutical Research (2017), 34(1):161-174. 
 
The following chapter describes the investigation of finding a potent carrier for the 
intracellular delivery of nanobodies for imaging of target proteins in live cells. 
Potential intracellular molecular targets can be accessed in fixed and permeabilized 
cells only. Intracellular protein delivery may expand possible applications of 
nanobodies for the treatment of live cells for bioimaging and functional biological or 
therapeutic purposes. Besides, labeling of proteins, prior to their delivery is possible, 
broadening the scope of dyes which can be used from intracellular expressed 
fluorescent proteins to any desired marker. 
For nanobody delivery, our investigations aimed at non-covalent interactions with 
oligomers for the following reasons. Due to the small nanobody size, covalent 
modification with dye and additional linkers appears to be problematic. 
Nanobodies have a conserved core sequence, providing the beta-sheet based 
barrel-like domain structure. Variation occurs mostly in their complementarity 
determining regions (CDRs), which are responsible for specific antigen recognition 
[147]. This results in very similar structures with only slightly modified properties from 
adapting to target other proteins or molecules of interest.  
When designing nanobody carriers directed towards target cells, various extra- and 
intracellular barriers have to be overcome. To ensure efficient nanobody delivery, the 
approach in the current work was to form stable nanoparticles by mixing nanobody 
with cationizable carrier oligomers.  
Taking advantage of the above described quite conserved structural characteristics, I 
have analyzed sixteen different sequence-defined cationic oligoaminoamides (Table 
5) [51, 141, 142, 148] from a library of more than 1000 oligomers for their potential to 
deliver nanobodies effectively into cells. I have investigated PEGylated as well as 
non-PEGylated carriers exhibiting different topologies. Carrier subunits comprise the 
diaminoethane building blocks Stp (succinoyl tetraethylene pentamine) or Sph 
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(succinoyl pentaethylene hexamine), and α,ε-amidated lysines as branching points. 
Optionally histidines as protonable buffering units or oleic acids to enhance 
endosomal escape, as well as cysteines which are supposed to serve for 
bioreversible crosslinkage of nanobody-bound oligomers, thus expected to stabilize 
the nanobody-oligomer network [50]. Ligand-PEG was included as functional 
shielding and cell targeting domain and glutamic acid as non-functional subunits. 
The schematic formulation strategy is shown in Figure 5.  
 
Figure 5: Schematic formulation strategy of nanobodies. a) After fluorescent labeling of the 
nanobody (I), the nanobody is mixed with a carrier oligomer leading to non-covalent interactions (II). b) 
The nanobody/oligomer nanoparticles are incubated with the cells leading to either receptor specific or 
non-specific cellular uptake (III). After endosomal escape and freeing from the oligomer (IV) the native 
nanobody can diffuse within the cell (V). In this scheme, diffusion into the nucleus and binding to focal 
PCNA-GFP as target structures in the nucleus is depicted (VI). Adapted from [59]. 
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In order to visualize its cellular uptake and localization as well as its interaction with a 
target protein the nanobody was first labeled with a dye (I) followed by mixing and 
incubating with an oligomer (II) to form stable nanoparticles (Figure 5a). Thereafter 
the nanobody/oligomer complexes were incubated with the cells (Figure 5b), resulting 
in both receptor dependent and - independent cellular uptake (III). After successful 
endosomal escape (IV) the nanobody diffuses to its target protein (V) which can be 
visualized upon binding of the labeled nanobody (VI). 
In the end, two related precise sequence-defined oligoaminoamide carriers (Figure 6) 
were found which are suitable to efficiently deliver different labeled nanobodies into 
cells. 
 
Figure 6: Structure of the 4-arm oligomers which showed the best delivery efficiency. 735 
containing folic acid (FolA) as targeting ligand and 734 comprising glutamic acid instead of a targeting 
ligand; Stp, succinoyl tetraethylene pentamine; Lys, Cys, amino acids L-lysine, L-cysteine. Adapted 
from [59]. 
 
3.1.1 Heterologous expression and purification of GFP binding nanobody 
and lamin-nanobody 
Both nanobodies (GFP binding nanobody (α-GFP-Nb) and lamin-nanobody (α-lamin 
Nb)) were expressed in Escherichia coli WK6 cells as has been described in [63, 64]. 
Given the fact that for the following delivery experiments quite a lot of nanobody was 
needed, expression and purification in larger scale was attempted. The purity of both 
nanobodies was investigated on SDS-gel after staining with Coomassie (α-GFP-Nb: 
Figure 7a; α-lamin-Nb: Figure 7b). Both nanobodies have a size of 13.7 kDa. 
From 10 L E. coli WK6 culture 25 mg pure α-GFP-Nb were obtained. In case of α-
lamin-Nb 30 mg were obtained from 4 L E.coli WK6 culture. Functionality of 
nanobodies was evaluated after modification with a dye (Atto647N NHS ester) by 
staining of their target proteins in different fixated cell lines (3.1.2). 
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Figure 7: Analysis of purified nanobodies. After purification of nanobodies from E.coli WK6 cells, 
different amounts of nanobody were separated on a SDS-PAGE and stained with Coomassie. a) 
Purified α-GFP-Nb from left to right, Protein Ladder (Precision Plus Protein Standard, Bio-Rad, USA), 
20 µg, 10 µg, 5 µg. b) Purified α-lamin-Nb from left to right, Protein Ladder (PEQ Lab Protein Marker 
III, Germany), 5 µg, 10 µg. 
 
3.1.2 Evaluation of nanobodies and their molecular targets 
For first general screening experiments, GFP was selected as a target protein. 
Delivery and binding of a α-GFP-Nb fused to a fluorescent protein - so called 
chromobodies [64] - to its target protein has recently been shown by Chiu et al. [149]. 
Furthermore, there are plenty of existing cell lines, where GFP has been fused to a 
variety of proteins with well-characterized subcellular localization, providing ―visible‖ 
antigens to directly test the delivery of α-GFP-Nb in different subcellular 
compartments [63, 70, 72]. Secondly, lamin was selected as an endogenous target 
protein. It is localized at the nuclear membrane. Therefore, binding of the labeled 
lamin binding nanobody (α-lamin-Nb) results in the visualization of the typical round 
nuclear rim structure. Interaction of intracellular expressed lamin-chromobody with 
lamin had already been shown in Drosophila melanogaster S2 and HeLa cells [64]. 
Both nanobodies were fluorescently labeled with NHS-Atto647N by coupling to 
primary amines, i.e. lysine residues and N-terminal amino acids, and purified (Figure 
8).  
As can be seen in Figure 8 both nanobodies show clear bands when stained with 
Coomassie. Upon imaging at a wavelength of 646 nm a thick band at the specific 
size of the nanobodies of 13.7 kDa is visible. The faint band around 25 kDa could be 
a result of dimerization of nanobodies. But as the detection at 646 nm is far more 
sensitive than the Coomassie staining and the additional band is just visible at 
646 nm it is negligible. 
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Figure 8: SDS-PAGE analysis of the modification of α-GFP-Nb (a) and α-lamin-Nb (b) with NHS-
Atto647N dye. Grey pictures, imaging of gels at a wavelenght of 646 nm using Typhoon (GE 
Healthcare). Blue pictures, imaging of Coomassie staining. a) 1: Atto647N-labeled α-GFP-Nb 2: α-
GFP-Nb without modification, 3: Protein Standard Broad Range (NEB); b) 4: Atto647N-labeled α-
lamin-Nb 5: α-lamin-Nb without modification, 6: Protein Standard Broad Range (NEB). Adapted from 
[59]. 
 
To investigate if the binding affinity of nanobodies was not affected by dye coupling, 
staining of fixated cells was performed with both labeled nanobodies and four 
different folate receptor expressing cell lines, HeLa_PCNA-GFP, HeLa_Actin-GFP, 
HeLa_Tubulin-GFP, and KB_wt cells (Figure 10), which were later on used for the 
protein delivery experiments.  
All cell lines were paraformaldehyde fixated and stained wih 0.5 µM Atto647N-
labeled α-GFP-Nb (Figure 9a-c) or 0.5 µM Atto647N-labeled α-lamin-Nb (Figure 9d) 
to demonstrate that the modification of primary amines i.e. lysine residues and N-
terminal amino acids of nanobodies with NHS-Atto647N does not affect specific 
binding to their target proteins.  
Applying labeled α-GFP-Nb, specific staining could be shown for all three different 
GFP-tagged proteins (Figure 9a-c) Staining of KB_wt cells with labeled α-lamin-Nb 
lead to specific staining of endogenous lamin (Figure 9d), confirming that nanobody 
activity was not affected by dye coupling. 
For the following screening experiments, amongst others, also oligomers targeted to 
the folate receptor should be used. Therefore the surface expression level of folic 
acid receptor in all used cell lines was investigated by flow cytometry using an 
Allophycocyanin (APC)-conjugated anti folic acid receptor 1 IgG1 antibody. 
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Figure 9: Staining of different paraformaldehyde fixated cell lines with Atto647N-labeled α-GFP-
Nb or  α-lamin-Nb. Paraformaldehyde fixated cell lines were stained wih 0.5 µM Atto647N-labeled α-
GFP-Nb (a-c) or 0.5 µM Atto647N-labeled α-lamin-Nb (d) to demonstrate that the modification of 
primary amines i.e. lysine residues and N-terminal amino acids of nanobodies with NHS-Atto647N 
does not affect specific binding to their target proteins. First column, GFP fluorescence of GFP tagged 
proteins; second column, Atto647N fluorescence of labeled α-GFP-Nb or labeled α-lamin-Nb; third 
column, nuclear staining with DAPI; fourth column, merge of all three channels. Scale bars: 25 µm. a) 
Staining of HeLa_PCNA-GFP cells with α-GFP-Nb. b) Staining of HeLa_Tubulin-GFP cells with α-
GFP-Nb. c) Staining of HeLa_Actin-GFP cells with α-GFP-Nb. d) Staining of KB_wt cells with α-lamin-
Nb. Adapted from [59]. 
 
Figure 10 shows enhanced expression of folic acid receptor in all different cell lines. 
KB_wt cells show the highest expression level (blue) followed by HeLa_PCNA-GFP 
cells (red). HeLa_Tubulin-GFP and HeLa_Actin-GFP cells show slightly lower 
expression levels. 
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Figure 10: Determination of the surface expression level of the folic acid receptor in different 
cell lines by flow cytometry. Control cells (dotted lines) were treated with isotype control, mouse 
IgG1. Allophycocyanin (APC)-conjugated anti folic acid receptor 1 IgG1 antibody was used for the 
detection of the folic acid receptor (solid lines). Blue, KB_wt; red, HeLa_PCNA-GFP; green, 
HeLa_Tubulin-GFP; orange, HeLa_Actin-GFP. Adapted from [59]. 
 
3.1.3 Screening of different oligomers for nanobody delivery 
Dye modified nanobody on its own does not diffuse into live cells, as it is shown in 
Figure 11. 
For effective delivery of α-GFP-Nb into living cells, cationizable oligomers from an 
existing library of cationic oligoaminoamides were screened (Table 5).  
All oligomers had been synthesized by solid-phase supported synthesis to gain well 
defined chemical structures and topologies. For the library screen, labeled α-GFP-Nb 
was mixed with different oligomers and incubated at 37 °C for 4 h to form non-
covalent nanobody/oligomer formulations as explained above. HeLa_PCNA-GFP 
cells [64, 138] exhibiting a nucleoplasmic epitope were used to investigate protein 
delivery efficiency. Cells were incubated with two different amounts of labeled α-
GFP-Nb/oligomer mixtures (final concentration of 1.5 µM and 3.6 µM nanobody). The 
formulations were prepared in HEPES buffer (pH 8.0) and incubated on cells in 
folate-free, but serum containing medium. Folate-free medium was used to ensure 
that folate receptors can be accessed by the folate targeted oligomers without folate 
competition. All nanobody/oligomer formulations were tested at molar ratios of 1:1, 
1:5 and 1:10. As the molar ratios of 1:1 and 1:10 did not lead to an as efficient 
cellular uptake, just the results of the 1:5 ratio are presented in this work. 
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Figure 11: Confocal laser scanning microscopy of live cells incubated with pure Atto647N-
labeled α-GFP-Nb or α-lamin-Nb. Different cell lines were incubated with 3.6 µM Atto647N-labeled α-
GFP-Nb (a-c) or α-lamin-Nb (d) for 18 h, followed by 4 h incubation in fresh media. First column, GFP 
fluorescence of GFP tagged proteins; second column, Atto647N fluorescence of α-GFP-Nb or α-lamin-
Nb; third column, nuclear staining with Hoechst dye; fourth column, merge of all three channels. Scale 
bars: 25 µm. a) HeLa_PCNA-GFP cells; b) HeLa_Tubulin-GFP cells; c) HeLa_Actin-GFP cells; d) 
KB_wt cells. Adapted from [59]. 
 
An overview of cellular uptake and effective delivery leading to specific binding of 
intracellular PCNA-GFP is given in Table 5. 
Cellular uptake was considered to be positive if α-GFP-Nb was visualized inside 
cellular vesicles. It is marked with ―+‖ in Table 5 ―Cellular uptake‖. Co-localization of 
α-GFP-Nb and PCNA-GFP in the nucleus was regarded as specific binding to target 
protein and is marked with ―+‖ in Table 5 ―Specific binding to target protein‖. ―+-― 
describes the fact that delivery experiments using α-GFP-Nb formulated with 730 or 
731 at a molar ratio of five, lead to co-localization with PCNA-GFP, but the signal was 
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far less intense than if oligomer 734 or 735 were used. The delivery of α-GFP-Nb at a 
final concentration of 1.5 µM did not result in any significant cellular uptake and 
therefore just the results for a final concentration of 3.6 µM are depicted in Table 5. A 
more detailed description of the structures can be found in [142]. 
 
Table 5: Summary of oligoaminoamide oligomers used for nanobody delivery.  
ID  Topology Sequence (C-to N- terminal) Cellular 
uptake 
Specific 
binding to 
target protein 
Ref 
392  
4-arm 
A-K-(K-(Stp3-C)2)2  - - [51] 
402  A-K-(K-(Stp4-C) 2)2  - - [51] 
606  A-K-[H-K-(H-Sph-Sph-H-Sph-H-C)2]2 + - [141] 
730  K-(PEG24-E)-K-(K-OleA2)-K(Stp4-C)2  + +- [144] 
731  K-(PEG24-FolA)-K-(K-OleA2)-K(Stp4-C)2  + +- [144] 
732  K-(PEG24-E)-K-[K-(Stp3-C)2]2  +- - [142] 
733  K-(PEG24-FolA)-K-[K-(Stp3-C)2]2  +- - [142] 
734  K-(PEG24-E)-K-[K-(Stp4-C)2]2  + + [142] 
735  K-(PEG24-FolA)-K-[K-(Stp4-C)2]2  + + [142] 
728  
2-arm 
K-(PEG24-E)-K-(Stp4-C-K-OleA2)2  + - [53] 
729  K-(PEG24-FolA)-K-(Stp4-C-K-OleA2)2  + - [53] 
737  K-(PEG24-FolA)-K-(Stp4-C)2  - - [53] 
788  K-(PEG24-E)-K-[(H-Stp)3-H-C]2  - - [142] 
789  K-(PEG24-FolA)-K-[(H-Stp)3-H-C]2  - - [142] 
488 U-shape K-(Stp4-K-(K-OleA2)-C)2 - - [50] 
622  comb 
structure 
C-[K(Stp)]8-C  + - [148] 
ID: identification number of oligomers. PEG24: polyethylene glycol containing 24 ethylene oxide monomer units, 
FolA: folic acid, OleA: oleic acid, SuccA: succinic acid, Stp: succinoyl tetraethylene pentamine, Sph: succinoyl 
pentaethylene hexamine, A, C, E, H, K: amino acids;  +: positive effect, -: negative effect, + -:  indicating a slight 
effect 
 
As a result of the analysis, larger oligomers (4-arm structures) lead to better cellular 
uptake than smaller oligomers (2-arm, U-shape or comb structures). Oligomers 
comprising histidines or Sph did not improve cellular uptake or release of cellular 
vesicles. Transductions using 3.6 µM labeled α-GFP-Nb formulated with 735 at a 
molar ratio of 1:5 resulted in the highest efficiency in specific binding of PCNA-GFP in 
the nucleus (binding of nuclear PCNA-GFP in 40 % of the cells, 3.1.7, Table 6). 
3.6 µM of the α-GFP-Nb formulation with 734, the non-targeted counterpart of 735, 
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also lead to intracellular binding of PCNA-GFP, but with a slightly lower efficiency of 
30% (3.1.7, Table 6).  
 
3.1.4 Investigation of nanobody/oligomer nanoparticles using FCS 
The interaction of nanobody and the two most effective oligomers was investigated 
using fluorescence correlation spectroscopy (FCS). FCS is a highly sensitive single-
molecule technique for measuring hydrodynamic radii of fluorescent molecules or 
particles in highly diluted solutions in the nanomolar concentration range [150]. The 
normalized results are shown in Figure 12.  
 
Figure 12: Fluorescent correlation spectroscopy of α-GFP-Nb and oligomers. Non-labeled 
nanobodies spiked with 1 % Atto647N-labeled nanobodies were mixed with 735 or 734 at a molar ratio 
of 1:5 and incubated for 4 h at 37 °C. Normalized average correlation curves show RH of 2 nm for non-
formulated nanobody (black), RH of 15 nm – 20 nm for nanobody/735 nanoparticles (green) or 
nanobody/734 nanoparticles (red). Measurements were carried out by Dr. Tobias Preiß (Faculty of 
Physics, LMU München). Adapted from [59]. 
 
The GFP-binding nanobody possesses a hydrodynamic radius (RH) of 2 nm which fits 
well with its published size of 2 nm x 4 nm [63]. The formulation of α-GFP-Nb/735 at 
a molar ratio of 1:5 resulted in a homogenous solution containing two particle 
fractions; one with a RH of 15 nm consisting of complexes of multiple Nbs with 735, 
and one fraction with a RH of 2 nm presenting just slightly or not modified monomeric 
nanobody. In case of the α-GFP-Nb/734 mixtures a slightly different RH of 20 nm for 
the nanoparticles was found. 
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3.1.5 Terminal cysteines are important for nanoparticle formation 
Additionally, the importance of incorporated terminal cysteines within the oligomeric 
structure was evaluated by comparing samples of α-GFP-Nb/735 or /734 mixtures 
with free cysteines to samples where the terminal cysteines were blocked by N-
ethylmaleimide (NEM) (Figure 13) using FCS. After modification of the terminal 
cysteines, only particles of the size of monomeric nanobodies were found. Thus no 
stable binding of nanobody with oligomer could be observed. To confirm these 
findings, microscopy was performed using NEM modified oligomers 735 and 734 
(data not shown). Consistent with FCS measurements, no cellular uptake or binding 
to intracellular PCNA-GFP was found, leading to the assumption that cysteines are 
absolutely essential for nanoparticle stabilization. 
 
Figure 13: Fluorescence correlation spectroscopy of α-GFP-Nb and oligomers with NEM 
blockade. α-GFP-Nb spiked with 1% Atto647N-labeled α-GFP-Nb was mixed with oligomer 735 or 
734 with NEM blockade at a molar ratio of 1:5 and incubated for 4 h at 37°C. Fluorescent correlation 
spectroscopy measurements were carried out at a final concentration of α-GFP-Nb of 0.5 mg/mL in 
HEPES buffer. Normalized average correlation curves show R
H
 of 2 nm for α-GFP-Nb (black) and no 
change in correlation curves upon incubation with 735 (green) or 734 (red) indicating that free terminal 
cysteines are absolutely essential for the formation of α-GFP-Nb/oligomer nanoparticles. 
Measurements were carried out by Dr. Tobias Preiß (Faculty of Physics, LMU München). Adapted 
from [59]. 
 
To further investigate the mechanism of nanoparticle formation, the oxidation of free 
cysteines of oligomer 735 and 734 was followed during the 4 h incubation time 
(Figure 14). A continuous oxidation could be observed resulting in a final oxidation of 
90 % of the thiols. 
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Figure 14: Investigation of thiol oxidation during nanobody/oligomer nanoparticle formation. 
The oxidation of free thiols during the formation of nanobody/oligomer nanoparticles was investigated 
over a period of 4 h. α-GFP-Nb was mixed with oligomer 735 or 734 at a molar ratio of 1:5 and 
incubated for 4 h at 37°C. At the indicated time points, samples were drawn and the amount of free 
thiols was determined by Ellman‘s assay. The percentage of free cysteines left in the reaction was 
calculated ± SD (n=3). Black bars, nanobody/735; grey bars, nanobody/734. Adapted from [59]. 
 
3.1.6 Targeting efficiency of oligomer 735 
To evaluate the folate receptor specific uptake of the nanobody/735 formulations, 
cellular internalization experiments on KB_wt cells were carried out. The α-GFP-Nb 
was labeled with carboxyfluorescein (α-GFP-Nb-CF). Fluorescein loses its 
fluorescence at acidic pH [151]. Thus the selection of this dye allows quenching of 
the fluorescence of extracellular bound nanobody by performing the measurement in 
acidic buffer. Cells were incubated with 3.6 µM α-GFP-Nb-CF formulated with 
oligomers 735 or 734 at a molar ratio of 1:5 for 45 min and uptake efficiency was 
determined by flow cytometry (Figure 15). The targeting ligand containing 
nanobody/735 nanoparticles showed enhanced cellular uptake compared to the 
folate-free nanobody/734 formulations (Figure 15a). To verify if nanoparticles are 
specifically taken up via the folate receptor, folate competition experiments were 
carried out. Cells were pre-incubated with saturating 100 µM folic-acid before the 
uptake experiments. As it is depicted in Figure 15b, short-time uptake of α-GFP-Nb-
CF/735 could be inhibited by the addition of folic acid.  
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Figure 15: Cellular internalization of carboxyfluorescein (CF) modified α-GFP-Nb. CF-
nanobodies were mixed with oligomer 735 or 734 at a molar ratio of 1:5 and incubated for 4 h at 
37 °C. a) KB_wt cells were transduced with 3.6 µM nanobody/735 (blue) or /734 (red). After 1 h 
incubation at 37 °C cellular internalization was determined by flow cytometry. b) Free folic acid 
competition experiments: KB_wt cells were pre-incubated for 30 min with 100 µM free folic acid. 
Afterwards cells were transduced with 3.6 µM α-GFP-Nb/735 (left) or 3.6 µM α-GFP-Nb/734 (right). 
After 45 min incubation at 37 °C, cellular internalization was determined by flow cytometry. Green, with 
100 µM folic acid inhibition; blue or red, without folic acid inhibition; grey, control incubation of cells 
with HEPES buffer. Adapted from [59]. 
 
Although comparison of cellular internalization experiments using oligomers 735 and 
734 after 45 min showed higher uptake efficiency using the folic acid modified 
oligomer 735, flow cytometry analysis (Figure 16) and microscopic examination 
(3.1.7, Figure 19) of the cells after 19 h, also resulted in a quite high uptake of non-
targeted nanobody/734 nanoparticles. 
 
Figure 16: Flow cytometric analysis of cellular uptake of α-GFP-Nb/735 or 734 after 19 h. 
Atto647N-labeled α-GFP-Nb was mixed with oligomer 735 or 734 at a molar ratio of 1:5 and incubated 
for 4 h at 37 °C. Afterwards cells were incubated for 1 h with 3.6 µM labeled nanobody formulated with 
oligomer 735 (left) or oligomer 734 (right) (solid lines) or pure nanobody (dotted lines), followed by 
18 h incubation in fresh media. Cellular uptake of α-GFP-Nb into different recombinant HeLa cell lines 
was investigated. Red, HeLa_PCNA-GFP cells; blue, HeLa_Actin-GFP cells; green, HeLa_Tubulin-
GFP cells; grey, exemplary HEPES control in HeLa_PCNA-GFP cells. Adapted from [59]. 
 
Additionally, the zeta potential of all nanobody/oligomer formulations was evaluated, 
showing a positive zeta potential of ~+15 mV. 
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3.1.7 Evaluation of specific binding of GFP binding nanobody to target 
proteins 
Figure 17 depicts the transduction of Atto647N-labeled α-GFP-Nb using oligomer 735 
into HeLa_PCNA-GFP cells.  Cells were incubated with α-GFP-Nb/735 at a molar 
ratio of 1:5 for 1 h followed by incubation in fresh media for 18 h.  
 
Figure 17: Confocal laser scanning microscopy of live cells after transduction with α-GFP-
Nb/735. HeLa_PCNA-GFP cells were incubated for 1 h with 3.6 µM Atto647N-labeled α-GFP-Nb 
formulated with oligomer 735 at a molar ratio of 1:5, followed by 18 h incubation in fresh media. First 
column, GFP fluorescence of GFP tagged proteins; second column, Atto647N fluorescence of α-GFP-
Nb; third column, nuclear staining with Hoechst dye; fourth column, merge of all three channels. Scale 
bars: 25 µm. 
Thick arrows indicate cells in S Phase where the typical punctuated patterns of PCNA-GFP at the 
replication foci is visible. Stars indicating cells in G1 and G2 phase; dashed arrows (second and fourth 
column) exemplary indicating nanoparticles being trapped in cellular vesicles. Adapted from [59]. 
 
In the pictures of the first column the specific punctuated pattern of concentrated 
PCNA-GFP at replication foci (thick arrows) as it is visible in S-phase and the diffuse 
pattern (white stars) indicating the G1- and G2-phase is visible. The second pictures 
depict the co-localization of the specific pattern of PCNA-GFP and α-GFP-Nb at the 
replication foci (thick arrows), but also co-localization of α-GFP-Nb and PCNA-GFP in 
G1 and G2 (white stars), indicating binding of the nanobody to its GFP-tagged target 
protein through the whole cell cycle.  
The delivery efficiency of the selected α-GFP-Nb/oligomer nanoparticles was 
furthermore investigated on HeLa_Actin-GFP and HeLa_Tubulin-GFP cells, 
exhibiting two different targets at the cytoskeleton. Transduction experiments were 
carried out with 3.6 µM Atto647N-labeled Nb formulated with 735 at a molar ratio of 
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1:5, as has been described above for HeLa_PCNA-GFP cells. Figure 18a displays 
the delivery into HeLa_Actin-GFP and Figure 18b into HeLa_Tubulin-GFP cells.  
 
Figure 18: Confocal laser scanning microscopy of live cells after transduction with α-GFP-
Nb/735. Different recombinant HeLa cell lines were incubated for 1 h with 3.6 µM Atto647N labeled α-
GFP-Nb formulated with oligomer 735 at a molar ratio of 1:5, followed by 18 h incubation in fresh 
media. First column, GFP fluorescence of GFP tagged proteins; second column, Atto647N 
fluorescence of α-GFP-Nb; third column, nuclear staining with Hoechst dye; fourth column, merge of 
all three channels. Dashed arrows indicate exemplary nanoparticles being trapped in cellular vesicles. 
Scale bars: 25 µm. a) HeLa_Actin-GFP cells; b) HeLa_Tubulin-GFP cells. Adapted from [59]. 
 
In both cell lines specific co-localization of α-GFP-Nb (second row) with GFP tagged 
proteins (first row) can be seen. This demonstrates the versatility of the delivery 
approach. Images applying the non-targeted oligomer 734 as delivery agent are 
depicted in Figure 19. The experiment was carried out as has been described above 
for nanobody/735 mixtures. Incubation of nanobody/734 mixtures for 1h on the cells 
followed by 18 h incubation in fresh media, also resulted in quite high uptake 
efficiencies, similar to the above described flow cytometry experiments (Figure 16). 
Apart from specific binding of the α-GFP-Nb to target proteins, Figure 17-19 (second 
column) display small intense dots (dashed arrows). These dots are oligomer/protein 
nanoparticles still being entrapped in cellular vesicles, indicating the escape from 
these endolysosomal vesicles as the main bottleneck. Additionally, the efficiency of 
specific binding to target protein was determined by microscopic evaluation of at least 
500 cells per value (Table 6). Cells in which specific co-localization of nanobody and 
target protein was visible were counted. The percentage of cells in which co-
localization of nanobody and target protein occurred was calculated as follows: 
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(number of cells with co-localization of nanobody and target protein/total number of 
cells) x 100%. This resulted in specific co-localization of nanobody and GFP-tagged 
proteins in 40 % of HeLa_PCNA-GFP, 60 % of HeLa_Tubulin-GFP and 50 % of 
HeLa-Actin-GFP cells. 
 
Figure 19: Confocal laser scanning microscopy of live cells after transduction  with α-GFP-
Nb/734. Different recombinant HeLa cell lines were incubated for 1 h with the 3.6 µM Atto647N 
labeled α-GFP-Nb formulated with 734 at a molar ratio of 1:5, followed by 18 h incubation in fresh 
media. First column, GFP fluorescence of GFP tagged proteins; second column, Atto647N 
fluorescence of α-GFP-Nb; third column, nuclear staining with Hoechst dye; fourth column, merge of 
all three channels. Dashed arrows indicate exemplary nanoparticles being trapped in cellular vesicles. 
Scale bars: 25 µm. a) HeLa_PCNA-GFP cells; b) HeLa_Actin-GFP cells; c) HeLa_Tubulin-GFP cells. 
Adapted from [59]. 
 
Table 6: Efficiencies of co-localization of nanobody and target protein 
HeLa_PCNA-GFP HeLa-Actin-GFP HeLa_Tubulin-GFP KB_wt 
α-GFP-Nb α-GFP-Nb α-GFP-Nb α-lamin-Nb 
735 734 735 734 735 734 735 734 
50% 30% 60% 30% 50% 35% 70% 40% 
40% 20% 40% 35% 60% 50% 60% 40% 
35% 20% 60% 40% 70% 50% 50% 30% 
Average 
40% 30% 50% 35% 60% 45% 60% 40% 
Evaluation of at least 500 cells per value. Cells in which specific co-localization of nanobody and target 
protein was visible were counted. The percentage of cells in which co-localization of nanobody and 
target protein occurred was calculated as follows: (number of cells with co-localization of nanobody 
and target protein/total number of cells) x 100%. 
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3.1.8 Evaluation of cytotoxicity of nanobodies and oligomers 735 and 734 
Metabolic activity was determined for HeLa_PCNA-GFP, _Actin-GFP, _Tubulin-GFP 
and KB_wt cells by a dimethylthiazolyldiphenyltetrazolium bromide (MTT) assay. 
Therefore nanobodies were formulated with oligomer 735 or 734 at a molar ratio of 
1:5, and formulations were incubated for 1 h on the cells followed by 18 h incubation 
in fresh medium. α-GFP-Nbs were used for all recombinant HeLa cell lines and α-
lamin-Nb for KB_wt cells, showing absence of significant toxicity for the used 
nanobodies and the oligomer/nanobody formulations under the applied conditions 
(Figure 20). 
 
Figure 20: Evaluation of cytotoxicity of nanobody formulated with oligomer 735 or 734. 
Nanobody was formulated with oligomer 735 or 734 at a molar ratio of 1:5. Cells were incubated for 
1 h with the protein/oligomer mixture at a final nanobody concentration of 3.6 µM, followed by 18 h 
incubation in fresh media. Dark grey, free nanobody; light grey, transduction of cells with 
nanobody/735, patterned, transduction of cells with nanobody/734. Atto647N-labeled α-GFP-Nb was 
used for all recombinant HeLa cell lines and Atto647N-labeled α-lamin-Nb for KB_wt cells. Data are 
presented as % metabolic activity of control cells ± SD (n=5). Adapted from [59]. 
 
3.1.9 Application of the delivery strategy to a lamin binding nanobody 
Taking advantage of the fact that nanobodies exhibit low variations in terms of size, 
structure and surface properties, the delivery strategy outlined above should be 
easily transferable to various other nanobodies. To investigate this, the delivery of a 
lamin binding nanobody (α-lamin-Nb) into KB_wt cells was evaluated. First, the 
association of Atto647N-labeled α-lamin-Nb with either oligomer 735 or 734 in 
HEPES buffer (pH 8.0) after incubation for 4 h at 37 °C was investigated by FCS 
(Figure 21), giving similar results as for α-GFP-Nb (3.1.4, Figure 12).  
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Figure 21: Fluorescent correlation spectroscopy of α-lamin-Nb and oligomers. Non-labeled 
nanobodies spiked with 1% Atto647N-labeled nanobodies were mixed with oligomer 735 or 734 at a 
molar ratio of 1:5 and incubated for 4 h at 37 °C. Normalized average correlation curves show RH of 
2 nm for non-formulated nanobody (black), RH of 15 nm – 20 nm for nanobody/735 nanoparticles 
(green) or nanobody/734 nanoparticles (red). Adapted from [59]. 
 
The labeled α-lamin-Nb was found to have a RH of 2 nm, α-lamin-Nb/oligomer 
mixtures resulted in two fractions with RH of 2 nm for non-bound or modified 
monomeric α-lamin-Nb, and RH of 20 nm for formulated α-lamin-Nb/oligomer. 
For transduction experiments, Atto647N-labeled α-lamin-Nb/oligomer formulations 
were incubated for 1 h on the cells at a final concentration of 3.6 µM nanobody in 
serum containing folate-free RPMI medium, followed by 18 h incubation in fresh 
medium. 
 
Figure 22: Cellular internalization of carboxyfluorescein (CF) modified α-lamin-Nb. CF-
nanobodies were mixed with oligomer 735 or 734 at a molar ratio of 1:5 and incubated for 4 h at 
37 °C. a) KB_wt cells were transduced with 3.6 µM nanobody/735 (blue) or /734 (red). After 1 h 
incubation at 37 °C cellular internalization was determined by flow cytometry. b) Free folic acid 
competition experiments: KB_wt cells were pre-incubated for 30 min with 100 µM free folic acid. 
Afterwards cells were transduced with 3.6 µM α-lamin-Nb/735 (left) or 3.6 µM α-lamin-Nb/734 (right). 
After 45 min incubation at 37 °C, cellular internalization was determined by flow cytometry. Green, with 
100 µM folic acid inhibition; blue or red, without folic acid inhibition; grey, control incubation of cells 
with HEPES. Adapted from [59]. 
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Microscopic evaluation showed specific binding of Atto647N-labeled nanobody to 
lamin in 60 % of KB_wt cells for the folat receptor-targeted 735 formulation, and 40 % 
for the non-targeted 734 formulation (Table 6).  
 
Figure 23: Confocal laser scanning microscopy of live KB_wt cells after transduction with α-
lamin-Nb/735. Cells were incubated with 3.6 µM Atto647N-labeled α-lamin-Nb formulated with 735 at 
a molar ratio of 1:5. KB_wt cells were incubated for 1 h with the nanobody/oligomer mixture, followed 
by 18 h incubation in fresh media. First column, Atto647N fluorescence of labeled α-lamin-Nb which 
binds to endogenous lamina lining the nucleus visualizing the typical nuclear rim structure; second 
column, nuclear staining with Hoechst dye; third column, merge of both channels. Dashed arrows 
exemplary indicating nanoparticles being trapped in cellular vesicles. Scale bars: 25 µm. Adapted from 
[59]. 
 
Cellular internalization experiments resulted in folate receptor specific uptake of CF-
labeled α-lamin-Nb/735 after 45 min incubation (Figure 22).  
Figure 23 depicts the delivery of Atto647N-labeled α-lamin-Nb/735 nanoparticles into 
KB_wt cells leading to co-localization of delivered nanobody with endogenous lamina 
lining the nucleus. The delivery of α-lamin-Nb/734 is shown in Figure 24. As for the α-
GFP-Nb, some nanobody was still being entrapped in intracellular vesicles showing 
no co-localization with nuclear lamin (dashed arrow shows exemplary vesicles). 
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Figure 24: Confocal laser scanning microscopy of live KB_wt cells after transduction with α-
lamin-Nb/734. Cells were incubated with 3.6 µM Atto647N-labeled α-lamin-Nb formulated with 
oligomer 734 at a molar ratio of 1:5. KB_wt cells were incubated for 1 h with the nanobody/oligomer 
mixture, followed by 18 h incubation in fresh media. First column, Atto647N fluorescence of labeled α-
lamin-Nb which binds to endogenous lamina lining the nucleus visualizing the typical nuclear rim 
structure; second column, nuclear staining with Hoechst dye; third column, merge of both channels. 
Dashed arrows exemplary indicating nanoparticles being trapped in cellular vesicles. Scale bars: 
25 µm. Adapted from [59]. 
 
3.1.10 Live cell imaging of intracellular delivered lamin nanobody 
To further evaluate the uptake and delivery process, real-time imaging of the delivery 
of Atto647N-labeled α-lamin-Nb/735 nanoparticles into KB_wt cells was performed. 
For this purpose, the transduction was carried out as described above. Time series 
were either taken 1.5 h or 19 h after transduction. Selected frames of these time 
series are shown in Figure 25. Figure 25 depicts images following the escape of 
cellular vesicles right after cellular uptake of α-lamin-Nb/735 nanoparticles. For this 
time series pictures were taken every 5 min for 2 h. For cell 1 and 2, the first picture 
(0 min) shows nanoparticles suggested to be entrapped in cellular vesicles. In the 
second picture (70 min) the even distribution of α-lamin-Nb through the cell can be 
seen. Additionally concentrated dots are visible resulting from nanobody suggested 
to be entrapped in cellular vesicles (dashed arrows show exemplary vesicles). After 
120 min highlighting of the nuclear rim structure that is characteristic of the nuclear 
lamina is visible (red circle), caused by specific binding of the labeled α-lamin-Nb to 
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nuclear lamin. Concentrated dots (dashed arrows show exemplary vesicles) are a 
result of nanoparticles suggested to be entrapped in cellular vesicles. In cell 3 no 
release from cellular vesicles is visible. 
 
Figure 25: Real-time imaging of the delivery of α-lamin-Nb/735 into KB_wt cells. Cells were 
incubated with 3.6 µM Atto647N-labeled α-lamin-Nb, formulated with 735 at a molar ratio of 1:5 for 1 h, 
followed by incubation in fresh media. Time series were taken by widefield fluorescence microscopy. 
Selected frames from these time series are shown. Scale bars: 25 µm. Time series was started 1.5 h 
after transduction of the cells. Cell 1 and 2, 0 min, nanobody is trapped in cellular vesicles; 70 min, 
even distribution of nanobody throughout the cell, some nanobody is still being trapped in cellular 
vesicles (dashed arrows); 120 min, specific co-localization of labeled nanobody with the lamina lining 
the nucleus can be seen. Concentrated dots (dashed arrows) are resulting from nanoparticles still 
being trapped in cellular vesicles. Cell 3, nanoparticles are trapped in cellular vesicles for the length of 
the time series. Schemes depicting cells without specific binding of α-lamin-Nb (0 min) and after 
specific binding of nanobody to nuclear lamin (120 min) indicated by red coloring of the nuclear 
membrane in cell 1 and 2. Adapted from [59]. 
 
Selected frames from the time series following a cell through cell division, after 
successful transduction of α–lamin-Nb are shown in Figure 26. Pictures were taken 
every 5 min for 2 h and afterwards every 15 min for additional 22 h. From the 
beginning of the imaging (0 min), specific co-localization of α-lamin-Nb and 
endogenous lamina lining the nucleus could be observed (thick arrow). At that time 
this cell was probably in G2 phase. Concentrated dots (dashed arrows show 
exemplary vesicles) are again resulting from nanoparticles being entrapped in cellular 
vesicles. From 275 min to 350 min the cell could be followed through cell division. 
Specific binding of α-lamin-Nb to the nuclear lamina could still be found at 515 min 
and 815 min in the two freshly divided cells. 
In sum, functional nanobodies were delivered into live cells leading after escape from 
cellular vesicles to specific binding of an endogenous target, and the target was 
visualized throughout the cell cycle. 
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Figure 26: Real-time imaging of binding of α-lamin-Nb to nuclear lamin throughout cell division. 
Cells were incubated with 3.6 µM Atto647N-labeled α-lamin-Nb, formulated with 735 at a molar ratio of 
1:5 for 1 h, followed by incubation in fresh media. Time series were taken by widefield fluorescence 
microscopy. Selected frames from these time series are shown. Scale bars: 25 µm. Imaging was 
started 19 h after transduction of the cells. At that time this cell was probably in G2  phase (0 min). 
Specific binding of α-lamin-Nb to the lamina lining the nucleus (thick arrows) can be seen. 
Concentrated dots (dashed arrows) are resulting from nanoparticles being trapped in cellular vesicles. 
The cell could be followed through mitosis (275 min - 350 min). Scale bars: 25 µm. Adapted from [59]. 
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3.2 MOF nanoparticles as defined carrier system for His-tagged 
functional units 
Parts of this chapter (3.2.3-3.2.9, 3.2.12) have been adapted from: 
 
Multifunctional nanoparticles by coordinative self-assembly of His-tagged units with 
metal-organic frameworks. Ruth Röder, Tobias Preiß, Patrick Hirschle, Benjamin 
Steinborn, Andreas Zimpel, Miriam Höhn, Joachim O. Rädler, Thomas Bein, Ernst 
Wagner, Stefan Wuttke and Ulrich Lächelt. Journal of the American Chemical Society 
(2017), 139(6): 2359-2368.  
 
 
In the following chapter, the investigation of the coordinative interaction of 
oligohistidine-tags (His-tags) with metal-organic frameworks (MOFs) as a novel 
external functionalization concept for MOF NPs is presented. This His-tag dependent 
interaction was developed by Dr. Ulrich Lächelt and Dr. Stefan Wuttke (LMU 
München). It is based on a self assembly process and the inherent properties of the 
compounds. An overview of MOFs has been given in the introduction (1.5). MOFs 
are a class of materials composed of inorganic building units, metal ions or metal 
oxide clusters, which are coordinatively connected by organic linkers to create porous 
three-dimensional frameworks Figure 27a.  
 
 
 
Figure 27: Coordinative self-assembly of His-tagged molecules with MOF NPs. a) Molecular 
composition of MOFs; b) Coordinative bond between the imidazole group of histidines acting as Lewis 
base and coordinatively unsaturated metal sites (CUS) acting as Lewis acid. Multifunctional MOF NPs 
can be generated by coordinative attachment of different functional units via self-assembly; c) 
Schematic illustration of acidic detachment due to histidine protonation. Adapted from [158]. 
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Their crystallinity, chemically functionalizable pores and potential systematic 
structural variations are some factors amongst others that allow to precisely design 
these materials for particular purposes [152, 153]. The described concept uses the 
interactions between Lewis bases, such as the imidazole function of histidine and 
coordinatively unsaturated metal sites present on the external surface of MOF NPs to 
self-assemble different functional units onto MOF NPs (Figure 27b).  
Since His-tags can readily be integrated into peptides or proteins by synthetic, 
recombinant or bioconjugation techniques, they appear to be ideal connectors to 
create a versatile inorganic/bioorganic interface at the MOF NPs‘ surface. The same 
interaction (Figure 27b) is routinely used for the purification of recombinant proteins 
by immobilized metal ion chromatography [154, 155]. Applicability of the coordinative 
His-tag interactions for intracellular delivery of proteins has been demonstrated by 
using conjugates of nitrilotriacetic acid derivatives and cell-penetrating peptides [44, 
156], polymers [157] or silica NPs [149]. Since the metalsites are already an integral 
part of the coordinative MOF structure, the external secondary modification via 
coordinate bonds in the presented approach of ‗self-assembling multifunctional 
coordination particles‘ (SAMCOPs) is considered a powerful tool for the combinatorial 
and stoichiometric generation of functional MOFs.  
 
Figure 28: Scanning electron microscopy (SEM) images of MIL-88A (left), HKUST-1 (middle) 
and Zr-fum (right). Lower row depicts enlarged images of the pictures in the upper row. White scale 
bars upper row: 5 µm; lower row as indicated in the images. SEM images were taken by Dr. Steffen 
Schmidt and Patrick Hirschle (Department of Chemistry, LMU München). Adapted from [158]. 
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A set of three exemplary MOF structures, MIL-88A (Fe3+/fumaric acid) [121], HKUST-
1 (Cu2+/trimesic acid) [140] and Zr-fum (Zr4+/fumaric acid) [129]) each based on a 
different metal component, was selected for testing the assembly strategy (Figure 
28).  
First, the external binding of various His-tagged synthetic peptides and recombinant 
or chemically H6-modified proteins was investigated. The set of functional units used 
in this study is summarized in Table 7.  
 
Table 7: His-tagged functional units used for the assembly with MOF NPs. 
Code Sequence[a] / Description Function 
A6, H6-Acr Acridine-PEG28-H6-NH2 
Photometric detection 
H0/3/6-Acr Acridine-STOTDA-H0/3/6 
H6-A647N ATTO647N-PEG12-H6-NH2 
Fluorescence 
H6-CF Carboxyfluorescein-PEG12-H6-NH2 
H6-GFP Recombinant nlsEGFP (H6-Tag) 
Model protein 
H6-Tf* 
Transferrin, conjugated with H6-PEG36 and 
ATTO647N 
H6-luciferase Recombinant luciferase (H6-Tag)  
H6-Bak H6-GGQVGRQLAIIGDDINR-NH2 
Apoptotic peptides H6-Bad H6-GNLWAAQRYGRELRRMSDEFVD-NH2 
H6-KLK H6-GGKLAKLAKKLAKLAK-NH2 
H6-CytC CytochromeC conjugated with H6 Apoptotic protein 
[a] Peptide sequences are indicated from N- to C-terminus using the one-letter code for α-
amino acids (Hn, n = number of histidines); * ATTO647N label  
 
Dr. Ulrich Lächelt could show the external modification of MIL-88A, HKUST-1 and Zr-
fum MOF nanoparticles with the His-tag model peptide H6-Acridine (H6-Acr), in 
HEPES buffered glucose (HBG) at pH 7.4 by the detection of residual free peptide in 
the supernatant after incubation and centrifugation of the MOF suspensions (Figure 
29). Figure 29a depicts the chemical structure and control chromatogram of model 
compounds H6-Acr and A6-Acr. For detection of the residual free peptide in the 
supernatant, H6-Acr or A6-Acr control were incubated with different MOF NPs in HBG 
at pH 7.4 for 15 min. After centrifugation, the supernatant was analyzed by RP-HPLC 
(λ=360 nm, Figure 29b). The exclusive reduction of H6-Acr (in contrast to A6-Acr) in 
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the supernatant represents qualitative evidence for the histidine dependent 
interaction with all three investigated MOF species. 
 
Figure 29: Acridine (Acr) peptide binding to MIL-88A (left), HKUST-1 (middle) and Zr-fum (right) 
particles. a) Chemical structure and control chromatogram of model compounds H6-Acr and A6-Acr; 
b) Different MOF NPs were incubated with H6-Acr or A6-Acr in HBG pH 7.4, followed by centrifugation. 
The residual free peptides in the supernatant were qualitatively determined by RP-HPLC, (H6 vs. A6, 
λ=360 nm). HPLC measurements were carried out by Dr. Ulrich Lächelt (Pharmaceutical 
Biotechnology, LMU München). Adapted from [158]. 
 
Additionally, using fluorescence correlation spectroscopy (FCS) the binding of 
fluorescently labeled H6-tags (H6-A647N) to MOF NPs was measured at low 
concentrations with single-molecule sensitivity (Figure 30). First H6-A647N on its own 
was measured (Figure 30 grey curves), followed by a second measurement after the 
addition of MOF NPs (Figure 30, colored curves). The FCS measurements were 
carried out by Dr. Tobias Preiß (Faculty of Physics, LMU München). 
 
 
Figure 30: Investigation of interaction of H6-A647N with different MOF NPs. FCS measurements 
of H6-A647N were performed before (grey) and after MOF addition (colored). Inserts show 
normalization of the same data. FCS measurements were carried out by Dr. Tobias Preiß (Faculty of 
Physics, LMU München). Adapted from [158]. 
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Figure 30 shows a significant increase in the autocorrelation amplitude after addition 
of all three MOF species, indicating a reduction of the H6-tag number concentration 
most likely due to multiple binding to MOF NPs. In case of MIL-88A and HKUST-1, 
however, no change in the characteristic correlation decay time could be detected. 
This can probably be attributed to MOF induced fluorescence quenching [159, 160], 
as well as rather large effective particle sizes resulting from aggregation, which both 
can cause a decline of detectable tags after binding.  
The following chapter will now show the further characterization of the His-tag MOF 
interaction with a focus on the potential biological application of this system. 
Cytotoxicity as well as its potential as carrier for small molecules, proteins and 
peptides will be evaluated. 
MIL-88A, HKUST-1 and Zr-fum have been synthesized by Patrick Hirschle (PhD 
study, Department of Chemistry, LMU München).  
H6-CF, H6-A647N and H6-Tf have been synthesized by Dr. Ulrich Lächelt (Group 
leader, Pharmaceutical Biotechnology, LMU München), H0/3/6-Acr were synthesized 
by Benjamin Steinborn (PhD study, Pharmaceutical Biotechnology, LMU München). 
The synthesis of all other functional units is described in Material and Methods 
(Chapter 2). 
 
3.2.1 Heterologous expression and purification of H6-GFP 
H6-GFP was expressed in E.coli BL21(DE3)plysS as has been described in Maier et 
al. [54]. The purified protein was analyzed on SDS-PAGE after staining with 
Coomassie (Figure 31). H6-GFP has a size of 26.9 kDa. 
 
Figure 31: Analysis of purified H6-GFP. Different amounts of the purified H6-GFP, were separated on a 10 % 
SDS-PAGE and stained with Coomassie. 1: 40 µg, 2: 15 µg, 3: 10 µg, 4: 5 µg. Precision Plus Protein standard 
(BioRad, USA). 
From 10 L bacteria culture 30 mg H6-GFP were obtained. 
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3.2.2 Cloning, heterologous expression and purification of H6-luciferase  
A well-established system in our lab to quantitatively analyze pDNA- or siRNA 
transfection is the delivery of either a luciferase containing plasmid, or siRNA to 
inhibit luciferase expression. Adapting to this system we intended to purify a H6-
tagged luciferase in order to establish a similar read out system for the delivery of 
proteins. This system would be beneficial in different ways. First it would make 
screening experiments similar to pDNA or siRNA transfections possible. Furthermore 
it would not only proof the successful intracellular delivery of a protein but would 
beyond that verify the functionality of an enzyme after the whole delivery process. 
The His-tag was first needed for easy protein purification via Ni-affinity 
chromatography, but could then be used for the coupling to different MOF NPs. 
After cloning of luciferase into pET-28a vector (Novagen, Merck Millipore, Germany), 
to obtain a His-tag containing protein, the accurateness of this cloning experiment 
was verified by a restriction digest with Hind III and EcoRI (Figure 32a). 
 
Figure 32: Analysis of cloning of luciferase into pET-28a and purity of resulting expressed and 
purified H6-luciferase. a) DNA ladder, 1, linearized plasmid, 2, plasmid digested with HindIII and 
EcoRI resulting in two fragments at 5369bps and 1758 bps. b) PEQ Lab Protein Marker III (Germany), 
1, Bacteria lysate, 2, Flow through of affinity purification, 3, washing step, 4, 10 µg H6-luciferase, 5, 
20 µg H6-luciferase. 
 
The whole plasmid has a size of 7127 bps. After the restriction digest, two fragments 
with the size of 1758 bps (H6-luciferase) and 5369 bps (pET-28a) were obtained, 
verifying the correct cloning. 
This expression plasmid was then transformed into RosettaBL21(DE3)pLysS. 
Expression was induced by the addition of 500 mM IPTG. The whole purification 
process was monitored on SDS-PAGE (Figure 32b). From 4 L bacteria culture ~ 
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10 mg H6-luciferase were obtained. To test the functionality of the purified H6-
luciferase, a luciferase assay was carried out (2.20.3), resulting in ~1 x 1012 RLU/mg 
luciferase. 
 
3.2.3 Cytotoxicity studies of different MOFs  
To evaluate the suitability of MOF NPs as intracellular carrier system, the toxicity of 
MIL-88A (Fe3+/fumaric acid) [121], HKUST-1 (Cu2+/trimesic acid) [140] as well as Zr-
fum (Zr4+/fumaric acid) [129] was investigated on HeLa_wt cells. Cells were 
incubated with different MOF NP concentrations for 48 h followed by evaluation of 
cell viability by MTT assay (Figure 33a). 
 
Figure 33: Evaluation of cytotoxicity of different MOF nanoparticles. HeLa_wt cells were 
incubated with different amounts of Zr-fum (dark grey), MIL-88A (light grey) and HKUST-1 (pattern) for 
48 h (a) or 2 h (b). c) Incubation of HeLa_wt cells with 10 µg MOFs modified with different His-tags or 
without His-tags (-). CF: carboxyfluorescein, Tf: transferrin. Data are presented as % metabolic activity 
of control cells ± SD (n=5) (MTT assay). Adapted from [158]. 
 
MIL-88A and Zr-fum were very well tolerated, HKUST-1 exhibited considerable 
cytotoxicity. Therefore incubation times were reduced to 2 h, deleting observable 
effects on metabolic activity after 48 h (Figure 33b). Additionally also the effect on 
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metabolic activity of the different His-tags was evaluated, showing no effect (Figure 
33c). 
 
3.2.4 Investigation of His-tag binding to different MOF NPs 
Apart from, the in the introduction to this chapter described investigation of binding 
using RP-HPLC, the His-tag specific binding of H6-Acr compared to A6-Acr was 
verified by zeta potential measurements (Figure 34). Therefore MOF NPs were 
incubated with H6-Acr or A6-Acr as a control. The change in Zeta potential with and 
without the addition of MOF NPs was investigated. A significant shift towards 
neutrality caused by the His-tag containing derivatives only could be detected for all 
three different MOF NPs. 
 
 
Figure 34: Effect of peptide binding to MOF NP on their zeta potential. After incubation of MOF 
NPs with A6-Acr (patterned bar), H6-Acr (black bar) or without His-tag (white bar) the change in zeta 
potential was measured by dynamic light scattering. Zeta potentials were calculated by the 
Smoluchowski equation, each sample was measured 3 times with 10 to 30 subruns at 25 °C. Adapted 
from [158]. 
 
3.2.5 Investigation of stability of His-tag Zr-fum interaction  
For first evaluations of the suitability of the functionalized MOF NPs for their use in 
cell culture, the stability of the Zr-fum H6-A647N interaction under different conditions 
was investigated by FCS (Figure 35). Free H6-tags (blue) showed fast single 
molecule diffusion prior to NP addition (Figure 35, left). After the addition of Zr-fum 
NPs at pH 7.4 (orange) the collective diffusion was shifted towards higher diffusion 
times revealing H6-tag binding to Zr-fum NPs. Following acidification (green) the 
diffusion rate increased relative to the pH 7.4 measurement indicating partial 
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detachment of tags from the MOF NP surface, due to the protonation of histidines. 
Also the interaction in DMEM medium containing 10 % FBS was investigated (Figure 
35, right). Importantly, H6-tag association with Zr-fum NPs remained stable, 
confirming the suitability for use under cell culture conditions. These FCS 
measurements were carried out by Dr. Tobias Preiß (Faculty of Physics, LMU 
München). 
 
Figure 35: Investigation of Zr-fum/H6-A647N interaction under different conditions. Left: The 
addition of Zr-fum NPs to free H6-A647N (blue), lead to a shift of the collective diffusion time towards 
higher diffusion times (orange). Upon acidification, the diffusion rate increased (green). Right: 
Measurements in DMEM (10 % FBS) of free H6-A647N (blue) and Zr-fum/H6-A647N (orange). FCS 
measurements were carried out by Dr. Tobias Preiß (Faculty of Physics, LMU München). Adapted 
from [158]. 
 
Additionally, a time course experiment was carried out to investigate the pH 
dependent stability of Zr-fum/H6-A647N over a longer period of time (Figure 36). After 
functionalization of Zr-fum NPs with H6-A647N for 15 min, MOF NP suspensions 
were set to a defined pH and incubated for 0.5 h, 3 h or 24 h. After centrifugation, 
data was obtained by photometric determination (λ=646 nm) of free H6-A647N in the 
supernatant. The experiment was carried out by Benjamin Steinborn (PhD study, 
Pharmaceutical Biotechnology, LMU München). Figure 36 shows stable association 
of Zr-fum/H6-A647N for 24 h at pH 7.4 and rapid partial (pH 5) or complete (pH 3) 
release upon acidification. This is consistent with the hypothesis of unprotonated 
histidines acting as Lewis base and being responsible for binding (Figure 27). It is 
suggested that the incomplete detachment at pH 5 is caused by a lowered pKa of the 
imidazole group due to metal ion binding [161] and an equilibrium between protons 
and metal ions competing for histidine interactions. 
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Figure 36: pH dependent stability of H6-tag binding to Zr-fum NPs. Experimental data obtained by 
photometric determination (λ=646 nm) of free H6-A647N in the supernatant after centrifugation; Zr-fum 
NPs were loaded with H6-A647N at pH 7.4 for 15 min (left). MOF NP suspensions were then acidified 
to a defined pH and incubated for indicated times (right). Reaction tubes below show the samples after 
24 h at pH 7.4 (left), pH 5 (middle), pH 3 (right) and centrifugation; decoloration of MOF pellets due to 
acidic H6-A647N detachment at pH 3 can be observed. The experiment was carried out by Benjamin 
Steinborn (PhD study, Pharmaceutical Biotechnology, LMU München). Adapted from [158]. 
 
3.2.6 Evaluation of simultaneous binding of two entities to a single particle 
As a distinct advantage of the self-assembly concept demonstrated here is the 
possible one-step multifunctionalization of MOF NPs by simultaneously mixing 
different H6-tagged functional units with bare MOF NPs. This fact was first evaluated 
by fluorescence cross-correlation spectroscopy (FCCS) measurements. Two His-
tagged proteins with distinct fluorescence spectra - recombinant GFP with genetically 
encoded His-tag: H6-GFP, and human transferrin chemically conjugated with a H6-tag 
and Atto647N label: H6-Tf* - were used to investigate simultaneous binding of both 
entities to single MOF NPs (Figure 37). To a solution containing equimolar amounts 
of both proteins, Zr-fum NPs were added and the shift in the autocorrelation curve 
was investigated. Figure 37 shows the autocorrelation and cross-correlation curves of 
mixed H6-GFP and H6-Tf* solutions before and after the addition of Zr-fum NPs. We 
found no coincidence of H6-GFP and H6-Tf* without NPs since the cross-correlation 
curve of protein mixture is close to baseline (Figure 37 light grey dotted, not exactly 
baseline due to crosstalk of GFP into red channel). After addition of Zr-fum NPs the 
analysis of the cross-correlation (Figure 37 dark grey) shows a high ratio of co-
localization of both proteins which is interpreted as simultaneous attachment of H6-
GFP and H6-Tf* to the same NPs surface.  
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Figure 37: Fluorescence cross-correlation spectroscopy (FCCS) measurements of H6-GFP and 
H6-Tf*. FCCS measurements of H6-GFP (blue) and H6-Tf* (red) in HBG (pH 7.4) were carried out 
before (dotted), and after (solid) the addition of Zr-fum MOF NP. Cross-correlation before (dotted grey) 
and after (solid grey) Zr-fum addition. FCCS measurements were performed by Dr. Tobias Preiß 
(Faculty of Physics, LMU München). Adapted from [158]. 
 
3.2.7 Evaluation of cellular uptake using flow cytometry and confocal laser 
scanning microscopy 
After demonstrating that MOF NPs can effectively be functionalized with His-tags, 
and that MOF NPs do not exhibit significant cytotoxicity under the used conditions, 
cellular uptake of MOF NPs was investigated. All three different MOF species were 
functionalized with H6-tagged fluorescent dye (H6-carboxyfluorescein, H6-CF) or H6-
GFP and incubated on HeLa_wt cells for 24 h. In case of HKUST-1 NPs, due to their 
cytotoxicity (Figure 33) incubation was reduced to 2 h. Cellular uptake was 
investigated by flow cytometry and confocal laser scanning microscopy (CLSM, 
Figure 38 and 39). MIL-88A and HKUST-1 MOF NPs contained huge particles with a 
tendency to aggregate and showed quenching effects, as has been described above, 
resulting in poor detectability of cellular uptake (Figure 38a, b). Incubation of cells 
with pure His-tags without the addition of MOF NPs did not show any cellular uptake 
(Figure 38c). Zr-fum/H6-CF or Zr-fum/H6-GFP showed cellular uptake in flow 
cytometry analysis (Figure 39a) and CLSM images (Figure 39b). The mean 
fluorescence intensity (MFI, inset) of cells treated with Zr-fum/H6-CF increased 20-
fold compared to free H6-CF. The MFI of cells treated with Zr-fum/H6-GFP even 
showed 30-fold higher values compared to free H6-GFP. 
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Figure 38: Cellular uptake of H6-GFP or H6-CF functionalized MIL-88A or HKUST-1 MOF NPs. H6-
GFP or H6-CF were incubated with MOF NPs for 15 min at room temperature. Mixtures were put on 
HeLa_wt cells at a concentration of 0.1 mg MOF NP/nmol His-tag per mL medium. MIL-88A MOF NPs 
were incubated on the cells for 24 h. HKUST-1 MOF NPs for 2 h. Flow cytometric analysis: MOF 
NP/H6-GFP (black), H6-GFP (dotted black), MOF NP/H6-CF (dark grey), H6-CF (dotted dark grey), 
HBG (light grey). Inset shows mean fluorescence intensity (MFI) normalized on HBG. Ctrl indicating 
incubations without the addition of MOF NPs. Confocal laser scanning microscopy (CLSM) images 
from left to right: green fluorescence of H6-GFP or H6-CF, nuclear staining with Hoechst dye, 
brightfield picture, merge of all three channels. Scale bars: 25 µm.  
a) Evaluation of cellular uptake using MIL-88A MOF NPs. Scale bars: 25 µm. b) Evaluation using 
HKUST-1 MOF NPs. Scale bars: 50 µm. c) Control incubations without the addition of MOF NPs H6-
GFP (upper row), H6-CF (lower row). Scale bars: 25 µm. 
Please note, that both MIL-88A and HKUST-1 MOF NPs have high quenching abilities, and especially 
the flow cytometric analysis might not be sensitive enough to detect the actual amount of internalized 
H6-GFP, H6-CF. The same might also be the case for CLSM. Adapted from [158]. 
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Figure 39: Cellular uptake of H6-GFP or H6-CF functionalized Zr-fum NPs. H6-GFP or H6-CF were 
incubated with MOF NPs for 15 min at room temperature. Mixtures were put on HeLa_wt cells at a 
concentration of 0.1 mg MOF NP/nmol His-tag per mL medium and incubated for 24 h. a) Flow 
cytometric analysis: Zr-fum/H6-CF or H6-GFP (black), pure H6-CF or H6-GFP (dotted black), HBG (light 
grey). Inset shows mean fluorescence intensity (MFI) normalized on HBG. Ctrl indicating incubations 
without the addition of MOF NPs. b) Confocal laser scanning microscopy (CLSM) images from left to 
right: green fluorescence of H6-GFP or H6-CF, nuclear staining with Hoechst dye, brightfield picture, 
merge of all three channels. Scale bars: 25 µm. Adapted from [158]. 
 
3.2.8 Cellular uptake of double-functionalized Zr-fum nanoparticles 
The possible one-step multifunctionalization of MOF NPs by simultaneously mixing 
different His-tagged units with bare MOF NPs facilitates the creation of 
multifunctional MOF NPs with various stoichiometric ratios as required for 
optimization of spatio-temporal co-delivery into cells. As the simultaneous assembly 
of H6-GFP and H6-Tf* with Zr-fum MOF NPs had been confirmed by FCCS 
measurements (Figure 37), HeLa_wt cells were subjected to these double-
functionalized particles (Zr-fum/H6-GFP+H6-Tf*) for 24 h, and the internalization was 
investigated (Figure 40). Considerable co-localization of H6-GFP and H6-Tf* could be 
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observed (Figure 40a and b, upper row), as indicated by the yellow coloring in the 
merge images. In contrast to free H6-GFP, free H6-Tf* was also taken up by the cells 
without the addition of Zr-fum MOF NPs to a certain extent (Figure 40 a and b, lower 
row). This can be explained by the fact that HeLa cells express the transferrin 
receptor (Figure 41), thus enabling receptor mediated uptake of free H6-Tf*. 
 
Figure 40: Co-delivery of H6-GFP and H6-Tf* into HeLa_wt cells. His-tags were incubated with Zr-
fum MOF NPs for 15 min at room temperature. Different mixtures were incubated for 24 h on HeLa_wt 
cells at a concentration of 0.1 mg Zr-fum MOF NP and 1 nmol His-tags per mL medium, followed by 
CLSM imaging or flow cytometric analysis. Cellular uptake of Zr-fum/H6-GFP+H6-Tf* (upper row) or 
control without MOF NPs (lower row). a) CLSM images. left to right: fluorescence of H6-GFP, 
fluorescence of H6-Tf*, nuclear staining with Hoechst dye, brightfield picture, merge of all four 
channels, yellow color indicates co-localization of H6-GFP and H6-Tf*. Scale bars: 25 μm. b) Flow 
cytometry analysis:  Evaluation of delivery of Zr-fum/H6-GFP +H6-Tf* (upper row) or control without the 
addition of Zr-fum MOF NPs (lower row). Left to right: HBG control, H6-GFP, H6-Tf*, H6-GFP + H6-Tf*. 
Adapted from [158]. 
 
However, despite the MOF independent uptake route of H6-Tf*, association with Zr-
fum resulted in 5-fold higher internalization, confirming an additional boost due to NP 
mediated uptake.  
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In summary, the evidence for simultaneous assembly of different functional units with 
Zr-fum MOF NPs as well as concurrent transport into living cells indicates the 
successful creation of multifunctional programmable MOF NP interfaces capable of 
manipulating cellular processes. 
  
Figure 41: Determination of surface expression level of transferrin receptor (TfR) in HeLa_wt 
cells by flow cytometry. Control cells (dotted black) were treated with mouse IgG1. Mouse anti-
hCD71 antibody was used for the detection of the TfR (solid black). Alexa Fluor 488 Goat Anti -Mouse 
IgG(H+L) secondary antibody was used for the detection of receptor expression. Grey, PBS. Adapted 
from [158]. 
 
3.2.9 Investigation of the endocytosis mechanism of MOF NPs 
The cellular uptake pathway of MOF NPs was investigated using Zr-fum/H6-GFP 
nanoparticles as a model system. First investigations where cells were pre-incubated 
for 30 min at 4 °C to reduce cellular metabolism and block energy dependent 
processes, before incubation with Zr-fum/H6-GFP for 2 h on ice, revealed a mainly 
energy dependent uptake pathway. To further analyze the endocytotic pathway, 
cellular uptake experiments were carried out in the presence of different endocytosis 
inhibitors. Chlorpromazine inhibiting clathrine mediated endocytosis, amiloride 
inhibiting macropinocytosis and genistein inhibiting caveloae mediated endocytosis 
were used to discriminate the particular endocytotic routes. 
Cells were always pre-incubated with the different inhibitors for 30 min followed by 
incubation with Zr-fum/H6-GFP NPs for 2 h. Afterwards the cellular fluorescence was 
assayed by flow cytometry. Amiloride showed the greatest inhibition suggesting 
macropinocytosis is having major contribution to the uptake of Zr-fum/H6-GFP 
nanoparticles. Since some effect of genestein was observed, caveloae mediated 
uptake might also be involved.  
Looking at the intracellular distribution of internalized H6-GFP, or H6-CF via Zr-fum 
MOF NPs in detail (Figure 39), the spotty arrangement indicates high vesicular 
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entrapment and suggests endosomal escape to be a hurdle for cytosolic delivery.
  
 
Figure 42: Evaluation of endocytosis inhibition of Zr-fum/H6-GFP nanoparticles. H6-GFP was 
incubated with Zr-fum NPs for 15 min at room temperature. HeLa_wt cells were pre-incubated with the 
different inhibitors or at 4 °C for 30 min. Afterwards Zr-fum/H6-GFP NPs were added followed by 
incubation for 2 h at 37 °C or 4 °C. Flow cytometric analysis was carried out in PBS (pH 4.0) to quench 
the extracellular fluorescence. Cellular uptake was evaluated by calculation of the mean fluorescence 
intensity (MFI). Data is presented as % cellular uptake, of cellular uptake of Zr-fum/H6-GFP NPs at 
37 °C. ± SD (n=3). Adapted from [158]. 
 
3.2.10 Screening of different functionalizing units to enhance cellular uptake 
or endosomal escape 
3.2.10.1 Evaluation of different lipids to enhance cellular uptake and 
endosomal escape 
Liposomes were one of the first nanosized drug delivery systems ever to be 
produced [162]. Compared to other nanoparticles, liposomes usually have a reduced 
cytotoxicity and liposomal encapsulation can help to reduce clearance by the immune 
system, thus increasing circulation time of various drugs in the system.  
In the upcoming chapter we have applied the two phospholipids 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phospho-
ethanolamine (DOPE) to enhance cellular uptake and endosomal escape of the MOF 
NPs. 
Results 
80 
  
Phospholipids are phosphorus containing, amphiphilic lipids, with a hydrophilic head 
and two hydrophobic fatty acid ―tails‖. Building the bilayer of bio membranes, they are 
a major component of all cell membranes. Phospholipids in general have a very wide 
range of application in drug delivery systems, examples are: Doxorubicin (Lipo-Dox®, 
Doxil®) [163], Cytosine (DepoCyt®) or Morphine sulfate (DepoDurTM) [164, 165].  
Both in plants and animals, phosphatidylcholine (PC) and phosphatidylethanolamine 
(PE) are the most common phospholipids [166]. Contrary to that, membranes of 
liposomes consist usually to a better part of PC. Due to the low hydration of its polar 
head group, PE has the ability to form non-bilayer structures under physiological 
conditions, destabilizes membranes, and induces membrane fusion [167]. 
DOPE is usually used to prepare pH sensitive liposomes, but it has difficulties to form 
liposomes on its own. Therefore usually materials containing titratable acidic groups 
must be added. At neutral pH the fatty acid carboxyl group can provide effective 
electrostatitc repulsion, while at acidic pH, the carboxyl groups are protonated, 
inverting from a bilayer- to a non-bilayer phase (also called hexagonal II phase) [165, 
168].  
Wuttke et al. [86] have shown the successful coating of MIL-100(Fe) and MIL-101(Cr) 
with DOPC, by a controlled solvent-exchange deposition of the lipid onto the MOF 
surface. These MOF@lipids systems were able to effectively store dye molecules 
leading to cellular uptake into cells. 
The results of the encapsulation of functionalized MOFs into micelles but also the 
effect of just adding lipids to the functionalized MOF solutions without any prolonged 
micelle formulation reactions are presented in the following section. 
Functionalized Zr-fum NPs (Zr-fum/H6-CF or Zr-fum/H6-GFP) were either coated with 
DOPC (micelle formation) or DOPC was just added to the solution. Afterwards, 
cellular uptake of MOF NPs into HeLa_wt cells was analyzed by flow cytometry 
(Figure 43). In general, the addition of DOPC lead to enhanced cellular uptake of His-
tag functionalized Zr-fum NPs. Without the addition of MOF NPs no cellular uptake of 
free His-tags could be detected (Figure 43; MFI: grey or patterned bars, histograms: 
patterned curves). Cellular uptake of Zr-fum/H6-CF encapsulated in DOPC micelles 
(Figure 43 left) did not seem to be as high as cellular uptake just after the addition of 
DOPC (Figure 43 right). Comparison of cellular uptake of bare Zr-fum/H6-CF shows a 
decreased uptake of the samples used for micelle formation. Due to the micelle 
formation protocol, the functionalization of Zr-fum NPs was carried out in a ten times 
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higher volume than the functionalization of samples where the DOPC solution was 
just added. Hence in case of H6-CF, the concentration of His-tag and MOF seems to 
have a significant impact on effective functionalization of MOF NPs. Disregarding this 
volume dependent effect, cellular uptake of Zr-fum/H6-CF NPs could significantly be 
enhanced by just adding increasing volumes of DOPC until a final concentration in 
the well of 21.6 µM. 
 
Figure 43: Flow cytometry analysis of the influence of the addition of DOPC to functionalized 
Zr-fum NPs. After functionalization of Zr-fum NPs with H6-CF or H6-GFP (30 µg Zr-fum/0.22 nmol H6-
CF or H6-GFP per well), DOPC was added to the solution. NPs were either encapsulated in DOPC 
micelles, according to protocol [86] (left), or DOPC was just added to the solution (right). Samples 
were incubated on KB_wt cells for 24 h. Calculated mean fluorescence intensities (MFI) values were 
normalized on HBG. Experiments were always carried out with or without the addition of Zr-fum NPs. 
MFI histograms: Zr-fum/H6-CF (black), H6-CF (grey), Zr-fum/H6-GFP (white), H6-GFP (patterned). Flow 
cytometry: Zr-fum/His tag (solid curves), His-tag (patterned curves). Final DOPC concentration in the 
well; 43.2 µM (blue), 21.6 µM (red), 10.8 µM (green), 1.08 µM (orange), - : without the addition of 
DOPC (turquoise), HBG control (grey). Samples were prepared in duplicates. 
 
Higher concentrations did not further enhance cellular uptake. Coating of Zr-fum/H6-
CF with DOPC did show a negligible effect. Compared to H6-CF, the volume in which 
MOF NPs were functionalized with H6-GFP had much lower impact on cellular 
uptake. Including DOPC in the reaction just had a slight, but-dose dependent effect 
on Zr-fum/H6-GFP NPs, which did not differ significantly between the samples in 
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which Zr-fum/H6-GFP NPs were encapsulated in DOPC micelles or the ones where 
DOPC was just added. Here concentrations higher than 21.6 µM even seemed to 
worsen cellular uptake.  
To further investigate the influence of DOPC on intracellular distribution of 
internalized functionalized Zr-fum NPs, CLSM was performed. Figure 44 shows 
images of H6-CF (upper two rows) or H6-GFP (lower two rows) functionalized Zr-fum 
NPs, to which 10.8 nmol DOPC (first and third row) were optionally added, before 
incubating them on KB_wt cells for 24 h. 
 
Figure 44: Analysis of the influence of the addition of DOPC to functionalized Zr-fum NPs on 
cellular uptake. After functionalization of 30 µg Zr-fum NPs with 0.22 nmol H6-CF (first and second 
row) or H6-GFP (third and fourth row), 10.8 nmol DOPC (first and third row; final concentration in the 
well 21.6 µM) were added to the solution. The samples were incubated on KB_wt cells for 24 h and 
images of live cells in PBS (pH 7.4) were taken by CLSM. First column: fluorescence of H6-CF or H6-
GFP at 488 nm; second column: staining of nucleus using Hoechst dye; third column: brightfield 
images; fourth column: merge of all three channels. Scale bars: 25 µm. 
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Figure 45: Analysis of the influence of the addition of DOPC and/ or DOPE to Zr-fum/H6-GFP 
NPs on cellular uptake and endosomal escape. After functionalization of 30 µg Zr-fum NPs with 
0.22 nmol H6-GFP, 10.8 nmol DOPC (first row), 10.8 nmol DOPE (third row) or a mixture of 5.4 nmol 
DOPC and 5.4 nmol DOPE (fifth row) were added. Optionally mixturesH6-GFP/ lipid mixtures were 
prepared without the addition of Zr-fum NPs (second, fourth, sixth row). The samples were incubated 
on KB_wt cells for 24 h and images of live cells in PBS (pH 7.4) were taken by CLSM. First column: 
fluorescence of H6-GFP at 488 nm; second column: staining of nucleus using Hoechst dye; third 
column: brightfield images; fourth column: merge of all three channels. Scale bars: 25 µm. 
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CLSM images confirm the results of the flow cytometry experiments described above 
(Figure 43) in which the addition of DOPC enhanced cellular uptake of functionalized 
Zr-fum NPs.  
Regarding the intracellular distribution of H6-GFP or H6-CF there is no significant 
difference between samples with or without DOPC.  
Furthermore the addition of a second phospholipid, DOPE, was investigated. As 
described above DOPE is supposed to have endosomolytic properties. H6-GFP 
carries a nuclear localization signal, thus after successful endosomal escape it 
should diffuse to the nucleus resulting in a distinct nuclear signal. Figure 45 depicts 
the investigation of the intracellular distribution of Zr-fum/H6-GFP after the addition of 
DOPC, DOPE or a mixture of DOPC and DOPE. As a control, the effect of just mixing 
the phospholipids with H6-GFP without the addition of Zr-fum NPs was evaluated. 
Compared to the addition of DOPC Figure 45 (first and second row), the addition of 
DOPE lead to agglomeration of Zr-fum/H6-GFP Figure 45 (third row) without further 
enhancement of cellular uptake or visible change in intracellular distribution. This can 
probably be explained by the fact that DOPE tends to form non-bilayer structures 
under physiologic conditions and can destabilize membranes [167]. The 
agglomeration on the cellular surface could be reversed upon the addition of DOPC 
Figure 45 (fifth and sixth row). Contrary to the initial assumption that DOPE would 
enhance the endosomal escape, no change in intracellular distribution of H6-GFP 
could be observed. Samples without Zr-fum NPs did not lead to any cellular uptake, 
demonstrating again that the MOFs are absolutely needed for successful cellular 
uptake of H6-GFP. 
 
3.2.10.2 Evaluation of different peptides to enhance endosomal escape 
The endosomal escape seemed to be the main bottle neck when using different MOF 
NPs as carriers. Therefore, different His-tagged peptides were designed which were 
proposed to enhance the endosomal escape. An overview of the different peptides 
including their identification numbers is listed in Table 8.  
To investigate their general feasibility for their usage in cell experiments, their 
influence on metabolic activity was investigated on HUH7_wt cells (Figure 46) after 
48 h incubation. Up to a concentration of 5 µM none of the lytic peptides exhibited 
significant toxicity.  
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Table 8: Overview of lytic peptides 
ID Description 
855 H6-CMA-2  
856 H6-LauA 
857 H6-K(OleA)2 
858 H6-K3(OleA)2 
859 H6-R3-K(OleA)2 
ID: identification numbers; LauA: lauric acid; OleA: oleic acid, α-amino acids are abbreviated in one-
letter code. Peptides were synthesized by Dr. Ulrich Lächelt (Pharmaceutical Biotechnology, LMU 
München). 
 
 
Figure 46: Evaluation of cytotoxicity of different lytic peptides. HUH7_wt cells were incubated 
with different concentrations of different lytic peptides for 48 h. Metabolic activity was determined by 
MTT assay. Data are presented as % metabolic activity of control cells, treated just with HBG. ± SD 
(n=5). 
 
To evaluate the influence of the different lytic peptides on destabilizing the 
endosomal membrane and to compare their pH dependent lytic activity, an 
erythrocyte leakage assay was carried (Figure 47). CMA-2 (855: H6 modified CMA-2) 
is a melittin derivative first synthesized by Boeckle et al. [169]. It was designed to 
shift the lytic activity of melittin at pH 7 leading to high toxicity including cell lysis, to 
the lower endosomal pH of 5. Therefore positively charged domains of melittin, which 
are important for its lytic activity were modified with glutamic acid residues or histidine 
residues. These residues are fully protonated at acidic pH restoring complete lytic 
activity of the peptides [169, 170]. 856-859 are newly designed peptides. 
In hemolysis studies (Figure 47) all different peptides showed pH dependent lytic 
activity with the highest lytic potential at the late endosomal pH 5.5. H6-CMA-2 
exhibited the highest lytic activity, while H6-LauA exhibited the lowest, but still 
showed pH dependency. Comparing the different oleic acid containing peptides, 
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incorporation of additional lysines (H6-K3-K(OleA)2) seemed to reduce pH specificity, 
while the additional three arginines (H6-R3-K(OleA)2) did not make any difference. 
Afterwards the effect of including these lytic peptides in cellular uptake experiments 
using Zr-fum MOF NPs as carrier to deliver H6-GFP was evaluated (Figure 48). 
 
Figure 47: Erythrocyte leakage assay of different lytic peptides. Evaluation of lytic activity of His-
tagged lytic peptides at physiological pH 7.4 (black), early endosomal pH 6.5 (grey) and late 
endosomal pH 5.5 (pattern). Data are presented as % of Triton treated cells ± SD (n=4). 
 
H6-peptides were mixed with H6-GFP at a molar ratio of two (H6-peptide; 0.148 nmol, 
H6-GFP; 0.074 nmol) and incubated with 10 µg Zr-fum NPs before incubation on 
HUH7_wt cells for 24 h. Subsequently, the influence of the lytic peptides on the 
endosomal escape was evaluated by CLSM (Figure 48). 0.148 nmol H6-peptide 
equals a final concentration of 0.5 µM in the well, which is far lower than the effective 
concentrations determined in the hemolysis study. Taking into consideration that the 
final endosomal concentrations might be much higher, the used concentrations are 
reasonable. Just mixing of H6-GFP and H6-peptide without the addition of Zr-fum 
MOF NPs did not lead to visible cellular uptake of H6-GFP (data not shown). In 
summary, all Zr-fum/H6-GFP + H6-lytic peptide combinations resulted in slight cellular 
uptake, but coming along with agglomeration of H6-GFP. In general, endosomal 
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escape was not visibly enhanced. Just in case of H6-CMA-2 (Figure 48a) destruction 
of the cellular nucleus occurred, indicating endosomal escape, though H6-GFP was 
still just visible in cellular vesicles.  
 
Figure 48: Cellular uptake of Zr-fum/H6-GFP additionally functionalized with H6-lytic peptides. 
After functionalization of 10 µg Zr-fum NPs with 0.074 nmol H6-GFP, 0.148 nmol H6-CMA-2 (first row), 
H6-K3(OleA)2 (second row), H6-R3-K(OleA)2 (third row), H6-LauA (fourth row) or H6-K(OleA)2 (fifth row). 
The samples were incubated on HUH7_wt cells for 24 h and images of live cells in PBS (pH 7.4) were 
taken by CLSM. First column: fluorescence of H6-GFP at 488 nm; second column: staining of nucleus 
using Hoechst dye; third column: brightfield images; fourth column (fourth and fifth row): F-Actin 
staining using phalloidin rhodamine; fourth or fifth column: merge of all three or four channels. Scale 
bars: 25 µm. 
 
Samples containing 20 µg Zr-fum NPs were also evaluated but did not lead to 
enhanced cellular uptake or enhancement of endosomal escape. Functionalization 
with 1.5 times H6-peptide (0.22 nmol) was investigated for H6-CMA-2, H6-K3-(OleA)2 
and H6-R3-K(OleA)2 resulting in all cases in agglomeration and extracellular binding 
of GFP, without cellular uptake. 
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3.2.10.3 Evaluation of the effect of DBCO-K-H6-K(H6-DBCO)2 modified H6-GFP 
on cellular uptake and endosomal escape 
In another attempt to overcome the two particular barriers, the intracellular delivery 
and the endosomal escape. H6-GFP was modified with DBCO-K-H6-K(H6-DBCO)2 
using the acid labile AzMMMan as a linker (Figure 49).  
 
 
Figure 49. Modification of H6-GFP with AzMMMan and DBCO-K-H6-K(H6-DBCO)2. H6-GFP was 
incubated with AzMMMan at a molar ratio of 1:8 for 2 h at 25 °C (I). After purification, DBCO-K-H6-
K(H6-DBCO)2 was added at a molar ratio of H6-GFP : DBCO-K-H6-K(H6-DBCO)2 of 1:25 (1:1 if 
calculated on the lysines of H6-GFP) and incubated for 3 h at 37 °C (II). 
 
The positive effect of the addition of histidines on overcoming these two barriers, has 
amongst others, been extensively investigated in our lab [141]. The addition of this 
huge amount of 18 histidines should on the one hand result in a high positive surface 
charge mediating unspecific interaction with negatively charged cell membranes and 
therefore enhance cellular uptake. More importantly, with a pKa of the imidazole 
groups around six, histidines offer high endosomal buffer capacity [171]. To 
investigate the effect of this modification, H6-GFP was used as a model protein. To 
assure that after successful endosomal escape, the native protein can be regained, 
H6-GFP was first modified with an acid labile linker (azidomethyl-methylmaleic 
anhydride, AzMMMan) (Figure 49, I), to which DBCO-K-H6-K(H6-DBCO)2 could then 
be coupled via click-chemistry (Figure 49, II). The effective acid labile modification of 
proteins with this linker has first been shown by Maier et al. [54]. The AzMMMan 
linker was synthesized as has been described previously [107]. The successful 
modification of H6-GFP with the AzMMMan linker was proven by further conjugation 
via click-chemistry to a DBCO-PEG5000. This modification can be investigated on 
SDS PAGE. Successful modification is indicated by the retardation of H6-GFP-
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AzMMMan-DBCO- PEG5000 at the top of the gel (Figure 50a). Additionally the acid 
lability of this modification could be shown by incubation of the samples in PBS pH 4, 
pH 5, pH 6 and pH 8 for 2 h at 37 °C, followed by analysis on SDS PAGE (Figure 
50b).To not destroy the labile AzMMMan linkage, the samples were loaded on the gel 
without prior boiling.  
 
Figure 50: Acid labile modification of H6-GFP. After modification of H6-GFP with azidomethyl-
methylmaleic anhydride (AzM), DBCO-PEG5000 was coupled to the linker via click-chemistry. Different 
samples were subjected to SDS PAGE without prior boiling. a) from left to right: H6-GFP-AzM-PEG5000, 
H6-GFP-Azm, H6-GFP, empty, Blue Prestained Protein Standard, Broad Range (NEB, Germany). b) 
pH dependent cleavage of AzM-PEG5000. Samples containing GFP-Azm-PEG5000 were incubated with 
PBS at indicated pH for 2 h at 37 °C. From left to right: pH 4, pH 5, pH 6, pH 8, without incubation, 
pure H6-GFP, empty, Precision Plus Protein standard (BioRad, USA). 
 
The successful modification of H6-GFP with PEG5000 is depicted in Figure 50a (first 
lane), indicated by the band at the top of the gel. Compared to PEG5000 modified H6-
GFP, AzMMMan modified H6-GFP or pure H6-GFP show bands at the GFP specific 
size of 26.9 kDa. The second visible band for pure H6-GFP is probably a result of not 
boiling the sample. Secondary structures, which would otherwise be destroyed upon 
subjecting them to higher temperatures might be left intact. The pH lability of the 
modification is shown in Figure 50b. Bands at the top of the gel indicate freshly 
prepared samples, or samples which were incubated at pH 8. If samples are 
incubated at pH 6, bands start to smear, indicating a slight cleavage of AzMMMan-
PEG5000 resulting in bands at the size of free GFP for the incubation at pH 4 and 5. 
After successful verification of the modification of H6-GFP with AzMMMan, H6-GFP-
AzMMMan was modified with DBCO-K-H6-K(H6-DBCO)2 (Figure 49, II). H6-GFP-
AzMMMan was incubated with DBCO-K-H6-K(H6-DBCO)2 at a molar ratio of 1:25 (1:1 
if calculated on the lysines of H6-GFP) and incubated for 3 h at 37°C.  
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Afterwards, the effect on cellular uptake and escape of endolysosomal vesicles was 
investigated by CLSM. Therefore, 30 µg Zr-fum MOF NPs were functionalized with 
either 0.1 nmol, 0.3 nmol or 0.4 nmol of the modified H6-GFP. Afterwards HeLa_wt 
cells were incubated with the functionalized Zr-fum NPs for 24 h followed by imaging 
of the live cells. Images of each condition are depicted in Figure 51.  
The modification with 0.1 nmol H6-GFP-AzMMMan-DBCO-K-H6-K(H6-DBCO)2  did 
not lead to an enhancement neither in cellular uptake nor in the endolysosomal 
escape. The modification with 0.3 nmol H6-GFP-AzMMMan-DBCO-K-H6-K(H6-
DBCO)2 lead to enhanced cellular uptake as well as endolysosomal escape (Figure 
51a, second row). Although no visible endosomal escape occurred in the better part 
of the cells. The modification with 0.4 nmol H6-GFP-AzMMMan-DBCO-K-H6-K(H6-
DBCO)2 (Figure 51a, third row) did not make an improvement, but rather lead to 
agglomerates. Incubation of cells without the addition of MOF NPs did not show any 
cellular uptake (Figure 51b), but in case of 0.4 nmol H6-GFP-AzMMMan-DBCO-K-H6-
K(H6-DBCO)2, agglomerates are visible. 
 
Figure 51 (first part): Cellular uptake of H6-GFP-AzMMMan-DBCO-K-H6-K(H6-DBCO)2 
functionalized Zr-fum MOF NPs. After incubation of HeLa_wt cells with different samples for 24 h, 
CLSM images of live cells were taken in PBS (pH 7.4). a) Zr-fum NPs were functionalized with 
different amounts of H6-GFP-AzMMMan-DBCO-K-H6-K(H6-DBCO)2. Scale bars: 25 µm. 
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Figure 51 (continued): Cellular uptake of H6-GFP-AzMMMan-DBCO-K-H6-K(H6-DBCO)2 
functionalized Zr-fum MOF NPs. After incubation of HeLa_wt cells with different samples for 24 h, 
CLSM images of live cells were taken in PBS (pH 7.4). b) Control incubations of HeLa_wt cells with 
different amounts of H6-GFP-AzMMMan-DBCO-K-H6-K(H6-DBCO)2 without the addition of Zr-fum NPs. 
Scale bars: 25 µm. 
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3.2.11 Investigation of cellular uptake using luciferase as a read-out system 
The following short chapter is included to present the initial experiments to establish 
a luciferase based read-out system similar to the one which is used on a regular 
basis in our lab for the analysis of pDNA and siRNA transfections. The chapter points 
at the bottlenecks of the system laying the foundation for further improvements and 
applications. 
 
Figure 52: Delivery of luciferase. After delivery of luciferase, cell permeable D-luciferin is added. 
Successfully delivered luciferase is able to use endogenous ATP to react with D-luciferin resulting in 
light which can then be used for a read-out. 
 
After successful purification and verification of functionality (3.2.2), binding of 
luciferase to MOF NPs was investigated. For the reasons described above, 
experiments were carried out using Zr-fum MOF NPs. 
70 ng H6-luciferase were incubated for 15 min with 50 µg Zr-fum NPs. Unbound H6-
luciferase was removed (centrifugation and removal of supernatant) and resulting 
functionalized MOF NPs were washed another three times with PBS (pH 7.4). After 
each step, samples of 10 µg functionalized MOF NPs were drawn. RLU/well were 
measured for all different samples, PBS (pH 7.4) and 14 ng H6-luciferase. 
Figure 53a shows a high H6-luciferase activity for pure H6-luciferase (white bar) which 
just slightly decreases after incubation with Zr-fum MOF NPs (black bar). After 
several washing steps (grey bars), measurable luciferase activity decreases a bit, 
indicating washing away of unbound H6-luciferase, but all in all H6-luciferase can be 
bound to Zr-fum MOF NPs without disturbance of its functionality.  
Ahead of the transduction experiments (Figure 55), the potential of measuring 
intracellular luciferase activity by just adding D-luciferin to the buffer was evaluated in 
stable KB_eGFPLuc cells (Figure 53b).  
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Figure 53: Evaluation of H6-luciferase binding to Zr-fum MOF NPs and luciferase activity in live 
cells. a) 14 ng H6-luciferase were incubated with 10 µg Zr-fum MOF NPs for 15 min. Functionalized 
Zr-fum NPs were washed three times with PBS. RLU/ well of PBS (light grey), 14 ng pure H6-
luciferase (white), Zr-fum/H6-luciferase (black) and Zr-fum/H6-luciferase after washing steps with PBS 
(Wash 1-3, different shades of grey) were measured ±SD (n=3). b) Evaluation of luciferase activity in 
live stable KB_eGFPLuc cells upon the addition of different amounts of D-luciferin, compared to the 
luciferase activity in lyzed cells measured with LAR buffer. ±SD (n=3). Luciferase activity was 
measured on a Centro LB 960 plate reader luminometer (Berthold Technologies, Bad Wildbad, 
Germany). 
 
The initial idea was that intracellular delivered luciferase ought to be able to use 
endogenous ATP to react with D-luciferin. Therefore, successful delivered functional 
luciferase should be distinguishable from just extracellular bound luciferase. The 
luciferase signal in live cells was a bit lower than in lyzed cells. The concentration 
and incubation time of D-luciferin did not make any difference. 0.5 mM D-luciferin 
were chosen for further transduction experiments as it equals the amount of D-
luciferin in LAR buffer (Table 2). 
After successful modification of Zr-fum NPs with H6-luciferase, and proving that 
intracellular luciferase can be measured in live cells, cellular uptake and cytotoxicity 
in KB_wt cells were investigated. Based on previous results (3.2.10) the effect of 
different additional functionalization units to enhance cellular uptake and endosomal 
escape was evaluated. To enhance cellular uptake, the experiment was either 
performed in serum free medium, or DOPC was added. The addition of DOPE, H6-
Inf, H20-tag or incubation in medium containing the endolysosomotropic agent 
chloroquine, was supposed to enhance endosomal escape. As can be seen in Figure 
54 none of the functionalization units or functionalized MOF NPs had an influence on 
the metabolic activity of the cells. 
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Figure 54: Evaluation of metabolic activity of transduction of luciferase into KB_wt cells. KB_wt 
cells were incubated with Zr-fum/H6-luciferase (10 µg/500 ng, 0.008 nmol) including different additional 
functionalization units as indicated. 28.8 nmol DOPC; 14.4 nmol DOPC/14.4 nmol DOPE; 0.03 nmol 
H20; 0.13 nmol H6-Inf; 0.13 nmol H20/0.13 nmol H6-Inf; – describes the incubation just with Zr-fum/H6-
luciferase. Samples w/o chloroquine (black) were incubated for 48 h- samples with chloroquine (grey) 
for 4 h on the cells. Metabolic activity was determined by MTT assay. Data are presented as % 
metabolic activity of control cells, treated just with HBG. Samples were prepared in duplicates. 
 
The results of the transduction experiments are depicted in Figure 55. Just 
measuring the activity of delivered H6-luciferase in live cells by the addition of cell-
permeable D-luciferin to the buffer did not result in any significant signal (Figure 55, 
black and white bar).  
As no positive control was available the different steps of the delivery experiments 
were evaluated in a quick more detailed approach. To analyze if the cellular uptake 
simply did not work, or if the bottleneck was the endosomal escape, after measuring 
the extracellular luciferase signal (data not shown) the cells were lyzed and the total 
luciferase signal was measured. The signal of intracellular luciferase was then 
determined as the total luciferase signal minus the extracellular luciferase signal 
(Figure 55, dark grey and light grey bars). 
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Figure 55: Transduction of luciferase into KB_wt cells. KB_wt cells were incubated with Zr-fum/H6-
luciferase (10 µg/500 ng, 0.008 nmol) including different additional functionalization units as indicated. 
28.8 nmol DOPC;14.4 nmol DOPC/14.4 nmol DOPE; 0.03 nmol H20; 0.13 nmol H6-Inf; 0.13 nmol 
H20/0.13 nmol H6-Inf; – describes the incubation just with Zr-fum/H6-luciferase. Samples w/o 
chloroquine (left) were incubated for 48 h - samples with chloroquine (right) for 4 h on the cells. As 
control (Ctrl), cells were incubated with H6-luciferase and functionalization units without the addition of 
Zr-fum NPs. After incubation, intracellular luciferase was measured after the addition of 0.5 mM D-
luciferin (black and grey). Dark grey and light grey: substraction of extracellular measured luciferase 
signal from luciferase signal of lyzed cells (measurements were carried out in LAR buffer). Samples 
were prepared in duplicates. 
 
Just samples containing additional functional units to improve the endosomal escape 
resulted in an enhanced luciferase signal. The best result was obtained for samples 
containing the endosomolytic peptide H6-Inf. If incubation was carried out in the 
presence of chloroquine luciferase signals could be enhanced. Samples in the 
presence of H6-Inf and chloroquine exhibited the highest luciferase signal suggesting 
the main bottleneck being the endosomal escape. Another problem seems to be the 
transduction efficiency. Compared to measuring pure H6-luciferase signal, the signal 
measured after transduction is very low. This in addition to the fact that the luciferase 
signal in live cells was in general lower than in lyzed cells adds up to an explanation 
why measuring a signal of transduced H6-luciferase in live cells was quite hard.  
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3.2.12 Application of Zr-fum MOF NPs as a carrier system for apoptosis 
inducing peptides and cytochromeC 
In regard to the intracellular distribution of internalized entities, the major limitation of 
the presented concept as delivery system seems to be the entrapment within cellular 
vesicles. To further evaluate the potential of Zr-fum MOF NPs as carrier system for 
cytosolic cargo release, transduction of membrane impermeable bioactive pro-
apoptotic peptides (Bak, Bad, KLK) and mitochondrial cytochromeC (CytC) protein 
was investigated and cell killing was used as reporter for successful cytosolic 
delivery. H6-Bak and H6-Bad are two peptides derived from the BH3 domain of Bak 
and Bad proteins which promote apoptosis by inducing the mitochondrial mediated 
apoptosis pathway [172].  
Figure 56: Evaluation of toxicity and binding to Zr-fum MOF NPs of apoptosis inducing H6- 
peptides and H6-CytC. a) H6-Bak (pattern), H6-Bad (black), H6-KLK (light grey) or H6-CytC (dark grey) 
were incubated with Zr-fum MOF NPs (Zr-fum/His-tag: 0.2 mg/nmol) for 15 min at room temperature. 
Samples were diluted to 0.1 mg Zr-fum/mL HBG (pH 7.4) and zeta potential was measured. Zeta 
potentials were calculated by the Smoluchowski equation, each sample was measured 3 times with 10 
to 30 subruns at 25 °C. All samples differ significantly p<0.0001 from non-modified Zr-fum MOF NPs. 
White: unmodified Zr-fum MOF NPs, pattern: H6-Bak, black: H6-Bad, light grey: H6-KLK, dark grey: H6-
CytC. b) After incubation of HeLa_wt cells with different peptide concentrations for 48 h, metabolic 
activity was determined by MTT assay. H6-Bak (pattern), H6-Bad (black), H6-KLK (light grey) or H6-
CytC (dark grey). Data are presented as % metabolic activity of control cells ± SD (n=5). Please note 
that for H6-CytC the highest concentration was 200 μM. Adapted from [158]. 
 
H6-KLK is an artificial peptide designed to selectively kill bacteria [173]. It also 
disrupts mitochondrial membranes while showing low extracellular toxicity [174]. 
CytC is a small mitochondrial heme protein and a crucial player in the intrinsic 
mitochondrial apoptosis pathway. After its release from the mitochondrion it binds to 
apoptotic protease-activating factor 1, APAF-1, promoting assembly of the 
apoptosome and activation of cell death [175]. H6-tags were chemically conjugated to 
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CytC or integrated at the N-terminus of the peptide sequences derived from the BH3 
domain of Bak and Bad proteins [172] or the artificial KLK peptide [173, 174]. Binding 
of these pro-apoptotic factors to Zr-fum NPs was confirmed by measuring the change 
of zeta potential upon addition of the MOF NPs (Figure 56a). For biological 
evaluation, HeLa_wt cells were treated for 48 h with different concentrations of pure 
pro-apoptotic factors to evaluate their intrinsic cytotoxicity (Figure 56b). Changes in 
metabolic activity were evaluated by MTT assay. Up to a concentration of 20  µM all 
pro-apoptotic factors did not exhibit any detectable toxicity. Afterwards cells were 
treated for 48 h with functionalized Zr-fum NPs (Zr-fum/H6-Bak, /H6-Bad, /H6-KLK or 
/H6-CytC, 10 μM) and cell viability was assessed again by MTT assay (Figure 57).  
 
 
Figure 57: Induction of cell killing upon incubation with Zr-fum MOF NPs functionalized with 
pro-apoptotic factors. HeLa_wt cells were incubated for 48 h with Zr-fum NPs functionalized with 
different pro-apoptotic factors. Final concentration of H6-Bak, H6-Bad, H6-KLK, H6-CytC was 10 μM. 
Black bar: functionalized Zr-fum NPs, grey bar: pure pro-apoptotic factor, white bar: bare Zr-fum NPs. 
Data are presented as % metabolic activity of control cells ± SD (n=3) (MTT assay). *** p<0.0003, ** 
p<0.01. Adapted from [158]. 
 
Approximately 60 % cell killing could be detected in case of all functionalized Zr-fum 
NPs. These findings indicate that, despite the bottleneck of vesicular entrapment, 
significant fractions of cargo molecules were able to escape and induce biological 
effects in the cytosol. 
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4 Discussion 
4.1 Delivery of nanobodies for imaging of target proteins 
This chapter has been adapted from: 
Intracellular Delivery of Nanobodies for Imaging of Target Proteins in Live Cells. Ruth 
Röder, Jonas Helma, Tobias Preiß, Joachim O. Rädler, Heinrich Leonhardt, Ernst 
Wagner. Pharmaceutical Research (2017), 34(1):161-174. 
 
The intracellular delivery of nanobodies is of high research interest in the field of live 
cell imaging as well as for therapeutic approaches, but so far there is no effective 
delivery system available. In the current thesis, a library of sequence-defined 
oligoaminoamides was evaluated for their ability to efficiently transduce a GFP 
binding nanobody in different folic acid receptor expressing recombinant HeLa cell 
lines. Previous protein delivery experiments from our lab were based on the 
bioreversible covalent modification of proteins with oligomers [52-54]. The current 
work aimed at non-covalent formulation, where nanoparticles are formed through 
mixing nanobody and oligomers. An initial oligomer library screen identified two 
oligomers (735 and 734) which upon incubation with a GFP binding nanobody lead to 
stable nanoparticle formation, resulting in efficient intracellular delivery and specific 
co-localization of labeled nanobody with GFP-tagged target proteins. These two 
oligomers differ only by the presence (735) or absence (734) of folate as possible 
targeting ligand. They were initially described by He et al. [142] for testing receptor-
mediated delivery of pDNA and siRNA, contain a PEG molecule for nanoparticle 
shielding and prevention of unspecific aggregations, optionally linked with folic acid 
as receptor-targeting ligand, attached to a four-arm core oligoaminoamide structure 
comprising a repeating sequence pattern of four cationizable Stp units (assumed to 
facilitate endosomal escape) and one terminal cysteine per arm (for disulfide 
formation between neighboring oligomers). According to our initial screening 
experiments, comparing these two oligomers 735 or 734 with the others, the 
relatively larger size and topology seems to be critical for effective 
nanobody/oligomer nanoparticle formation. In this setup especially the inclusion of 
cysteines within the oligomeric structure was proven as absolutely necessary for the 
generation of stable nanoparticles by disulfide crosslinkage upon cysteine oxidation 
during the four hours incubation after nanobody/oligomer mixing. Blocking of the 
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terminal cysteine mercapto groups by maleimide prevented stable particle formation. 
Oligomer disulfide formation before nanobody complexation was also unsuccessful 
(data not shown).This is consistent with previous work which demonstrated favorable 
effects of disulfide crosslinkage on siRNA polyplex formation [48, 50, 176, 177]. As 
the RH of the nanobodies used in this study is comparable to the RH of siRNA of 
2.2 nm [178, 179] but with a far lower negative charge density the requirement of 
cysteines for stable nanoparticle formation fits well with the aforesaid findings. 
Altogether the findings suggest that the oligomers are first non-covalently bound to 
the surface of nanobodies where disulfide formation between oligomers triggers the 
formation of stable nanoparticles. 
Oligomer 735 contains folic acid as targeting ligand. We could show that upon short-
time incubation nanoparticles containing oligomer 735 exhibit higher cellular uptake 
compared to particles formed with the non-targeted oligomer 734. Cellular 
internalization was shown to be blocked upon pre-incubation of the cells with free 
folic acid, suggesting receptor-dependent cellular uptake. Nanoparticles containing 
oligomer 734 however also lead to quite high uptake efficiency when cellular uptake 
was investigated after 24 h. There are two possible explanations for this; one is the 
positive charge of the protein/oligomer complexes. In contrast to almost neutral 
polyplexes formed with highly negatively charged nucleic acids, nanobodies do not 
effectively neutralize the cationic charges of the oligomer, exhibiting a zeta potential 
of ~+15 mV for all nanobody/oligomer formulations. Therefore positively charged 
nanobody/oligomer nanoparticles may interact with cells either via the folate receptor 
or directly with negative charged cell membranes, leading to receptor independent 
cellular uptake. Moreover, FCS data indicate formation of slightly more nanobody 
nanoparticles for 734 than for 735, resulting in more nanobody cargo being available 
for non-specific cellular uptake. 
The escape from endolysosomal cellular vesicles is suggested to be the major 
bottleneck for cytosolic delivery of macromolecules. Therefore it is not surprising to 
observe a significant fraction of internalized labeled nanobody remaining localized in 
intracellular vesicles. The four arm oligomer 735 contains a significant number of 
sixteen cationizable Stp [46] units (sixty-four aminoethylene units) per oligomer which 
by endosomal acidification should be sufficient to trigger endosomal escape 
analogously to the ‗proton sponge effect‘ as observed for polyethylenimine [19, 180]. 
It has to be noted that according to the oligomer screen by He et al. [142] as well as 
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related work on pDNA delivery [47, 141], 735 and analogous oligomers did not 
possess optimized proton sponge activity and require the presence of the 
endolysomotropic agent chloroquine for effective endosomal escape. In this respect 
the successful protein delivery at slightly higher doses of incorporated 735 carrier is 
encouraging, but the persistent endosomal bottleneck for this oligomer also suggests 
an important direction for further optimization of oligomers. 
To broaden our delivery technology towards a universal nanobody transduction 
system, we also applied it for a lamin binding nanobody. After successful delivery of 
α-lamin-Nb, we were able to visualize nuclear lamin, an endogenous target, and to 
follow it through the whole cell cycle in living cells. As nanobodies have a quite 
conserved structure and differ mostly in their complementarity determining regions, 
their properties in terms of oligomer binding ought to be quite similar. Thus this 
system should be transferable to many kinds of nanobodies- being able to target a 
huge variety of intracellular molecular targets. 
 
4.2 MOF nanoparticles as a defined carrier system for His-tagged 
functional units 
This chapter has been adapted from:  
Multifunctional nanoparticles by coordinative self-assembly of His-tagged units with 
metal-organic frameworks. Ruth Röder, Tobias Preiß, Patrick Hirschle, Benjamin 
Steinborn, Andreas Zimpel, Miriam Höhn, Joachim O. Rädler, Thomas Bein, Ernst 
Wagner, Stefan Wuttke and Ulrich Lächelt. Journal of the American Chemical Society 
(2017), 139(6): 2359-2368.  
 
MOFs are quite new compounds with their fields of application ranging from their 
usage as catalysts [84, 131-135], over absorption and storage of various materials 
[82, 83, 123] to their use in biomedical applications such as drug delivery [85, 86, 
125, 136, 137] or imaging [121]. In the work at hand, a new functionalization concept 
of MOF nanoparticles (NPs) which was developed by Dr. Ulrich Lächelt (Group 
Leader, Pharmaceutical Biotechnology, LMU München) was to be evaluated referring 
to its use as possible carrier for the cellular delivery of various His-tagged 
compounds. The strategy uses the coordinate interaction such as the imidazole 
function of histidine acting as Lewis base and coordinatively unsaturated metal sites 
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present on the external surface of MOF NPs acting as Lewis acid, to assemble 
different functional units.  
The binding via coordination interactions has already been shown in different 
contexts [44, 149, 156, 157]. Here it was applied to generate multifunctional core-
shell MOF NPs for efficient delivery, taking on the one hand advantage of the fact 
that the metal binding sites are naturally abundant and homogeneously distributed 
within the MOFs, and on the other hand of the inherent His-tag of many recombinant 
proteins. The same interaction is routinely used for the purification of recombinant 
proteins by immobilized metal ion chromatography [154, 155]. If not, His-tags can 
easily be integrated into peptides or proteins by synthetic, recombinant or 
bioconjugation techniques.  
At first, the general feasibility of the selected MOF NPs, MIL-88A, HKUST-1 and Zr-
fum, was evaluated by MTT assay. MIL-88A and Zr-fum MOF NPs exhibited good 
bio-compatibility. Just HKUST-1 showed a decrease in metabolic activity, which could 
be overcome by shortening the incubation time.  
Secondly, the theory of the acid labile assembly of MOF NPs and His-tags was 
investigated. The acid labile release is of special importance, if a shielding and 
targeting layer has to be released to expose novel often endosomolytic activity. It can 
additionally be applied to free a cargo from its carrier. These investigations were 
carried out using Zr-fum MOF NPs as carrier and H6-A647N as cargo. FCS 
measurements as well as photometric evaluations showed pH dependent 
disassembly of His-tag and MOF in both irrespective experiments.  
The long-term stability as well as stability under cell culture conditions of His-tag 
functionalized MOF NPs was also investigated by photometric detection and FCS 
measurements. Photometric detections revealed stable association of Zr-fum/H6-
A647N for 24 h in aqueous solution at pH 7.4. FCS, measurements showed stable 
association of Zr-fum/H6-A647N in DMEM media containing 10 % FBS. 
In the following, cellular uptake could be observed using all three different MOF NPs 
and H6-CF or H6-GFP as cargo molecule. In case of HKUST-1 and MIL88-A 
agglomerations were clearly visible in CLSM images, confirming what had been 
observed in FCS and DLS measurements (data not shown). Therefore for further 
delivery experiments we focused on Zr-fum MOF NPs as a carrier.  
A distinct advantage of the self-assembly concept demonstrated in this work is the 
one-step multifunctionalization of MOF NPs by simultaneously mixing different His-
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tagged compounds with bare MOF NPs, being able to easily introduce efficient 
shielding and multifunctional targeting units as well as different small molecule 
therapeutics at the same time, without the need of complex further modifications. 
This assumption was first evaluated by FCCS measurements using two His-tagged 
proteins, H6-GFP and Atto647N labeled H6-Transferrin (H6-Tf*) with distinct 
fluorescence spectra. The analysis of the cross-correlation showed a high ratio of co-
localization of both proteins which was interpreted as attachment of H6-GFP and H6-
Tf* to the surface of the same MOF NP. In accordance with the FCCS 
measurements, cellular uptake experiments in HeLa_wt cells using these double 
functionalized Zr-fum MOF NPs showed considerable intracellular co-localization of 
H6-GFP and H6-Tf*. However, H6-Tf* was also take up on its own. This can be 
explained by the fact that HeLa_wt cells express the transferrin receptor leading to 
MOF independent uptake of H6-Tf*. Although a higher uptake could be observed in 
the presence of MOF NPs suggesting simultaneous uptake of several H6-Tf* coupled 
to the same MOF NP. 
To elucidate the cellular uptake pathway, of the functionalized MOF NPs, we 
investigated the endocytotic process using different cellular uptake inhibitors. The 
results indicated an energy dependent uptake route which seemed to be dominated 
by macropinocytosis as amiloride showed the greatest inhibitory effect on cellular 
uptake of Zr-fum/H6-GFP MOF NPs. A minor effect of genestein suggested that 
caveloae mediated endocytosis might also be involved to some extend. Recently, 
Orellana- Tavra et al. [181] investigated the endocytosis mechanism of UiO-66 
(Zr4+/terephtalate) MOF NPs. Consistently with the data presented here, they also 
showed that cellular uptake of UiO-66 is energy dependent with distinct involvement 
of macropinocytosis. However they identified clathrin- mediated endocytosis having a 
major contribution [181], too. 
To evaluate the potential of Zr-fum MOF NPs as carrier system for cytosolic cargo 
release, delivery of membrane impermeable bioactive pro-apoptotic peptides (Bak, 
Bad, KLK) and mitochondrial cytochromeC (CytC) protein was investigated. Notably, 
for the purification of H6-CytC carrying a H6-tag after chemical conjugation, 
immobilized metal-ion chromatography was used which is based on the same 
principle as the binding to the MOF NPs. The utilization of the same interaction for 
isolation and subsequent attachment to the carrier system is considered a very 
convenient and robust manufacturing process. Binding of these pro-apoptotic factors 
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to Zr-fum NPs was confirmed by measuring the change in zeta potential upon 
addition of MOF NPs. Assessing cell viability in HeLa_wt cells, approximately 60 % 
cell killing could be detected for Zr-fum MOF NPs functionalized with all four different 
pro-apoptotic factors. Without the addition of MOF-NPs, all pro-apoptotic factors did 
not exhibit any detectable toxicity up to a concentration of 20 µM. These findings 
indicate that, despite the bottleneck of vesicular entrapment, significant fractions of 
cargo molecules were able to escape and induce biological effects in the cytosol.  
In summary, the simultaneous assembly of different functional units with Zr-fum MOF 
NPs as well as transport into living cells indicated the successful creation of 
multifunctional programmable MOF NP interfaces capable of manipulating cellular 
processes. 
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5 Summary 
Targeted nanoparticles holding different bioresponsive functional units can be used 
as carriers in biomedical applications, for the intracellular delivery of therapeutic 
compounds such as nucleic acids or proteins and for related purposes such as 
bioimaging. Nanobodies, similar to antibodies, have a conserved core sequence and 
variations occur mostly in their complementary determining regions. An efficient 
carrier for one nanobody should be generally applicable to all kinds of nanobodies. In 
the first part of the thesis, such a universal carrier for nanobodies was developed. For 
establishing a system for the efficient delivery of nanobodies into living cells, a broad 
screening experiment was conducted evaluating different targeted and non-targeted 
sequence-defined oligoaminoamide carriers from our lab, for their potential to 
efficiently transduce a GFP binding nanobody into living HeLa_PCNA-GFP cells. The 
screening resulted in two related sequence-defined oligoaminoamide carriers, 735 
and 734 with and without folic acid as receptor targeting ligand. These two oligomers 
additionally contain sixteen Stp units to interact with the nanobody and enhance 
endosomal escape, cysteines to enhance oligomer crosslinking leading to the 
formation of stable nanoparticles and PEG as hydrophilic shielding agent. Mixing of 
nanobodies with these two oligomers and incubation for air-oxidation of cysteines 
lead to nanoparticles with a small size around 20 nm. They were suitable to efficiently 
deliver different labeled nanobodies into cells, as evidenced by interaction of 
nanobodies with their target proteins. This delivery approach was evaluated in two 
additional recombinant cell lines, HeLa_Actin-GFP and HeLa_Tubulin-GFP cells 
proving that the transduction of a GFP binding nanobody works in different cell lines. 
Furthermore, this delivery concept was extended to a lamin binding nanobody 
broadening the scope to direct imaging of an endogenous target.This demonstrates 
that due to the conserved structure and size of nanobodies, the evaluated sequence-
defined oligomers can be used to deliver nanobodies with diverse intracellular 
targets.  
Delivery systems are often optimized for the delivery of one class of compounds. It 
would be a great advancement to have a carrier system for multiple simultaneous 
cargos, which can be adapted to any application without intensive further 
investigations. The described multifunctionalization concept of metal-organic 
frameworks (MOFs) is one step into this direction.  
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In the second part of the thesis, the suitability of MOFs as carriers for various His-
tagged cargos was to be investigated. The inherent properties of the individual 
compounds (metal ions or metal oxide clusters of MOF nanoparticles (NPs), His-tag 
containing functional units) and the reversible nature of the His-tag-MOF interaction 
account for the strength of this approach. The used MOFs, MIL-88A, HKUST-1 and 
Zr-fum did not exhibit any cytotoxicity under the used conditions. Furthermore, 
cellular uptake of H6-GFP or H6-carboxyfluorescein functionalized MOF NPs was 
evaluated. All MOFs exhibited efficient cellular uptake, although MIL-88A and 
HKUST-1 showed high agglomerations compared to Zr-fum. Therefore further 
experiments were carried out with Zr-fum MOF NPs only. Co-delivery of H6-GFP and 
Atto647N labeled H6-transferrin demonstrated the possible one-step 
multifunctionalization of the MOF NPs by simply simultaneously mixing different His-
tagged units with bare MOF NPs. This shows the great advantage of the presented 
carrier system, as diverse functional compounds, just having a His-tag in common 
can be delivered at the same time without further modifications. The delivery of three 
pro-apoptotic peptides, Bad, Bak and KLK and the mitochondrial protein 
cytochromeC led to approximately 60 % cell killing, demonstrating the versatility for 
possible biomedical applications. 
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6 Appendix 
6.1 Abbreviations 
5ANV Fmoc-5-azido-L-norvaline 
Acr Acridine 
APAF-1 Apoptotic protease-activating factor 1 
APC Allophycocyanin 
AzMMMan Azidomethyl-methylmaleic anhydride 
BrMMan 3-(Bromomethyl)-4-methyl-2,5-furandione 
CDR Complementarity determining region 
CF Carboxyfluorescein 
Cit Citraconic acid amide 
CLSM Confocal laser scanning microscopy 
CPP Cell penetrating peptide 
CUS Unsaturated metal sites 
CytC CytochromeC 
DAPI 4′,6-Diamidino-2-phenylindole 
DBCO Dibenzocyclooctyl 
DMMan Dimethylmaleic anhydride 
DIPEA N,N-Diisopropylethylamine 
DMF Dimethylformamide 
DMSO Dimethylsulfoxide 
DNA Desoxyribonucleic acid 
DOPC 1,2-Dioleoyl-sn-glycero-3-phosphocholine 
DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
EDTA Ethylenediaminetetraacetic acid 
GFP Green fluorescence protein 
FBS Fetal bovine serum 
FCCS Fluorescence cross-correlation spectroscopy 
FCS Fluorescence correlation spectroscopy 
FITC Fluorescein isothiocyanate 
FolA Folic acid 
GBP GFP binding protein 
Gtp Glutaroyl tetraethylene pentamine 
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H6 Hexahistidine 
HBG Hepes-buffered glucose 
HBTU N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uranium hexa-
fluorophosphate 
HcAb Heavy-chain only camelid antibodies 
HEPES 2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethansulfonic acid 
HGFR Hepatocyte growth factor receptor 
His-tags Oligohistidine- tags 
HKUST-1 Hong Kong University of Science Technology -1 
HOBt 1-Hydroxy-benzotriazole 
iPS Induced pluripotent stem cells 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
IR Infrared spectroscopy 
LauA Lauric acid 
Luc Luciferase 
MIL-88A Materials from Institute Lavoisier -88A 
MOF Metal-organic framework 
mRNA Messenger ribonucleic acid 
MTBE Methyl tert-butyl ether 
MTT 3-(4,5-Dimethylthia-zol-2-yl)-2,5-diphenyltetrazolium bromide 
MWCO Molecular weight cut-off 
Nb Nanobody 
NEM N-Ethylmaleimide 
NHS N-Hydroxysuccinimide 
NLS Nuclear localization signal 
NMP N-Methyl-2-pyrrolidone 
NP Nanoparticle 
NTA Nitrilotriacetic acid 
OleA Oleic acid 
PAMAM Polyamidoamine 
PBS Phosphate buffered saline 
PCNA Proliferating-Cell-Nuclear-Antigen 
pDNA Plasmid desoxyribonucleic acid 
PEG Polyethyleneglycol 
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PEI Polyethyleneimine 
PFA Paraformaldehyde 
PIC Polyion complex 
Ptp Phtaloly tetraethylene pentamine 
Pybop (Benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluoro-
phosphate 
RNA Ribonucleic acid 
SBU Secondary building unit 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC Size exclusion chromatography 
siRNA Small interfering ribonucleic acid 
SMCC Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
SPDP N-Succinimidyl 3-(2-pyridyldithio)propionate 
Sph Succinoyl pentaethylene hexamine 
Stp Succinoyl tetraethylene pentamine 
TALENs Transcription activator-like effector nucleases 
Tf Transferrin 
TFA Trifluoroacetic acid 
Tis Triisopropylsilane 
TNF Tumor necrosis factor 
VHH Single domain antibody fragments 
Zr-fum Zirconium-fumaric acid 
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6.2 Gene and protein sequences 
6.2.1 Sequence of EGFPLuc Gene 
pET28A / Coding Region 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGG
CAGCCATATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGCGGATCCGAAT
TCGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTATCCGCTGGAA
GATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGCCCTGGT
TCCTGGAACAATTGCTTTTACAGATGCACATATCGAGGTGGACATCACTTACGCT
GAGTACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCTG
AATACAAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGC
CGGTGTTGGGCGCGTTATTTATCGGAGTTGCAGTTGCGCCCGCGAACGACATTT
ATAATGAACGTGAATTGCTCAACAGTATGGGCATTTCGCAGCCTACCGTGGTGT
TCGTTTCCAAAAAGGGGTTGCAAAAAATTTTGAACGTGCAAAAAAAGCTCCCAAT
CATCCAAAAAATTATTATCATGGATTCTAAAACGGATTACCAGGGATTTCAGTCG
ATGTACACGTTCGTCACATCTCATCTACCTCCCGGTTTTAATGAATACGATTTTG
TGCCAGAGTCCTTCGATAGGGACAAGACAATTGCACTGATCATGAACTCCTCTG
GATCTACTGGTCTGCCTAAAGGTGTCGCTCTGCCTCATAGAACTGCCTGCGTGA
GATTCTCGCATGCCAGAGATCCTATTTTTGGCAATCAAATCATTCCGGATACTGC
GATTTTAAGTGTTGTTCCATTCCATCACGGTTTTGGAATGTTTACTACACTCGGA
TATTTGATATGTGGATTTCGAGTCGTCTTAATGTATAGATTTGAAGAAGAGCTGT
TTCTGAGGAGCCTTCAGGATTACAAGATTCAAAGTGCGCTGCTGGTGCCAACCC
TATTCTCCTTCTTCGCCAAAAGCACTCTGATTGACAAATACGATTTATCTAATTTA
CACGAAATTGCTTCTGGTGGCGCTCCCCTCTCTAAGGAAGTCGGGGAAGCGGT
TGCCAAGAGGTTCCATCTGCCAGGTATCAGGCAAGGATATGGGCTCACTGAGA
CTACATCAGCTATTCTGATTACACCCGAGGGGGATGATAAACCGGGCGCGGTC
GGTAAAGTTGTTCCATTTTTTGAAGCGAAGGTTGTGGATCTGGATACCGGGAAA
ACGCTGGGCGTTAATCAAAGAGGCGAACTGTGTGTGAGAGGTCCTATGATTATG
TCCGGTTATGTAAACAATCCGGAAGCGACCAACGCCTTGATTGACAAGGATGGA
TGGCTACATTCTGGAGACATAGCTTACTGGGACGAAGACGAACACTTCTTCATC
GTTGACCGCCTGAAGTCTCTGATTAAGTACAAAGGCTATCAGGTGGCTCCCGCT
GAATTGGAATCCATCTTGCTCCAACACCCCAACATCTTCGACGCAGGTGTCGCA
GGTCTTCCCGACGATGACGCCGGTGAACTTCCCGCCGCCGTTGTTGTTTTGGA
Appendix 
110 
  
GCACGGAAAGACGATGACGGAAAAAGAGATCGTGGATTACGTCGCCAGTCAAG
TAACAACCGCGAAAAAGTTGCGCGGAGGAGTTGTGTTTGTGGACGAAGTACCG
AAAGGTCTTACCGGAAAACTCGACGCAAGAAAAATCAGAGAGATCCTCATAAAG
GCCAAGAAGGGCGGAAAGATCGCCGTGTAA 
 
6.2.2 Amino acid sequence of H6-luciferase 
Luciferase amino acid sequence (pET28a expression)  
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSEFEDAKNIKKGPAPFYPLED
GTAGEQLHKAMKRYALVPGTIAFTDAHIEVDITYAEYFEMSVRLAEAMKRYGLNTNH
RIVVCSENSLQFFMPVLGALFIGVAVAPANDIYNERELLNSMGISQPTVVFVSKKGLQ
KILNVQKKLPIIQKIIIMDSKTDYQGFQSMYTFVTSHLPPGFNEYDFVPESFDRDKTIA
LIMNSSGSTGLPKGVALPHRTACVRFSHARDPIFGNQIIPDTAILSVVPFHHGFGMFT
TLGYLICGFRVVLMYRFEEELFLRSLQDYKIQSALLVPTLFSFFAKSTLIDKYDLSNLH
EIASGGAPLSKEVGEAVAKRFHLPGIRQGYGLTETTSAILITPEGDDKPGAVGKVVPF
FEAKVVDLDTGKTLGVNQRGELCVRGPMIMSGYVNNPEATNALIDKDGWLHSGDIA
YWDEDEHFFIVDRLKSLIKYKGYQVAPAELESILLQHPNIFDAGVAGLPDDDAGELPA
AVVVLEHGKTMTEKEIVDYVASQVTTAKKLRGGVVFVDEVPKGLTGKLDARKIREILI
KAKKGGKIAV 
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6.3 Analytical data  
6.3.1 Analytics of BrMMan and AzMMMan 
 
1H proton NMR spectra (400 MHz, CDCl3) 
 
3-(Bromomethyl)-4-methyl-2,5-furandione  
 
BrMMan: 4.17 (s 2H), 2.17 (s 3H).  
DiBrMMan: 4.27 (s 4H) 
DMMan: 2.07 (s 6H) 
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3-(Azidomethyl)-4-methyl-2,5-furandione  
 
AzMMMan: 4.29 (s, 2H), 2.22 (s, 3H) 
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6.3.2 Analytics of apoptotic peptides 
H6-Bak  
Sequence: H6-GGQVGRQLAIIGDDINR-NH2 
 
 
Mass found: 2603.3 [M+H]+ 
H6-Bad  
Sequence: H6-GNLWAAQRYGRELRRMSDEFVD-NH2 
 
 
Mass found: 2490.3 [M+H]+ 
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H6-KLK  
Sequence: H6-GGKLAKLAKKLAKLAK-NH2 
 
 
 
 
Mass found: 2457.9 [M+H]+, 2481.5 [M+Na]+, 2497.7 [M+K]+ 
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6.4 Publications 
6.4.1 Original articles 
Ruth Röder, Tobias Preiß, Patrick Hirschle, Benjamin Steinborn, Andreas Zimpel, 
Miriam Höhn, Joachim O. Rädler, Thomas Bein, Ernst Wagner, Stefan Wuttke and 
Ulrich Lächelt. (2017) Multifunctional nanoparticles by coordinative self-assembly of 
His-tagged units with metal-organic frameworks. Journal of the American Chemical 
Society, 139(6): 2359-2368. 
Ruth Röder, Jonas Helma, Tobias Preiß, Joachim O. Rädler, Heinrich Leonhardt, 
Ernst Wagner. (2017) Intracellular Delivery of Nanobodies for Imaging of Target 
Proteins in Live Cells. Pharmaceutical Research, 34(1): 161-174 (Cover). 
Andreas Zimpel, Tobias Preiß, Ruth Röder, Hanna Engelke, Michael Ingrisch, 
Michael Peller, Joachim O. Rädler, Ernst Wagner, Thomas Bein, Ulrich Lächelt and 
Stefan Wuttke. (2016) Imparting Functionality to MOF nanoparticles by external 
surface selective covalent attachment of polymers. Chemistry of Materials, 28(10): 
3318-26. 
Peng Zhang, Dongsheng He, Philipp Michael Klein, Xiaowen Liu, Ruth Röder, 
Markus Döblinger, Ernst Wagner. (2015) Enhanced intracellular protein transduction 
by sequence defined tetra oleoyl-oligoaminoamides targeted for cancer therapy. 
Advanced Functional Materials, 25(42): 6627–36. 
Andreia F. Jorge, Ruth Röder, Petra Kos, Rita S. Dias, Ernst Wagner, Alberto A.C.C. 
Pais. (2015) Combining polyethylenimine and Fe(III) for mediating pDNA transfection. 
Biochimica et Biophysica Acta (BBA), General Subjects, 1850(6): 1325-35. 
 
6.4.2 Review 
Ruth Röder and Ernst Wagner. (2014) Sequence-defined shuttles for targeted 
nucleic acid and protein delivery. Therapeutic Delivery, 5(9): 1025–1045. 
 
6.4.3 Poster presentation and abstract 
Linda Beckert and Ruth Röder, Jennifer Altomonte, Libor Kostka, Tomas Etrych, 
Ernst Wagner, Traceless pH-sensitive coating of viral and non-viral vectores. CeNS 
Workshop Venice "Walk and Talk at the Nanoscale" and <Interact> 2015, Munich 
(Poster prize, 2nd place). 
 
Appendix 
116 
  
Jennifer Altomonte, Ruth Röder, Kim Agnes Munoz Álvarez, D Gunert, Ernst 
Wagner, Oliver Ebert. (2015) Development of delivery, targeting, and imaging 
strategies to improve oncolytic vesicular stomatitis virus therapy for hepatocellular 
carcinoma. Zeitschrift für Gastroenterology 53(01). 
 
6.5 Copyright 
Chapter 3.1, 4.1 and Figure 3, 5, 6, 8-26 reprinted/ adapted from "Intracellular 
Delivery of Nanobodies for Imaging of Target Proteins in Live Cells‖, 2016, 
Pharmaceutical Research, 2017;34(1):161-174., Ruth Röder, Jonas Helma, Tobias 
Preiß, Joachim O. Rädler, Heinrich Leonhardt, Ernst Wagner, © Springer 
Science+Business Media New York 2016 with permission of Springer. 
 
Chapter 1.1 – 1.3 and Figure 1 republished with permission of Future Science Ltd. 
―Sequence-defined shuttles for targeted nucleic acid and protein delivery‖, Ruth 
Röder and Ernst Wagner 5(9) 2014, permission conveyed through Copyright 
Clearance Center, Inc. 
 
Chapter 3.2, 4.2, 6.3.2 and Figure 27-30, 33-42, 56, 57 reprinted with permission 
from ―Multifunctional Nanoparticles by Coordinative Self-Assembly of His-Tagged 
Units with Metal–Organic Frameworks‖, Ruth Röder, Tobias Preiß, Patrick Hirschle, 
Benjamin Steinborn, Andreas Zimpel, Miriam Höhn, Joachim O. Rädler, Thomas 
Bein, Ernst Wagner, Stefan Wuttke and Ulrich Lächelt, Journal of the American 
Chemical Society, 2017;139(6):2359–2368. Copyright 2017 American Chemical 
Society. 
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